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Abstract 
The low density lipoprotein receptor-related protein-1 (LRP1) receptor 
modulates neuronal survival, neurite outgrowth, regeneration and calcium signaling. Its 
effects are thought to be ligand and cell specific, but how LRP1 is able to differentiate 
between different signals to produce specific responses is unclear. The subcellular 
localisation of LRP1 in neurons and glia of the central nervous system (CNS) was 
investigated to gain insight into the receptor’s role in specific cell types and during 
maturation. The role of LRP1 in calcium signaling and regeneration following injury 
was assessed using two of its ligands, metallothionein (MT) and emtinB. 
Expression and localisation of LRP1 in vivo and in vitro was determined using 
western blot analysis and immunochemistry. LRP1 was expressed in neurons and glia of 
post-natal day 2 (P2), P7 and adult rat brains. Greater immunoreactivity was 
demonstrated in P2 compared to adult brain, mainly due to increased expression in 
neurons and oligodendrocytes. Neuronal expression was greatest in cell bodies of 
hippocampal and cortical neurons in P2 and adult brain. Glial expression of LRP1 was 
greatest in oligodendrocytes of the corpus callosum and hippocampal fimbria, but 
LRP1-positive astrocytes and microglia were also present throughout the brain at both 
time points. These data suggest that LRP1 has a role in neuronal and glial function and 
that this changes during maturation. 
LRP1 was localised to cell bodies of hippocampal neurons 3, 7, 14 and 21 days 
in vitro (DIV). The receptor was also expressed on dendrites at all time points, and did 
not co-localise with synaptophysin, PSD-95 or the NMDA receptor subunit, NR2a, but 
did partially co-localise with NR2b. Addition of MT and emtinB did not induce calcium 
influx in live neurons demonstrating that LRP1 mediated synaptic regulation is not 
modulated by these ligands in this cell type. LRP1 was also expressed along and at the 
ends of 3DIV and some 7DIV axons, suggesting a role in neurite outgrowth. This 
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hippocampal neuron model was used to investigate the role of LRP1 in response to 
injury. LRP1 was expressed at the ends of extending neurites 24 hours after scratch 
injury, suggesting that it is involved in neurite regeneration. 10μg/mL MT did not 
promote neurite extension but 25μM emtinB significantly increased the number of 
neurites that extended along or into the scratch injury site (57.8 ± 4.6 neurites/cm injury 
site) compared to saline controls (27.7 ± 3.3 neurites/cm injury site; p<0.005) and 
cultures treated with both emtinB and the LRP1 inhibitor, receptor associated protein 
(36.5 ± 3.2 neurites/cm injury site; p<0.005). These findings demonstrate the ability for 
LRP1 to promote neurite extension following injury through stimulation by emtinB.  
This thesis presents the temporal, regional and subcellular expression profile of 
LRP1 in neurons and glia of the CNS and how this may influence the receptor’s 
function in specific cell types during normal and injury conditions. The data support a 
role for LRP1 in neuronal biology and provide the foundation for further investigation 
into how LRP1 regulates neuron function.  
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1 Chapter 1: Introduction 
1.1 GENERAL DEVELOPMENT OF NEURAL CONNECTIONS IN THE 
BRAIN 
There are billions of neurons in the brain responsible for our ability to sense, 
think and move. Without the correct regulation and maintenance of these cells, life 
would be impossible. Control of neuronal function in development and maturity is 
complex and affected by both intrinsic and extrinsic factors. Chemical transmission is 
fundamental to the function in the central nervous system (CNS) and is dependent on 
the formation of correct connections between neurons during embryonic development. 
Developing neurons detect attractive or repulsive cues from the extracellular 
environment. These cues activate intracellular pathways involved in modulating 
cytoskeleton rearrangement and axon movement (Yamada et al., 1970). This allows the 
extending axon to maneouver through the brain to reach its specific destination 
(reviewed by (Mueller, 1999)). The axon then forms and stabilises a synaptic 
connection that allows neurons to receive, interpret and forward chemical signals 
through the CNS (reviewed by (Vaughn, 1989)). Neurons continue to receive a range of 
extracellular signals through maturity in order to maintain cell integrity and function 
appropriately.  
The interaction of extracellular and intracellular elements to produce a response 
is highly precise. Extracellular proteins interact with specific membrane bound 
receptors that modulate intracellular protein activation and distribution. This in turn 
activates or inhibits transcription factor activity and gene and protein expression 
(reviewed in (Kadonaga, 2004)). For all neuron functions, the cell must receive 
extracellular cues that mediate intracellular changes and responses. 
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1.2 ROLE OF CELL SURFACE RECEPTORS IN INTEGRATING 
EXTRACELLULAR AND INTRACELLULAR ENVIRONMENTS 
One key link between extracellular and intracellular environments is the 
membrane receptor. Extracellular ligands bind to their specific surface receptors to 
induce a conformational change that elicits an intracellular chemical response (Elliott 
and Elliott, 2004). This enables cells to detect signals in their surrounding environment 
and to respond appropriately. These signals are not only receptor-ligand specific but 
also cell specific. Receptors and their intracellular signaling targets are only present in 
certain cell types or on specific subcellular locations within that cell. In addition, signals 
from other receptors can promote or inhibit responses (Nelson and Cox, 2008) (Figure 
1.1). This complex mix of ligand, receptor and cell expressed proteins ensures that 
responses are tightly regulated and appropriate.  
1.2.1 EXAMPLE OF A WELL UNDERSTOOD BUT COMPLEX NEURONAL 
SIGNALING PATHWAY: THE NEUROTROPHINS 
An example of, and one of the best understood, systems that displays the 
complex interactions between ligand, receptor and intracellular proteins to produce 
neuronal responses is the neurotrophin signaling pathway. Four neurotrophins have 
been identified in the mammalian system: nerve growth factor (NGF) (Cohen and Levi-
Montalcini, 1956), brain derived neurotrophin factor (BDNF) (Barde et al., 1982), 
neurotrophin-3 (NT-3) (Maisonpierre et al., 1990) and NT-4 (Hallbook et al., 1991). 
Neurotrophins are ligands for the tropomyosin-related kinase (Trk) receptors, TrkA, 
TrkB and TrkC, and the p75 neurotrophin receptor (p75
NTR
) (Klein et al., 1991, Squinto 
et al., 1991, Ip et al., 1992). Each neurotrophin binds to a specific Trk receptor but all 
neurotrophins are able to bind to p75
NTR
 (Hallbook et al., 1991, Kaplan et al., 1991, 
Lamballe et al., 1991, Squinto et al., 1991). Upon neurotrophin binding, Trk receptors 
phosphorylate intracellular proteins that activate pathways to promote neuronal growth, 
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migration, differentiation and survival (Datta et al., 1997, Xing et al., 1998). In 
comparison, neurotrophin stimulation of p75
NTR
 often activates pro-apoptotic pathways 
(Frade et al., 1996, Bamji et al., 1998).  
The outcomes of neurotrophin binding are complex and dependent on 
interactions between the receptor, the ligand that binds it, and other receptors and 
intracellular proteins expressed by the cell. For example, NGF induces apoptosis in 
retinal neurons (Frade et al., 1996) but promotes survival in sensory neurons, of which 
both effects are through activation of p75
NTR
 (Hamanoue et al., 1999). This 
demonstrates that the same ligand and receptor combination can mediate opposing 
effects in different cell types. BDNF protects against NGF and p75
NTR
 mediated 
apoptosis in retinal neurons through TrkB activation (Frade et al., 1997). This 
demonstrates how the balance of neurotrophins and interactions of their Trk and p75
NTR
 
receptors is crucial in determining cell outcomes. Trk receptors can promote neuronal 
survival through suppression of p75
NTR
 and pro-apoptotic pathways (Yoon et al., 1998). 
This explains, in part, why p75
NTR
 mediated apoptosis only occurs when Trk receptors 
are inactive or decreased in expression (Bamji et al., 1998, Davey and Davies, 1998). 
Interestingly, the affinity of neurotrophins to bind to Trk receptors is stronger and more 
selective in the presence of p75
NTR
 (Hempstead et al., 1991, Mahadeo et al., 1994, Bibel 
et al., 1999). The effect of neurotrophin receptor activation and subsequent outcomes is 
dependent on the identity of the neurotrophin and the proteins expressed by the target 
cell that can interact with the receptor.  
The objective of this thesis is to investigate another complex, but less 
understood, receptor system. As will be discussed, the low density lipoprotein receptor-
related protein-1 (LRP1) is a receptor that, similar to neurotrophin receptors, modulates 
a diverse range of neuronal responses. The receptor also has an unusually high number 
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of ligands, giving rise to the hypothesis that it assists neurons to integrate and respond 
to a range of extracellular cues.  
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Figure 1.1: Simplified diagram of some receptor-ligand interactions in different cell 
types. Ligand activation of a receptor leads to activation of intracellular proteins 
(square, oval and small triangle) to produce an effect (A). The same receptor and ligand 
in another cell type that expresses a different set of intracellular proteins can produce a 
different response (B). Interactions between receptors expressed upon the same cell can 
alter the cellular effect (C). 
 
   
   
Cell 1 Cell 2 
Effect 
1 
Effect  
1 
Cell 2 
Effect 
2 
A B C Ligand 1 
Receptor 1 
Ligand 2 
Receptor 2 
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1.3 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1 
(LRP1) 
LRP1 was first described in 1988 by Herz and colleagues as a 600kDa receptor 
found in great abundance in the liver and brain (Herz et al., 1988). The receptor is one 
of the eleven members of the low density lipoprotein (LDL) receptor family. Like other 
members of this family, the primary role of LRP1 was initially believed to be in 
apolipoprotein transport (Herz et al., 1988, Kowal et al., 1989). However, further 
analysis of the receptor found it to be identical to the α2-macroglobulin receptor, which 
bound many more ligands and mediated several signaling pathways unrelated to the 
LDL receptor (Strickland et al., 1990). LRP1 is now known to have over 40 ligands 
(Table 1.1) and is expressed in cells of the liver, kidney, bone, fat, lung, skin, spleen, 
ovaries and testes (Herz et al., 1988, Feldman and Sangha, 1992, Moestrup et al., 1992, 
Zheng et al., 1994, Igdoura et al., 1997, Niemeier et al., 2005). Expression is also 
present in neurons and glia of human and rodent central nervous systems (discussed 
below).  
LRP1 is highly conserved between bacterial, avian and mammalian species 
(Springer, 1998) and knock-out mice are embryonically unviable, demonstrating a vital 
role for the receptor during embryonic development. Though the reason for this lethality 
is not entirely understood, it could be due to blockage of embryo implantation or 
abnormalities in liver development (Herz et al., 1992, Roebroek et al., 2006). In 
genetically altered mice where brain and liver LRP1 expression is decreased by 75%, 
animals are viable and functionally normal despite increased levels of plasma proteins 
(Willnow et al., 1995). This indicates that reduced expression of the receptor is 
sufficient for normal embryonic development. Mouse strains with a conditional knock-
out in specific neuronal populations are also viable but display increased neuronal death 
and cognitive deficits as they age (May et al., 2004, Liu et al., 2010). While the primary 
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function of LRP1 remains unclear, it is apparent that the receptor has an essential role in 
mammalian systems during development and maturity.  
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Ligand Reference 
α2-macroglobulin 
(Moestrup and Gliemann, 
1989) 
(Gliemann et al., 1989) 
Amyloid-β (Deane et al., 2004) 
Apolipoprotein E (Kowal et al., 1989) 
 - Apolipoprotein E3 
(Nathan et al., 2002) 
(Matsuo et al., 2011) 
 - Apolipoprotein E4 
(Nathan et al., 2002) 
(Hashimoto et al., 2000) 
Amyloid precursor protein (Kounnas et al., 1995) 
β-very low density 
lipoprotein 
(Kowal et al., 1989) 
(Handelmann et al., 1992) 
C1s-C1 inhibitor complex (Storm et al., 1997) 
Calreticulin 
(Ogden et al., 2001) 
(Gardai et al., 2005) 
Cholesterol (Handelmann et al., 1992) 
Complement C3 (Meilinger et al., 1999) 
Connective tissue growth 
factor 
(Segarini et al., 2001) 
EmtinB (Ambjørn et al., 2008) 
Factor VIII 
(Lenting et al., 1999) 
(Saenko et al., 1999) 
Fibronectin (Salicioni et al., 2002) 
Gentamicin (Moestrup et al., 1995) 
gp96 (Binder et al., 2000) 
Hepatic lipase (Kounnas et al., 1995) 
 
Table 1.1: Ligands that bind LRP1. Low density lipoprotein receptor-related protein (LRP1) 
has over 40 ligands, of which 37 are listed, that bind primarily to regions II and IV of the 
extracellular domain. 
Ligand Reference 
Insulin-like growth factor 
binding protein-3 
(Huang et al., 2003) 
Lactoferrin (Willnow et al., 1992) 
Leptin (Liu et al., 2011) 
Lipoprotein lipase (Willnow et al., 1992) 
Matrix metalloproteinase-9 (Mantuano et al., 2008) 
Myelin basic protein (Gaultier et al., 2009) 
Myelin associated glycoprotein (Stiles et al., 2013) 
Midkine (Muramatsu et al., 2000) 
Metallothionein 1/2 (Ambjørn et al., 2008) 
Platelet-derived growth factor 
(Loukinova et al., 2002) 
(Boucher et al., 2002) 
Plasminogen activator inhibitor 
type 1 
(Nykjaer et al., 1994) 
Polymyxin B (Moestrup et al., 1995) 
Pseudomonas exotoxin A (Kounnas et al., 1992) 
Receptor associated protein 
(Strickland et al., 1990)  
(Herz et al., 1991) 
Transforming growth factor-β  (Huang et al., 2003) 
Thrombospondin-1 
(Godyna et al., 1995) 
(Chen et al., 1996) 
Thrombospondin-2 (Chen et al., 1996) 
Tissue-type plasminogen 
activator 
(Bu et al., 1992) 
(Orth et al., 1992) 
Tissue factor pathway inhibitor (Warshawsky et al., 1994) 
Urokinase plasminogen activator (Nykjaer et al., 1994) 
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1.3.1 STRUCTURE AND PROCESSING OF LRP1 
The human LRP1 gene is located on chromosome 12 (Myklebost et al., 1989) 
and codes a 4544 amino acid protein (Herz et al., 1988). After translation and transport 
to the endoplasmic reticulum, LRP1 binds with high affinity to a 39kDa chaperone 
called receptor associated protein (RAP) (Strickland et al., 1990) (Figure 1.2). This 
binding inhibits protein interaction and receptor clumping (Herz et al., 1991) and assists 
with correct protein folding (Bu and Rennke, 1996). The receptor is transported to the 
Golgi apparatus where it is cleaved by the enzyme furin to form two non-covalently 
bound subunits of 515kDa and 85kDa. The 515kDa fragment (also known as the α- or 
heavy chain) contains the majority of the extracellular domain and all ligand binding 
regions of the receptor. The 85kDa fragment (also known as the β- or light chain) is 
composed of the membrane anchor and cytoplasmic domain (Herz et al., 1990). RAP 
dissociates from LRP1 in the lower pH of the Golgi apparatus, leaving the receptor 
functionally active to be transported to the cell membrane (Bu et al., 1995). The 
importance of LRP1-RAP interactions during processing is confirmed in RAP deficient 
mouse models that demonstrate impaired LRP1 expression (Willnow et al., 1995). 
Conversely, overexpression of RAP leads to its increased secretion from the cell and 
inhibition of LRP1 on the cell membrane. When applied extracellularly, RAP acts as a 
competitive antagonist of LDL receptor family members and inhibits receptor-mediated 
effects (Willnow et al., 1994, Medh et al., 1995).  
LRP1 has distinct extracellular, transmembrane and intracellular motifs (Figure 
1.3). The extracellular domain is composed of four regions of cysteine rich ligand 
binding repeats separated by four regions of epidermal growth factor/β-sheet motifs, 
which are involved in ligand release (Davis et al., 1987). The majority of ligands bind to 
ligand binding regions II and IV, though binding can involve multiple regions (Neels et 
al., 1999, Mikhailenko et al., 2001). One of the reasons that the receptor can bind many 
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ligands is due to the 31 ligand binding repeats contained in its extracellular domain 
(Mikhailenko et al., 2001). A type 1 transmembrane domain spans the cell membrane, 
connecting the extracellular and intracellular domains (Herz et al., 1988).  
The LRP1intracellular domain contains a YxxL tyrosine motif, two di-leucine 
motifs and two NPxY tyrosine motifs (proximal and distal). The YxxL and di-leucine 
motifs are the primary mediators of LRP1 mediated endocytosis (Li et al., 2000). As for 
other members of the LDL family, this process occurs via clathrin-coated vesicles (Bu 
et al., 1994a). Upon receptor mediated signaling, clathrin is recruited to form vesicles 
containing the receptor and ligand that bud from the cell membrane. The receptor is 
then released and returned to the cell surface while the ligand is degraded in lysosomes 
((Van Kerkhof et al., 2005); reviewed by (Schwartz, 1995)). Though NPxY motifs can 
induce endocytosis (Bonifacino and Traub, 2003), they also associate with intracellular 
proteins and activate pathway signaling. 
The NPxY motifs bind to scaffold and adaptor proteins to activate intracellular 
signals. The ability of intracellular proteins to associate is dependent upon the motifs 
phosphorylation status. The majority of intracellular proteins bind to the phosphorylated 
distal NPxY motif, though the non-phosphorylated form is able to bind different 
proteins and activate separate pathways (Gotthardt et al., 2000, Guttman et al., 2009). 
Distal NPxY phosphorylation can occur via association of intracellular proteins (Barnes 
et al., 2001) or by activated platelet derived growth factor receptor (Boucher et al., 
2002, Loukinova et al., 2002) and leads to phosphorylation of the proximal NPxY motif 
(Betts et al., 2008). The primary role of the proximal NPxY motif appears to be in the 
synthesis of LRP1 (Reekmans et al., 2010), but when phosphorylated it can bind a 
number of proteins similar to the distal motif (Guttman et al., 2009). Therefore, the 
ability of LRP1 to activate intracellular signaling pathways is dependent on both 
intracellular protein composition and activity of co-receptors.  
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LRP1 activity is also regulated by cleavage of its extracellular and intracellular 
domains (Figure 1.2). The extracellular domain of LRP1 can be cleaved by the amyloid 
precursor protein enzyme β-secretase to release it from the membrane (von Arnim et al., 
2005). The soluble LRP1 heavy chain has been found free in blood and can bind free 
ligands to inhibit activation of the cell bound receptor (Quinn et al., 1997). The 
formation of this soluble fraction has been conserved between mammalian, avian, 
reptilian and mollusc species and implies an important role for it in regulating LRP1 
activity (Grimsley et al., 1999). Following β-secretase cleavage, the transmembrane 
domain can be cleaved by a γ-secretase complex (May et al., 2002). This releases the 
intracellular domain that can bind to adaptor proteins (Trommsdorff et al., 1998, 
Gotthardt et al., 2000) or enter the nucleus to interact directly with transcription factors 
(Kinoshita et al., 2003). γ-secretase cleavage is regulated by glycosylation of the 
receptor, a cell specific mechanism, which modulates LRP1 mediated transcription 
activation in different tissues (May et al., 2003).  
LRP1 can modulate a variety of cellular functions due to a structure that allows 
it to bind a range of extracellular ligands and intracellular proteins. However, the 
receptors activity is tightly regulated through cell specific mechanisms including 
phosphorylation, glycosylation and expression of signaling proteins, co-receptors and 
enzymes. This ensures that while LRP1 responses are diverse, they are also specific. 
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Figure 1.2: Processing and cleavage of LRP1.
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Figure 1.2 continued: Processing and cleavage of LRP1. Low density lipoprotein 
receptor-related protein (LRP1) is translated and transported to the endoplasmic 
reticulum where it is bound to receptor associated protein (RAP) to inhibit ligand 
binding, receptor clumping and to assist with correct protein folding. In the Golgi 
apparatus the receptor dissociates from RAP and is cleaved by furin to form a 515kDa 
heavy chain bound non-covalently to an 85kDa light chain. LRP1 is transported to the 
cell membrane. Extracellular ligands can bind to the receptor for endocytosis or to 
activate intracellular pathways. Alternatively, the extracellular domain can be cleaved 
by the amyloid precursor protein enzyme β-secretase to release a 571kDa soluble 
fraction, which in turn can lose its non-covalent bond to form 515kDa and 56kDa 
fractions. Soluble LRP1 can antagonize ligand binding in plasma and cerebral spinal 
fluid. LRP1 can be subsequently cleaved by γ-secretase, releasing the 21kDa 
intracellular domain which binds intracellular proteins or translocates to the nucleus to 
regulate transcription events. 
 
Adapted from (Bu, 2009) 
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Figure 1.3: Structure, cleavage and binding sites of LRP1. Low density lipoprotein 
receptor-related protein (LRP1) is a 600kDa receptor that is cleaved by the enzyme 
furin to form two non-covalently linked subunits, a 515kDa heavy or α-chain and an 
85kDa light or β-chain. The extracellular domain of the receptor contains four regions 
(I, II, II and IV) of cysteine rich ligand binding repeats separated by endothelial growth 
factor/β-sheet motifs that mediate ligand release. A type I transmembrane domain spans 
the cell membrane. The intracellular domain contains two NPxY motifs, which bind to 
and activate intracellular proteins, and a YxxL motif and two di-leucine motifs, which 
are involved in endocytosis. 
Adapted from (Herz et al., 1990) 
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1.3.2 LRP1 IN THE NERVOUS SYSTEM 
LRP1 is expressed in a range of cells of the peripheral and central nervous 
systems. Peripheral nervous system (PNS) expression of LRP1 has been demonstrated 
in dorsal root ganglia, the sciatic nerve, Schwann cells and satellite cells (Handelmann 
et al., 1992, Campana et al., 2006, Shi et al., 2009). In the human and rodent CNS, 
LRP1 is expressed in a range of cell types throughout the brain (Table 1.2). The primary 
function of LRP1 in the CNS is not well understood, but it is able to regulate protein 
transport into the brain, cell survival, neurite outgrowth, regeneration and signaling.  
LRP1 is expressed primarily on neuron cell bodies of the cerebral cortex, 
cerebellum, thalamus, brain stem and hippocampus, though there are some reports of 
reactivity along proximal and dendritic processes (Wolf et al., 1992, Rebeck et al., 
1993, Bu et al., 1994b, Ishiguro et al., 1995, Deane et al., 2004, May et al., 2004, Liu et 
al., 2007). Further work in vitro has supported these in vivo findings and allowed more 
defined identification of LRP1 in these cells. Expression has been reported in 
hippocampal, cortical, retinal ganglion and cerebellar granule neuron cell bodies and 
dendritic processes (Brown et al., 1997, May et al., 2004, Hayashi et al., 2007, Ambjørn 
et al., 2008, Shi et al., 2009). The primary glial cells positive for LRP1 in vivo are 
astrocytes, in which expression is present in cell bodies and processes (Wolf et al., 
1992, Rebeck et al., 1993, Zheng et al., 1994, Ishiguro et al., 1995). However, microglia 
and oligodendrocytes, as well as astrocytes, express the receptor in cell bodies and 
processes in vitro (Marzolo et al., 2000, Gaultier et al., 2009). Much of the interest in 
LRP1 expression in the CNS has evolved from findings that the receptor is involved in 
Alzheimer’s disease. 
LRP1 has been associated with late onset of Alzheimer’s disease by a number of 
mechanisms. The receptor has been genetically linked to the risk of developing the 
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disease (Saher et al., 2005), and its expression is significantly altered in brains of 
patients with mild cognitive impairment and Alzheimer’s disease (Donahue et al., 2006, 
Sultana et al., 2010). Forebrain LRP1 knock-out mice display Alzheimer’s disease-like 
symptoms as they age, suggesting a role for the receptor in preventing the disease (Liu 
et al., 2010). However, overexpression of a LRP1 mini receptor in the brain increases 
soluble amyloid-β and causes spatial learning and memory deficits typical to 
Alzheimer’s disease (Zerbinatti et al., 2004). In addition, two LRP1 ligands, 
apolipoprotein E (apoE) and α2-macroglobulin, have been genetically linked to the risk 
of developing Alzheimer’s disease (Eng et al., 1968, Zhou et al., 2000, Paxinos and 
Watson, 2007, Ashwell and Paxinos, 2008). The receptor also directly associates with 
and endocytoses amyloid precursor protein (Kounnas et al., 1995) and amyloid-β, which 
it clears from the brain and circulation via the blood brain barrier (BBB) and liver, 
respectively (Shibata et al., 2000, Deane et al., 2004, Zlokovic et al., 2010). 
LRP1 is expressed on endothelial cells, astrocytic processes, pericytes and at the 
basal membrane of microvessels through the brain (Moestrup et al., 1992, Wolf et al., 
1992, Deane et al., 2004, Polavarapu et al., 2007). The receptor regulates movement of 
proteins, such as amyloid-β, across the BBB (Shibata et al., 2000, Deane et al., 2004), 
whilst also maintaining the permeability of this barrier (Yepes et al., 2003). LRP1 is 
also expressed on ependymal cells of the choroid plexus, where it most likely involved 
in transport or secretion between the brain and cerebral spinal fluid (Zheng et al., 1994). 
LRP1 at the BBB and choroid plexus is involved in transport of molecules into and out 
of the brain. In this way the receptor regulates of the brains microenvironment and is 
able to indirectly affect the function of neurons and glia. However, LRP1 expressed 
upon these cells can directly affect their function, such as survival, neurite outgrowth, 
regeneration or synaptic responses. 
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Table 1.2: LRP1 is expressed in cells of the human, rat and mouse central nervous systems 
 
Tissue Cell Location on cell Technique Animal strain Reference 
H
U
M
A
N
 
Cerebral cortex 
Neurons Cell body 
IHC  
(DAB) 
NA 
(Moestrup 
et al., 
1992) 
Astrocytes (fibrillary) 
Cell body 
Processes 
Capillaries Basal membrane 
Cerebellum 
Granule cells Cell body 
Purkinje cells Cell body 
Capillaries Basal membrane 
Cerebral cortex 
Thalamus 
Dentate nucleus 
Pyramidal neurons 
Cell body  
Proximal processes IHC  
(DAB) NA 
(Wolf et 
al., 1992) 
Cerebellar cortex Astrocytes Perivascular processes 
Cerebral cortex     WB 
Temporal cortex 
Pyramidal neurons 
Cell body 
Dendritic processes 
Proximal axons 
IHC  
(DAB) 
NA 
(Rebeck et 
al., 1993) 
Astrocytes 
Cell body 
Processes 
Hippocampus 
Pyramidal neurons  
  (CA1, CA3, CA4) 
Cell body 
Dendritic processes 
Granule neurons (DG) 
Cell body 
Dendritic processes 
Frontal cortex Endothelial cells Cell body 
IHC  
(F) 
NA 
(Deane et 
al., 2004) 
       
R
A
T
 
Choroid plexus Ependymal cells Diffuse throughout 
IHC  
(F) 
Lewis 
(Zheng et 
al., 1994) 
CNS (NS) Neurons (not shown) Focal 
CNS (NS) Astrocytes (not shown) Focal 
Cerebral cortex Neurons   IP NS (P10) 
(Bu et al., 
1994a) 
Cerebral cortex 
Hippocampus 
Brain stem 
Cerebellum 
    RPA 
NS (adult) 
Hippocampus Neurons (DG, CA3) NS 
ISH 
Cerebellum Purkinje cells Cell body 
Cerebral cortex 
Neurons  
Glia 
Cell body 
ISH 
Hooded Wistar  
(E20) 
(Ishiguro 
et al., 
1995) 
Hippocampus 
Pyramidal neurons  
  (CA3) 
Cell body 
Hooded Wistar  
(Adult) 
Cerebral cortex Neurons Cell body 
Cerebellum 
Granule cells 
Purkinje cells 
Cell body 
Whole brain     NthB 
Hooded Wistar 
(E18 to adult) 
Whole brain     WB Sprague Dawley 
(Hayashi et 
al., 2007) 
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Tissue Cell Location on cell Technique Animal strain Reference 
M
O
U
S
E
 
Cerebral cortex Neurons Cell body 
IHC  
(DAB) 
C57BL/6 
(May et al., 
2004) 
'Other regions of 
brain' 
Neurons NS 
Whole brain     
NthB 
WB 
Hippocampus  
   CA1 
Neurons Cell body IHC  
(F) C57BL/6 
(Liu et al., 
2007) Frontal cortex Pyramidal neurons Cell body 
Forebrain     WB 
Forebrain     WB C57BL/6 
(Xu et al., 
2008) 
Whole brain     Slot blot NS 
(Herz et 
al., 1988) 
Microvessels NS   
IHC 
(DAB 
C57BL/6 
(Shibata et 
al., 2000) 
Cerebral cortex 
Hippocampus  
Thalamus  
Endothelial cells Cell body 
IHC  
(F) 
C57BL/6 
(Deane et 
al., 2004) 
Table 1.2 continued: LRP1 is expressed in cells of the human, rat and mouse central 
nervous systems. Low density lipoprotein receptor-related protein-1 (LRP1) expression 
is detected in cell bodies and processes of neurons, glia and other cells of human, rat 
and mouse central nervous systems. Both LRP1 mRNA and protein have been detected 
using a range of laboratory techniques and rodent strains.  
DAB: diaminobenzidine; DG: dentate gyrus; F: fluorescence; IHC: 
immunohistochemistry; IP: immunoprecipitation; ISH: in situ hybridisation; NA: not 
applicable; NS: not specified; NthB: northern blot; RPA: RNase protection assay; WB: 
western blot 
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1.3.2.1 Regulation of neuronal survival 
The development of in vitro models of neuron survival, neurite outgrowth, 
regeneration and signaling has enabled the investigation of LRP1 function in a range of 
neuron subtypes.  
LRP1 regulates neuronal survival in a manner dependent on cell type, ligand and 
apoptotic stimuli involved (Table 1.3). LRP1 knock-down increases apoptosis of mixed 
cortical and hippocampal neurons following trophic withdrawal and amyloid-β toxicity 
in vitro (Fuentealba et al., 2009). This demonstrates a role for the receptor in 
maintaining neuron health, a finding supported by evidence that direct stimulation of 
LRP1 affects neuron survival. apoE3 with cholesterol protects against amyloid-β 
mediated apoptosis in hippocampal neurons, an outcome inhibited by addition of 
antibodies against LRP1 (Sen et al., 2012). In comparison, apoE3 with cholesterol does 
not inhibit apoptosis of retinal ganglion cells following trophic withdrawal (Hayashi et 
al., 2007). However, apoE containing lipoproteins prevent apoptosis of these cells 
following trophic withdrawal and glutamate toxicity, effects that are abolished when 
LRP1 is inhibited (Hayashi et al., 2007, Hayashi et al., 2012). In comparison, LRP1 
induces apoptosis of dorsal root ganglia (DRG) hybrid F11 cells through apoE4, though 
apoE3 does not affect these cells survival. Both RAP and an anti-sense oligonucleotide 
that caused 40-70% knock-down of LRP1 inhibited apoE4 induced apoptosis. 
Interestingly, a high dose of apoE3 (200μg/mL vs 30μg/mL) induced apoptosis in F11 
cells (Hashimoto et al., 2000). The binding domain of α2-macroglobulin prevents 
apoptosis of DRGs, but interestingly, α2-macroglobulin itself does not affect survival of 
F11 cells (Hashimoto et al., 2000, Yamauchi et al., 2013). These findings demonstrate 
that LRP1 mediated effects are significantly dependent on cell type and ligand 
properties.  
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Ligand competition also affects LRP1 mediated neuron survival. α2-
macroglobulin is able to inhibit the protective effects of apoE-containing lipoproteins 
following glutamate toxicity, though high concentrations of the lipoproteins are able to 
overcome this antagonism (Hayashi et al., 2012). α2-macroglobulin and apoE3 also 
inhibit apoE4 mediated apoptosis in DRG hybrid F11 cells (Hashimoto et al., 2000). 
This shows that the balance of ligand concentrations is important in regulating LRP1 
effects. 
The type of stress the cell is under also affects LRP1 mediated effects. α2-
macroglobulin does not affect retinal ganglion cell outcome following glutamate 
toxicity (Hayashi et al., 2012) but prevents apoptosis of these cells following trophic 
withdrawal (Hayashi et al., 2007). ApoE4-lipoproteins are less effective than apoE3-
lipoproteins at preventing apoptosis in retinal ganglion cells following trophic 
withdrawal (49.8% apoptosis vs 24.5% apoptosis; (Hayashi et al., 2007)). However, 
both ligands prevent apoptosis to a similar degree following glutamate toxicity (both 
25-30% apoptosis; (Hayashi et al., 2012)). Therefore, the LRP1 response can depend on 
the type of stress the cell is under. This may be due to differences in extracellular 
protein composition following the stress or changes in intracellular protein expression in 
response to that stress. 
1.3.2.2 Regulation of neurite outgrowth and regeneration 
LRP1 influences neurite extension in both developing and mature neuron 
systems (Table 1.3). α2-macroglobulin increases both neurite length and LRP1 
expression on cortical neurons (Rogove et al., 1999). The α2-macroglobulin binding 
domain, in addition to matrix metalloproteinase-9 and apoE containing lipoproteins, 
also enhances developing DRG neurite outgrowth (Handelmann et al., 1992, Yamauchi 
et al., 2013). This shows that even structurally distinct ligands can induce the same 
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response. Furthermore, the binding domain of α2-macroglobulin increases neurite 
outgrowth of cerebellar granule neurons, an effect that is believed to involve an 
interaction of LRP1 with Trk receptors (Shi et al., 2009). In comparison, myelin 
associated glycoprotein inhibits neurite length of these and PC12 cells by a mechanism 
involving both LRP1 and p75
NTR
 (Stiles et al., 2013). Therefore, LRP1 mediated neurite 
outgrowth is dependent on the ligand that is present and also involves co-receptor 
interactions.  
Regeneration in the mature nervous system is regulated by LRP1 both in vivo 
and in vitro. Axonal sprouting and regeneration is increased in rat spinal cord injury 
following addition of the α2-macroglobulin binding domain to the injury site (Yoon et 
al., 1998). Outgrowth of retinal ganglion cell neurites following axotomy is enhanced 
after addition of apoE containing lipoproteins. This only occurs when the lipoprotein is 
applied to the distal end of the injured axons rather than the cell body and is inhibited by 
RAP (Hayashi et al., 2004). Further studies have found that addition of α2-
macroglobulin or LRP1 siRNA and antibodies inhibit apoE-lipoprotein mediated neurite 
regeneration in this model. Regeneration of retinal ganglion cells following axotomy is 
promoted by apoE3-containing lipoprotein, but not by apoE4-containing lipoprotein or 
α2-macroglobulin (Matsuo et al., 2011). These findings further indicate that LRP1 
functions are dictated by the ligands involved, but also show that the location of the 
receptor influences its effect. 
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Table 1.3: Effect of LRP1 activation on neuronal survival, neurite outgrowth and regeneration  
 
 
Cell type Ligand Treatment Effect LRP1 inhibition/evidence Reference 
N
E
U
R
O
N
A
L
 S
U
R
V
IV
A
L
 
Mixed cortical and  
  hippocampal neurons 
NA 
Untreated No effect 
Knock-down Fuentealba et al, 2009 
Trophic 
withdrawal 
Increases apoptosis 
Amyloid-β 
toxicity 
Hippocampal neurons apoE3 + cholesterol 
Amyloid-β 
toxicity 
Prevents apoptosis 
RAP 
LRP1 antibody 
Sen et al, 2012 
Retinal ganglion cells 
apoE3 + cholesterol 
Trophic 
withdrawal 
No effect NA 
Hayashi et al, 2007 
apoE-lipoprotein 
Prevents apoptosis 
RAP  
LRP1 antibody 
LRP1 siRNA 
apoE3-lipoprotein 
Assumed given apoE- lipoprotein 
effects 
apoE4-lipoprotein 
α2-M 
apoE-lipoprotein 
Glutamate 
cytotoxicity 
Prevents apoptosis 
LRP1 antibody 
Hayashi et al, 2012 
apoE3-lipoprotein 
Assumed given apoE- lipoprotein 
effects 
apoE4-lipoprotein 
α2-M No effect 
Dorsal root ganglia 
  hybrid F11 cells 
apoE3 
NA 
No effect RAP 
LRP1 anti-sense oligonucleotide 
Hashimoto et al, 2000 
apoE4 Increases apoptosis 
apoE3 (high dose) Increases apoptosis RAP 
α2-M No effect NA 
Dorsal root ganglia α2-M NA Prevents apoptosis RAP Yamauchi et al, 2013 
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Cell type Ligand Treatment Effect LRP1 inhibition Reference 
N
E
U
R
IT
E
  
O
U
T
G
R
O
W
T
H
 
Dorsal root ganglia 
α2-M binding domain 
Untreated Increases neurite length 
RAP 
Yamauchi et al, 2013 
MMP-9 None 
apoE-lipoprotein + β-VLDL LRP1 expressed upon cells Handelmann et al, 1992 
Cerebellar granule cells 
α2-M binding domain 
Untreated 
Increases neurite length RAP Shi et al, 2009 
MAG Inhibits neurite length 
RAP 
LRP1 siRNA 
Stiles et al, 2013 
PC12 cell line 
α2-M binding domain Increases neurite length RAP Shi et al, 2009 
Cortical neurons α2-M Untreated Increases neurite length 
RAP 
Increased LRP1 expression 
Qiu et al, 2004 
    
 
 
 
R
E
G
E
N
E
R
A
T
IO
N
 
Retinal ganglion cells 
apoE-lipoprotein  
Axotomy 
Increases neurite length 
RAP Hayashi et al, 2004 
apoE-lipoprotein 
LRP1 antibody 
LRP1 siRNA 
Matsuo et al, 2011 apoE3-lipoprotein 
Assumed given apoE- lipoprotein 
effects 
apoE4-liporotein 
No effect 
α-2M 
Table 1.3 continued: Effect of LRP1 activation on neuronal survival, neurite outgrowth and regeneration. Low density lipoprotein receptor-related 
protein-1 (LRP1) activation by structurally distinct ligands can promote, inhibit or have no effect on neuronal survival, neurite outgrowth or 
regeneration. These effects are ligand and cell type dependent. The role of LRP1 in these responses was determined using a number of LRP1 inhibitors. 
α2-M: α2-macroglobulin; apoE: apolipoprotein E; MAG: myelin associated glycoprotein; MMP-9: matrix metalloproteinase-9; NA: not applicable; 
RAP: receptor associated protein; tPA: tissue-type plasminogen activator 
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1.3.2.3 Regulation of synaptic function 
While LRP1 functions to regulate outgrowth and survival in a range of neuron 
subtypes, it can also affect neuronal synaptic function and calcium signaling (Table 
1.4). The distal NPxY motif of LRP1 associates with post-synaptic proteins such as 
post-synaptic density-95 (PSD-95) (Gotthardt et al., 2000, Martin et al., 2008). During 
synaptic transmission, N-methyl-D-aspartate (NMDA) activation of the NMDA 
receptor causes calcium influx. This process can be regulated by LRP1 through acute 
(5-10 minutes) or chronic (48 hours) incubation of ligands prior to NMDA addition. 
Acute incubation of tissue-type plasminogen activator (tPA) enhances NMDA mediated 
calcium influx in cortical neurons and is inhibited by RAP (Samson et al., 2008). In 
contrast, chronic pre-treatment of α2-macroglobulin or lactoferrin inhibits NMDA 
mediated calcium responses in hippocampal neurons. These effects were abolished by 
RAP. An acute treatment of α2-macroglobulin had no effect on NMDA responses (Qiu 
et al., 2002).  
In addition to affecting calcium pathways through ligand pre-treatment, LRP1 
can directly induce NMDA receptor mediated calcium influx. This demonstrates that the 
receptor is able to affect both fast and slow acting calcium pathways. Though pre-
treatment with lactoferrin inhibits hippocampal NMDA mediated calcium responses as 
mentioned above, it has no effect on immediate calcium influx upon addition to cortical 
neurons. However, α2-macroglobulin and antibodies to one of LRP1’s ligand binding 
domains induce NMDA dependent calcium influx in these cells (Bacskai et al., 2000). 
In contrast, a similar dose of α2-macroglobulin in hippocampal neurons had no effect on 
calcium response (Qiu et al., 2002). tPA addition to primary hippocampal neurons and 
hippocampal derived HT22 cells induces NMDA receptor dependent calcium influx. 
This is inhibited by RAP and reduced by PSD-95 knock-down, suggesting that LRP1 
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mediates NMDA receptor function through PSD-95 (Martin et al., 2008). Interestingly, 
tPA has no effect on calcium influx in cortical neurons, but as mentioned previously, 
pre-treatment of these cells with tPA promotes NMDA mediated calcium influx 
(Samson et al., 2008). Once again this shows that ligand concentration and cell type are 
important in dictating LRP1 responses. In addition to regulating NMDA receptor 
responses, LRP1 can modulate glutamate receptor responses. ApoE containing 
lipoproteins inhibit glutamate mediated calcium influx in retinal ganglion cells, an 
effect inhibited by addition of antibodies against LRP1 (Hayashi et al., 2012). This 
demonstrates an ability of the receptor to associate with and affect function of multiple 
other receptors.  
LRP1 is also able to affect synaptic activity in vivo. Forebrain LRP1 knock-out 
mice display increased dendritic spine degeneration and decreased synaptophysin, PSD-
95, NMDA receptor and glutamate receptor expression in both the cortex and 
hippocampus at 18 months of age. These mice display motor and memory deficits at 13 
months, with hyperactivity and long term potentiation (LTP) deficits at 18 months (Liu 
et al., 2010). Hyperactivity and abnormalities in motor function are also observed in 
Cre-Lox LRP1 knock-out in differentiated neurons of the brain, though these effects are 
first observed at three weeks of age (May et al., 2004). However, brain morphology of 
these mice shows no signs of neurodegeneration. This could be due to the shorter time 
point at which mice were analysed (3 to 6 months old) when compared to the extensive 
neurodegeneration observed in the 18 month old forebrain knock-out mice. The lack of 
degeneration in the Cre-Lox mice suggests that abnormalities in behaviour are due to 
changes in synaptic function and neurotransmission in the CNS. Interestingly, LTP was 
not affected in hippocampal slices taken from Cre-Lox mice (May et al., 2004). This is 
despite findings that direct addition of RAP to hippocampal slices inhibits both normal 
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and tPA induced LTP. LRP1 is expressed with tPA in slices and is the primary receptor 
that tPA bound to, supporting a role for LRP1 in this process (Zhuo et al., 2000). LRP1 
knock-out models demonstrate an important role for LRP1 in behavioural and motor 
functions, a role that involves both protection against neuron death and regulation of 
neurotransmission.  
1.3.2.4 LRP1 mediated signaling 
As LRP1 can affect calcium influx in a number of cell models (Table 1.4), and 
many LRP1 mediated responses are based on calcium events, it is likely that the 
receptor is able to mediate its effects through calcium signaling mechanisms. There are 
a range of mechanisms used to control LRP1 function. Not only is the presence of a 
ligand available to bind to the receptor important, but also the balance of all ligands and 
their interactions in the environment. Cell specific proteins, such as intracellular 
signaling proteins and co-receptors, also regulate LRP1 pathway activation upon ligand 
binding. The regulation of LRP1 is particular important as it is has so many effects, is 
expressed in a range of tissues and binds an abnormally large number of ligands. One of 
these ligands of particular interest due to its effects on neuronal biology is 
metallothionein (MT). 
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Table 1.4: Effect of LRP1 on synaptic calcium responses following pre-treatment or immediate addition of ligands. Pre-treatment with low density 
lipoprotein receptor-related protein-1 (LRP1) ligands can enhance, reduce or have no effect on NMDA mediated calcium influx in neurons. Addition of 
LRP1 ligand can cause immediate calcium responses including NMDA receptor dependent calcium influx or inhibition of spontaneous calcium 
oscillations. Some ligands had no immediate effect on calcium responses. 
α2-M: α2-macroglobulin; apoE: apolipoprotein E; NA: not applicable; NMDA: N-methyl-D-aspartate; RAP: receptor associated protein; tPA: tissue-
type plasminogen activator  
 
Cell type Ligand Treatment Response LRP1 inhibition Reference 
P
R
E
- 
T
R
E
A
T
M
E
N
T
 
Cortical neurons tPA Acute incubation (5 minutes) Enhances NMDA  mediated calcium influx RAP Samson et al, 2008 
Hippocampal neurons 
α2-M 
Acute incubation (5-10 minutes) No effect on NMDA mediated calcium influx NA 
Qiu et al, 2002 Chronic incubation (48 hours) Reduces NMDA  mediated calcium influx 
RAP 
Lactoferrin Chronic incubation (48 hours) Reduces NMDA  mediated calcium influx 
 
  
  
  
IM
M
E
D
IA
T
E
  
R
E
S
P
O
N
S
E
 
HT22 cells 
tPA NA Calcium influx (NMDA receptor dependent) 
RAP 
LRP1 NPxY mutation 
Martin et al, 2008 
Hippocampal neurons 
α2-M NA No effect NA Qiu et al, 2002 
Cortical neurons 
tPA NA No effect NA Samson et al, 2008 
α2-M NA Calcium influx (NMDA receptor dependent) RAP 
Bacskai et al, 2000 LRP1 antibody NA Calcium influx (NMDA receptor dependent) - 
Lactoferrin NA No effect NA 
Retinal ganglion cells apoE-lipoprotein Glutamate Inhibits glutamate mediated calcium influx LRP1 antibody Hayashi et al, 2012 
28 
 
1.4 METALLOTHIONEIN 
There are four different isoforms in the MT family: MT-I, MT-II, MT-II and 
MT-IV (Kägi et al., 1974, Lawson et al., 1990, Quaife et al., 1994). The most common 
and best characterised members of the MT family are MT-I and MT-II. These two 
isoforms are often referred in combination as MT-I/II as they are so similar in structure, 
function and regulation in the mouse system (Searle et al., 1984). However, this may 
not be true in other mammalian species, including humans (Blackstad et al., 1970). For 
the remainder of this thesis, MT-I/II will be referred to as MT.  
MTs possess seven cysteine rich sites that bind metals such as zinc and copper 
(Kägi et al., 1974, Kojima et al., 1976). MT sequesters heavy metals (Kelly et al., 1996, 
Seamans et al., 1997), regulates the availability of metals able to interact with other 
proteins (Udom and Brady, 1980, Jiang et al., 1998) and scavenges free radicals to 
protect cells from oxidative stress (Hussain et al., 1996, Ye et al., 2003). MT has two 
known receptors, LRP1 and LRP2 (Fitzgerald et al., 2007) and can activate intracellular 
pathways through binding these receptors (Klassen et al., 2004, Ambjørn et al., 2008). 
Through LRP mediated mechanisms, MT is able to regulate neuronal survival, 
outgrowth and regeneration. 
In recent years, peptides modeled after MT subunits have been developed that 
possess similar properties. These peptides, called emtins, include emtinAn, emtinAc, 
which are based on the N- and C-terminals of MT’s α-domain, respectively (Lopes et 
al., 1994), and emtinB, which is based on MT’s β-domain (Ambjørn et al., 2008). 
Emtins are able to cross the BBB (Henze et al., 1996) and bind LRPs (Ambjørn et al., 
2008). As these peptides do not bind metals or scavenge free radicals (Ambjørn et al., 
2008), it is plausible that LRP activation is their primary mode of action and allows 
them to mediate neurotrophic responses. 
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1.4.1 METALLOTHIONEIN AND EMTIN REGULATION OF NEURON FUNCTION 
MT-IIA, an isoform of MT-II, increases wound healing following in vivo 
cortical needle-stick injury and in vitro cortical axon transection (Chung et al., 2003). 
Addition of MT, emtinAc and emtinB to cerebellar granule neurons increases 
developing neurite outgrowth and protects against apoptosis triggered by potassium 
withdrawal. These effects occurred through activation of pro-survival pathways and 
were inhibited by RAP, demonstrating a LRP dependent mechanism (Lopes et al., 1994, 
Ambjørn et al., 2008). MT is also able to promote DRG outgrowth and stimulate 
regeneration of DRG axons in vitro after scratch injury through a similar mechanism. 
The role of LRPs in these outcomes was demonstrated by RAP inhibition of effects 
(Leung et al., 2011). These findings indicate that many of the neurotrophic effects of 
MT are mediated through LRP activation. 
In addition to acting directly upon neurons, MT can also indirectly affect 
function through actions on supportive glial cells such as astrocytes. Cultured astrocytes 
undergo pro-regenerative astrogliosis in the presence of MT leading to activation of 
pathways that increase cortical neuron axon regeneration following injury (Leung et al., 
2010). Astrocytes not only respond to MT but also secrete it to be taken up by 
surrounding cortical neurons, an action inhibited by RAP (Chung et al., 2008). MT and 
emtins promote neuronal survival and regeneration in a range of neuron models. LRP 
mediated intracellular signaling is likely to be involved in this process, though the exact 
role of LRP1 is currently unknown. 
Interestingly, different MT isoform can have opposing effects through LRP 
activation. MT is a chemoattractive cue in growth cone turning in developing DRGs, 
whereas MT-III is chemorepulsive. Both these responses are inhibited by siRNA against 
either or both LRP1 and LRP2 (Landowski et al., 2011). The metal composition of MT 
also affects its function. While zinc bound MT inhibits LTP in normal hippocampal 
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slices, non-metal bound MT has no effect in untreated slices and protects against an 
amyloid-beta mediated inhibition of LTP (Herbert et al., 2012). These findings are 
consistent with past reports that similar ligands can produce different effects through 
LRP1 activation, and that the nature of the ligand is crucial in dictating these effects.  
1.5 PROJECT HYPOTHESIS AND AIMS  
The range of LRP1 expression throughout the body, its many ligands and its 
ability to dictate numerous cellular processes suggest that this receptor may be a generic 
sensor of the extracellular environment. In the nervous system, it appears particularly 
important in maintaining healthy, functional neurons and glia. LRP1 regulation is 
complex but specific to produce precise effects. Understanding the specificity of LRP1 
in different conditions is important in determining how the receptor is able to regulate 
so many different functions. LRP1 activity is affected by the ligands available to bind it 
and cell specific proteins that interact with the receptor. These in turn are determined by 
the cell LRP1 is expressed upon and its location upon that cell. Therefore, the pattern of 
LRP1 expression and how this changes in development or injury will provide insight 
into the role of the receptor in different neuronal functions.  
MTs and emtins provide an interesting tool through which to study LRP1 
function as these proteins act through LRPs, have many effects on neuron function and 
there are a range of isoforms that can have different effects. Using MT isoforms, we can 
study the effects of LRP1 activation on neuronal function and gain insight into the 
receptors’ biology.  
This thesis forms the groundwork for exploring the proposal that the diversity 
and specificity of an LRP1 response modulates neuronal function, such as regeneration. 
In this regard, I hypothesise that 1) LRP1 protein expression in vivo and in vitro 
demonstrates developmental and regional differences, and 2) injury will induce changes 
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in cellular expression of LRP1 and regeneration will be promoted in an LRP dependent 
manner following addition of MT or emtinB. 
Thus, the aims of my project are as follows: 
1. Define the expression profile of LRP1 in neurons and glia of the developing and 
mature brain through western blots and immunohistochemistry  
2. Determine the expression profile of LRP1 in cultured hippocampal neurons and 
glia as they mature through western blots and immunocytochemistry 
3. Investigate whether MT and emtinB modulate calcium signaling in hippocampal 
neurons in vitro in an LRP1 dependent manner 
4. Develop an in vitro scratch injury model to determine whether MT and emtinB 
promote regeneration of hippocampal neuron axons in an LRP1 dependent 
manner 
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2 Chapter 2: In vivo characterisation of LRP1 in the maturing rat 
brain 
 INTRODUCTION 2.1
LRP1 is a multifunctional receptor that binds a wide range of structurally 
distinct ligands and is expressed in, and regulates the function of, neurons and glia of 
the brain (Moestrup et al., 1992, Wolf et al., 1992, Rebeck et al., 1993, Zheng et al., 
1994, Ishiguro et al., 1995). In vitro models demonstrate LRP1 mediated regulation of 
neuronal survival, neurite outgrowth, regeneration and calcium signaling in a range of 
neuron subtypes (Bacskai et al., 2000, Qiu et al., 2002, Hayashi et al., 2007, Martin et 
al., 2008, Fuentealba et al., 2009, Matsuo et al., 2011, Hayashi et al., 2012, Stiles et al., 
2013, Yamauchi et al., 2013). LRP1 mediated responses vary depending on both the 
expression of cell specific intracellular proteins and availability of extracellular ligands 
present to interact with and activate the receptor (Hashimoto et al., 2000, Qiu et al., 
2002, Shi et al., 2009, Matsuo et al., 2011, Stiles et al., 2013). Therefore, LRP1 effects 
may vary in different regions of the brain due to differences in cell types and 
extracellular ligands.  
Intracellular protein composition can vary at different subcellular locations in 
the same cell, and therefore LRP1 mediated effects may vary from one subcellular 
compartment to another. In neurons, the cell body is the primary location of protein 
synthesis, dendrites receive and interpret synaptic signals and axons transmit outgoing 
signals (Haines, 2002). Therefore, receptors located in these structures may be involved 
in these functions. Glia have fundamental roles in maintaining neuron health and 
function and LRP1 expression in these cells may have implications for neuron health. 
The glia cell body, similar to the neuron, is the site of protein synthesis, but glial 
processes can have a range of functions including structurally supporting neurons and 
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surveying and maintaining the surrounding environment (Haines, 2002, Nimmerjahn et 
al., 2005). Through investigation of its subcellular location in specific regional 
populations of neurons and glia, the role of LRP1 in a given cell type may be better 
understood. 
Experimental rodent models allow investigation of LRP1 function in vivo. The 
majority of LRP1 expression studies in rats have been conducted through detection of 
mRNA or immunoblots of protein (Bu et al., 1994b, Ishiguro et al., 1995, Hayashi et al., 
2007). When LRP1 protein was visualised using immunofluorescence in one study it 
was noted on neurons and astrocytes but specific cellular localisation of the receptor 
was not commented on (Zheng et al., 1994). Differences in LRP1 expression have also 
been previously noted between developing and mature brains (Moestrup et al., 1992, 
Ishiguro et al., 1995). However, specific distribution of the receptor and how this 
changes during maturation has not been investigated thoroughly. 
The function of neurons and glia during development is very different to their 
function in the mature brain. During embryonic development, neurons proliferate at the 
subventricular zone of the neural tube (Nicholls et al., 2001). Through binding to 
subtype specific surface molecules on radial glia processes, different neuron populations 
are directed to precise brain regions (Rakic, 1972, Nowakowski and Rakic, 1979, 
Edmondson et al., 1988, Zheng et al., 1996). Once in position, neurons differentiate and 
develop dendrites and axons (Nowakowski and Rakic, 1979). Extending axons are 
directed through the brain by attractive or repulsive extracellular cues, extracellular 
matrix substrates and cell adhesion molecules to form synapses with other neurons 
(Manthorpe et al., 1983, Neugebauer et al., 1988, Serafini et al., 1994, Luo et al., 1995). 
Following the formation of a synapse, a large number of neurons undergo apoptosis and 
synaptic pruning to refine innervation pathways (Hollyday and Hamburger, 1976, 
Nakamura and O'Leary, 1989, Blaschke et al., 1996). Synaptogenesis continues post-
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natally but decreases during maturation, though it can occur in adulthood to a lesser 
degree (Huttenlocher, 1979). Once functional neuronal networks have formed, healthy 
neurons and glia must be maintained to allow for chemotransmission (Nicholls et al., 
2001).   
A healthy and functional neuronal network requires the presence of astrocytes, 
oligodendrocytes and microglia. During development, astrocytes create an environment 
permissive for neuron migration, neurite extension and synaptic formation. Astrocytes 
produce extracellular matrix components such as laminin, express cell adhesion 
molecules such as neural cell adhesion molecule, and release growth factors such as 
NGF, all of which aid in neuron and neurite guidance (Liesi and Silver, 1988, 
Neugebauer et al., 1988, Yoshida and Gage, 1991). As the brain matures, the ability of 
astrocytes to mediate axon regeneration decreases (Smith et al., 1986). An absence of 
astrocytes in vitro results in the failure of neurons to form functional, mature synapses, 
demonstrating a critical role of these cells in development and stabilisation of these 
structures (Ullian et al., 2001). This may be in part through the production of 
thrombospondins. These proteins promote synaptogenesis but are downregulated in 
adult brains. It is believed that this decrease in thrombospondins contributes to the 
decreased synaptogenesis capabilities of adult brains (Christopherson et al., 2005). 
However, astrocytes in a mature brain continue to regulate synaptic function by direct 
control of synaptic transmission through release and uptake of neurotransmitters 
(reviewed by (Perea et al., 2009)). These cells also regulate cerebral blood flow, provide 
structural and physical support to neurons of the brain and are activated to promote 
immune responses in response to injury ((Haines, 2002, Zonta et al., 2002); reviewed by 
(Sofroniew and Vinters, 2010)) 
Oligodendrocytes are also essential for correct brain development and function 
through the myelination of neuron axons to aid in conductance. Differentiation of 
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precursor oligodendrocytes into mature, myelinating cells results in the gradual decline 
of proliferative and migratory properties and increase in myelination capabilities of 
these cells (Miller et al., 1985). Precursor oligodendrocyte cells differentiate to 
progenitor cells, then to pre-oligodendrocytes that begin to associate with axons. These 
cells form immature non-myelinating cell before becoming mature non-myelinating 
cells, and eventually differentiating into mature myelinating oligodendrocyte (reviewed 
by (Baumann and Pham-Dinh, 2001)). Myelination begins at different stages of 
development in different areas of the brain. Myelination of the rat spinal cord begins at 
foetal day 19, whereas it occurs in the brain stem and frontal cortex post-natal day 1 and 
7, respectively. This process in the brain continues until about 60 days post-natally 
(Bjelke and Seiger, 1989, Bjartmar et al., 1994, Hamano et al., 1996). Very little 
myelination occurs in adults and instead oligodendrocytes maintain myelin and replace 
it during injury. Mature oligodendrocytes are renewed by oligodendrocyte precursors 
present in the adult brain in cases such as injury (Ffrench-Constant and Raff, 1986). 
However, oligodendrocyte precursors present in the adult rat differ in morphology and 
have slower migration and differentiation rates to those found in post-natal day 1 brain. 
This is believed to be due to differences in the needs for new mature oligodendrocytes 
in the adult brain compared to the developing brain (Wolswijk and Noble, 1989).  
Microglia are the primary initiators of immune responses in the central nervous 
system. They possess many properties similar to macrophages in that they can 
phagocytose and present antigens to lymphocytes, and secrete inflammatory mediators 
such as interleukin-1 that activate astrocytes (Giulian and Baker, 1985, Giulian et al., 
1986, Hickey and Kimura, 1988). Microglia are present in the central nervous system in 
either amoeboid or ramified morphology. The majority of microglia in the foetal brain 
are amoeboid. These cells phagocytose apoptotic neurons during development and 
allow functional networks to be established (Ashwell, 1990, Brockhaus et al., 1996). 
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Amoeboid microglia differentiate to ramified ‘resting’ microglia during the first 15 days 
following birth (Ling, 1979, Murabe and Sano, 1982, Wu et al., 1992). Ramified 
microglia have reduced capacity for proliferation, secretion and phagocytosis (Ilschner 
and Brandt, 1996). However, upon activation during injury or infection in the adult 
brain ramified microglia convert back to amoeboid microglia to promote inflammatory 
responses and remove pathogens and debris (Stence et al., 2001).  
 The functions of neurons and glia change significantly from the developing to 
mature brain. This is due to changes in the functional activity of the brain and creation 
of an environment that accommodates these changes. Therefore, the role of receptors 
expressed upon these cells could be expected to change as well. This is particularly 
relevant for a receptor such as LRP1 that can mediate a wide range of effects such as 
survival, neurite outgrowth and signaling that are essential in both developing and 
mature brains (Hayashi et al., 2007, Martin et al., 2008, Shi et al., 2009, Stiles et al., 
2013).  
Through identification of LRP1 expression in cells within specific regions of the 
brain, and its subcellular location upon those cells, it is possible to gain a greater 
understanding into the role of the receptor in the brain. I hypothesise that LRP1 will be 
predominately expressed in cell bodies of neurons and glia of the rat brain, and that this 
expression will change from pup to adult brain. 
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 METHODS 2.2
All experiments involving the use of animals were approved by the Animal 
Experimentation Ethics Committee of the University of Tasmania (ethics number 
A0011957), and were conducted in accordance with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes. Sprague Dawley rats were used in 
all animal experiments.  
Buffer recipes and product information for all reagents can be found in 
appendices. An LRP1 antibody that targeted the C-terminal end of the light chain 
intracellular domain was used in western blots and immunohistochemistry. 
2.2.1 WESTERN BLOT 
Adult female rats (250-300g) were euthanised by carbon dioxide asphyxiation 
and post-natal day 2 and 7 rat pups (P2 and P7 respectively) were decapitated. Brain 
tissue was harvested from three separate animals for each time point. For each animal, 
the skull was removed and brain transferred to a petri dish. The cerebellum and part of 
the brain stem was discarded and the two brain hemispheres separated using scissors. 
The cortex and hippocampus were selected for identification of LRP1 as these regions 
have been found to express the receptor previously (Rebeck et al., 1993, Bu et al., 
1994b, Ishiguro et al., 1995). The hippocampus is also an interesting tissue as it is one 
of the sites in the adult brain to undergo neurogenesis (Eriksson et al., 1998). From one 
hemisphere the midbrain was removed to expose the hippocampus which was dissected 
out. The remaining thalamus and hypothalamus were removed leaving only cortex. 
Hippocampal and cortical tissue and the remaining hemisphere were snap frozen, 
crushed using a mortar and pestle in liquid nitrogen and stored at -80°C.  
A sample of tissue was homogenised in 100μL RIPA lysis buffer with 1:100 
protease inhibitor (Thermo Scientific, USA) using an ultra-turrax. Homogenate was 
centrifuged at 13,000g for 10 minutes at 4°C and the supernatant removed. Total protein 
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concentration was determined using a BCA protein assay (Bio-Rad, USA). A working 
reagent was prepared as directed by the manufacturer. Briefly, part A and part B 
solutions were mixed by a 50:1 ratio. 200μL of working reagent was added to each well 
of a 96 well plate. Bovine serum albumin protein standards at 0.5, 1.0, 1.5, 2.0, 2.5 and 
3.0mg/mL were prepared to calculate a protein standard curve. 1μL of protein standards 
or 1μL of brain sample were mixed with the BCA reagent and incubated for 30 minutes 
at 37°C. Triplicates were prepared for each sample. Absorbance at 595nm was 
measured using a SpectraMax M2 plate reader (Molecular Devices) and SoftMax Pro 
computer program (v 4.8). A standard curve was calculated and used to determine each 
sample’s concentration. 
1mm thick sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels were prepared as 10% resolving and 5% stacking gels (see appendices). 
5μL of Spectra protein ladder (Thermo Scientific, USA) was loaded into the first lane. 
20μg protein was loaded for each sample. Samples were run using a Mini-Protean Tetra 
electrophoresis system (Bio-Rad, USA) in running buffer at 200 volts for 35-45 
minutes. Transfer to nitrocellulose paper (Thermo Scientific, USA) was conducted 
overnight using an XCell Sure Lock electrophoresis system (Life Technologies, USA) 
at 20 volts at 4°C. The nitrocellulose membrane was protein blocked using 5% milk 
powder in phosphate buffered saline with 0.05% Tween-20 (PBS-Tw) for at least 60 
minutes. Primary antibodies to the light chain of LRP1 or β-actin (housekeeping 
protein) were applied in 5% milk powder in PBS-Tw overnight at 4°C (antibody 
concentrations and combinations in Table 2.1). Controls of whole brain blots omitting 
the primary antibodies were incubated with 5% milk powder alone. The secondary 
antibody in PBS-Tw was incubated while shaking for 1 hour at room temperature. 
Three 10-minute washes with PBS-Tw occurred after each antibody incubation. Signal 
was detected using a chemiluminescent substrate (Millipore, USA). Peroxide and 
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luminol components were mixed at a 1:1 ratio and incubated with the membrane for 5 
minutes at room temperature. The membrane was exposed for 600 seconds using a 
Chemi-Smart 5000 imaging system and Chemi-Capt 5000 computer program (v 12.8). 
Natural light was used to capture the ladder. Image contrast and brightness were 
uniformly enhanced using Adobe Photoshop (v 11.0.2).  
2.2.2 IMMUNOHISTOCHEMISTRY  
Three P2 and three P7 rats were decapitated and the skull removed to expose the 
brain which was dissected out and drop fixed in 4% paraformaldehyde overnight. Three 
adult male rats (~250g) were intraperitoneally injected with 0.1mL/100g pentobarbitone 
(60mg/mL; Troy Laboratories, Aus). Reflexes were tested and once negative rats were 
transcardially perfused with PBS followed by 4% paraformaldehyde. The brain was 
removed and transferred to 4% paraformaldehyde overnight. All brain tissue was placed 
sequentially in 10%, 20% and 30% sucrose overnight for cryoprotection.  
Brains were frozen in cryomatrix and sectioned coronally at 10μm on a Leica 
CM 1850 UV cryostat. Sections were washed with PBS and dried overnight at 37°C 
prior to antigen retrieval with citrate buffer. Sections were immersed in citrate buffer 
(see appendices) and cooked at maximum pressure in a pressure cooker for 6 minutes. 
Pressure was decreased to 65% for an additional 14 minutes. Sections were cooled to 
room temperature and washed for 10 minutes three times in PBS. They were then 
incubated in 10% goat serum (Vector Laboratories, USA) in 0.03% triton X-100 (Lab-
Chem, USA) in PBS for 30 minutes at room temperature to block non-specific protein 
binding. This was followed by incubation in primary antibodies diluted in 10% goat 
serum at room temperature for 1 hour and overnight at 4°C. LRP1 primary antibody was 
incubated with primary antibodies against either GFAP (astrocytes), MAP2 (dendrites), 
NeuN (neuron cell bodies), olig2 (oligodendrocytes), SMI-312 (axons) or tomato lectin 
(microglia; Table 2.1). Negative controls of sections omitting the primary antibodies 
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were incubated with 10% goat serum alone. Next, sections were incubated with 
secondary antibodies diluted in PBS for 1 hour at room temperature. Sections were 
washed three times by gentle shaking in PBS for 5 minutes following each antibody 
application. Nuclei were visualised by incubating sections with 10μg/mL DAPI 
(Molecular Probes, USA) for 5 minutes at room temperature. Glass coverslips were 
mounted to slides using fluorescent mounting media (Dako, USA) and dried overnight. 
To determine regional specificity of LRP1 in P2 and adult rats, sections located 
between -3.5 and -4.0 to bregma were immunostained for NeuN, GFAP, tomato lectin 
or olig2 were taken at 20X objective on an Olympus BX50 microscope using a 
Photomatrix Cool Snap HQ
2
 camera. Photographs were taken from the cerebral cortex 
(P2 = 8 sections; adult = 25 sections), hippocampus (P2 = 10 sections; adult = 12 
sections), corpus callosum (P2 = 3 sections; adult = 5 sections), thalamus (P2 = 4 
sections; adult = 7 sections) and hypothalamus (P2 = 3 sections; adult = 5 sections; 
Figures 2.1 and 2.2). Images were taken from the motor, somatosensory, auditory, 
entorhinal and piriform cortex and as there were no differences in LRP1-positive cells 
between these regions, values were pooled and recorded collectively as ‘cortex’. 
Similarly, the stratum radiatum and cornu ammonis (CA) regions, CA1, CA2 and CA3, 
of the hippocampus displayed no difference in positive LRP1 cells and values for these 
regions were pooled and recorded collectively as ‘CA’.  
To determine cellular specificity of LRP1, photographs of sections 
immunolabelled for LRP1 with either GFAP, MAP2, NeuN, olig2, SMI-312 or tomato 
lectin were taken at 40X objective on an Olympus BX50 microscope using a 
Photomatrix Cool Snap HQ
2
 camera. Images were merged and uniformly enhanced 
using Adobe Photoshop (v 11.0.2). Values were recorded as 0-1 (0), 1-10 (+), 10-50 
(++), 50-100 (+++) or >100 cells/mm
2
 (++++). 
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LRP1 R 1:1000 Goat anti-rabbit HRP 1:1000 
 
β-actin M 1:20,000 Goat anti-mouse HRP 1:5000 
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Primary Type Dilution Secondary Conjugate Dilution Target 
GFAP M 1:1000 Goat anti-mouse AlexaFluor®-488 1:1000 Astrocytes 
LRP1 R 1:1000 Goat anti-rabbit AlexaFluor®-594 1:1000 
C-terminus of 
LRP1 light chain 
MAP2 M 1:1000 Goat anti-mouse AlexaFluor®-488 1:1000 Dendrites 
NeuN M 1:100 Goat anti-mouse AlexaFluor®-488 1:1000 
Neuron cell 
bodies 
Olig2 M 1:500 Goat anti-mouse AlexaFluor®-488 1:1000 Oligodendrocytes 
SMI-312 M 1:1000 Goat anti-mouse AlexaFluor®-488 1:1000 Axons 
Tomato lectin 
(Biotin) 
  1:1000 Streptavidin AlexaFluor®-488 1:1000 Microglia 
Table 2.1: A list of working dilutions of primary antibodies, their targets and respective 
secondary antibodies used for western blot and immunohistochemistry analysis. 
Antibodies were either polyclonal rabbit (R) or monoclonal mouse (M) antibody.  
HRP: horse radish peroxidase 
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 Figure 2.1: Brain regions photographed for semi-quantitative values of LRP1 regional 
localisation in the post-natal day 2 rat brain. Images of LRP1 with either GFAP, NeuN, 
olig2 or tomato lectin were taken at 20X objective and LRP1-positive cells counted. 
Images were taken from regions of the cerebral cortex (Cx), corpus callosum (CC), 
cornu ammonis region of the hippocampus (CA), stratum radiatum and fimbria of the 
hippocampus (Hp SR and Hp Fi, respectively), dentate gyrus (DG), thalamus (Th) and 
hypothalamus (HyT).  
Scale bar = 1000μm  
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Figure 2.2: Brain regions photographed for semi-quantitative values of LRP1 regional 
localisation in the adult rat brain. Images of LRP1 with either GFAP, NeuN, olig2 or 
tomato lectin were taken at 20X objective and LRP1-positive cells counted. Images 
were taken from regions of the cortex (Cx), corpus callosum (CC), cornu ammonis of 
the hippocampus (CA), stratum radiatum and fimbria of the hippocampus (Hp SR and 
Hp Fi, respectively), dentate gyrus (DG), thalamus (Th) and hypothalamus (HyT). 
Scale bar = 1000μm  
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 RESULTS 2.3
2.3.1 CLEAVAGE PATTERN OF LRP1 CHANGES DURING DEVELOPMENT 
Western blot detection demonstrated that the processing of LRP1 changed 
during maturation. In whole brain, a ~85kDa band corresponding to the LRP1 light 
chain was the predominant form, and was expressed at higher levels in P2 and P7 
compared to adult tissue (Figure 2.3 A). P2 and P7 brains also expressed a ~130kDa and 
~100kDa band that was not present in the adult. Bands at ~80kDa and between ~40-
60kDa were present at all time points but decreased in strength from P2 to P7 to adult. 
Bands at both ~150kDa and ~40kDa were also in all time points but were stronger in 
adults compared to P2 and P7. A band at ~70kDa was only present in adult whole brain.   
The light chain ~85kDa band appeared to be expressed at slightly higher levels 
in P7 than P2 cortical tissue, though both were stronger than adult (Figure 2.3 B). As for 
whole brain, the ~130kDa and ~100kDa band observed in P2 and P7 cortical tissue was 
not present in adult. Faint bands from ~37-60kDa were present in P7 tissue but were 
stronger in adult. A ~70kDa band was only observed in adult tissue. Similar to whole 
brain and cortical tissue, hippocampal tissue of P2 and P7 rats showed higher 
expression of a ~85kDa form than adult tissue (Figure 2.3 C). A ~130kDa band was 
present in P2 and P7 tissue but not adult. Lower molecular weight bands ranging from 
~37-70kDa were more intense in adult than P2 and P7. 
Differences in LRP1 expression pattern between whole brain, cortical and 
hippocampal tissue were observed for each developmental time point. The light chain 
~85kDa band was expressed to a similar degree in all tissues of P2 rats (Figure 2.3 A-C, 
left 3 lanes). A ~130kDa band was present in whole brain and cortex but was present at 
lower levels in the hippocampus. Whole brain and cortical tissue expressed a ~100kDa 
band but this was not present in hippocampal tissue. A number of bands between ~40-
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70kDa were present in whole brain and these were fainter in hippocampal tissue and 
absent from cortical tissue. A ~80kDa band was only present in whole brain. 
Expression of LRP1 in P7 brain was very similar to P2 expression throughout all 
tissues (Figure 2.3 A-C, middle 3 lanes). The ~85kDa was present in comparable 
amounts in all tissue types, and a ~130kDa band was stronger in whole brain and 
cortical tissue compared to hippocampal tissue. Whole brain and cortex also expressed a 
~100kDa band that was absent from the hippocampus. The ~80kDa band was only in 
whole brain, and bands at ~40-70kDa were also stronger in this tissue, though some of 
these were faintly positive in cortical and hippocampal tissue.  
A similar amount of the ~85kDa band was in all adult tissue (Figure 2.3 A-C, 
right 3 lanes). Whole brain was the only tissue to express ~150kDa and ~80kDa bands. 
Bands at ~38kDa, ~40kDa and ~70kDa were present in whole brain and cortical tissue 
but not hippocampal tissue. A greater number of faint bands between ~45-60kDa were 
observed in hippocampal tissue, though some of these were also present in whole brain 
and cortex to a lesser extent. Negative controls of whole brain blots omitting primary 
antibodies showed no immunoreactivity (Figure 2.3 D). 
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Figure 2.3: LRP1 is expressed in post natal day 2 (P2), day 7 (P7) and adult rat 
hippocampus. Whole brain (A), cortical (B) or hippocampal tissue (C) was collected 
from 3 separate animals for either P2 (left 3 lanes), P7 (middle 3 lanes) or adult rats 
(Ad; right 3 lanes). 20μg total protein for each sample was run on an SDS-PAGE gel 
and probed with anti-LRP1 or anti-β-actin antibodies. Similar amounts of protein were 
loaded for each sample (β-actin). Controls of whole brain blots omitting primary 
antibodies were negative for non-specific secondary antibody binding (D). Molecular 
weights of bands were determined using a commercial protein ladder (L). 
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2.3.2 LRP1 IS EXPRESSED IN NEURON AND GLIA CELL BODIES OF P2, P7 AND 
ADULT RAT BRAINS 
Immunohistochemistry showed that LRP1 expression was present on neurons, 
astrocytes, oligodendrocytes and microglia of P2, P7 and adult rat brains. Punctate 
immunoreactivity of LRP1 in P2 and P7 rat brains appeared to be both cellular and 
extracellular throughout the cortex, hippocampus, thalamus, hypothalamus and corpus 
callosum. LRP1 immunoreactivity in adult brain was punctate and cellular throughout 
all regions of the brain.  
LRP1 was expressed at all time points in a subpopulation of neuronal cell bodies 
of the cerebral cortex (Figure 2.4 A, C, E) and pyramidal layer of the hippocampus 
(Figure 2.4 B, D, F), as well as some neurons in the thalamus and hypothalamus (data 
not shown). A small number of dendrites were LRP1-positive in the P2, but not P7 
cerebral cortex brain (Figure 2.5 A, C). The proximal segments of adult apical dendrites 
were LRP1-positive (Figure 2.5 E) while axons were negative for LRP1 
immunoreactivity at all time points and in all brain regions including the cerebral cortex 
and hippocampus (Figure 2.5 B, D, F).  
Subpopulations of astrocytes, oligodendrocytes and microglia express LRP1 in 
P2, P7 and adult rat brains. LRP1 was present in astrocyte cell bodies and foot processes 
lining some blood vessels (Figure 2.6 A-C). Cell bodies and processes of 
oligodendrocytes (Figure 2.7 A-C) and microglia were also LRP1-positive at all time 
points (Figure 2.8A-C). LRP1 expressing microglia had a ramified appearance. The 
receptor was expressed on some endothelial cells in P2 and P7 brains (Figure 2.8 A-B) 
but not in adult brains. The choroid plexus, used as a positive LRP1 control, was 
strongly LRP1 immunoreactive at all time points (Figure 2.9 A, C, E). Negative controls 
omitting primary antibodies showed no immunoreactivity (Figure 2.9 B, D, F).  
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Figure 2.4: LRP1 is expressed on neuron cell bodies of post-natal day 2 (P2), day 7 
(P7) and adult rat brain. 3 separate brains at each time point were sectioned at 10μm and 
immunolabelled for LRP1 (red) and NeuN (neuron cell bodies; green). Cell bodies of a 
subpopulation of neurons in the cerebral cortex and cornu ammonis regions (CA) of the 
hippocampus were LRP1-positive in P2 (A and B; arrows), P7 (C and D; arrows) and 
adult brains (E and F; arrows).  
Scale bar = 50μm 
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Figure 2.5: LRP1 is expressed upon dendrites of adults and some post-natal day 2 (P2) 
neurons. 3 separate brains at each time point were sectioned at 10μm and 
immunolabelled for LRP1 (red) and MAP2 (dendrites) or SMI-312 (axons; both green). 
Very few dendrites were LRP1-positive in P2 brain (A; arrow), and no dendrites were 
positive in post-natal day 7 (P7) brains (C). Proximal segments of adult neuron 
dendrites were LRP1-positive (E; arrows). Axons were not LRP1-positive in P2 (B), P7 
(D) or adult brain (F). Nuclei were counterstained with DAPI (blue). 
Scale bar = 50μm 
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Figure 2.6: LRP1 is expressed on astrocytes of post-natal day 2 (P2), day 7 (P7) and 
adult rat brain. 3 separate brains at each time point were sectioned at 10μm and 
immunolabelled for LRP1 (red) and GFAP (green). Astrocyte cell bodies in P2 (A; inset 
& arrow), P7 (B; inset and arrow) and adult brains (C; arrows), and foot processes 
around some blood vessels (c; inset and arrowheads), were LRP1-positive. Nuclei were 
counterstained with DAPI (blue). 
Scale bar (A, B, C) and inset in C = 50μm; A and B inset scale bar = 33μm 
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Figure 2.7: LRP1 is expressed on oligodendrocytes of post-natal day 2 (P2), day 7 (P7) 
and adult rat brain. 3 separate brains at each time point were sectioned at 10μm and 
immunolabelled for LRP1 (red) and olig2 (green). A subpopulation of oligodendrocytes 
were LRP1-positive in cell bodies and processes in P2 (A; arrows), P7 (B; arrows and 
inset) and adult brains (C; arrows and inset). Nuclei were counterstained with DAPI 
(blue). 
Scale bar = 50μm; B inset scale bar = 30μm; C inset scale bar = 33μm  
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Figure 2.8: LRP1 is expressed on microglia of post-natal day 2 (P2), day 7 (P7) and 
adult rat brain. 3 separate brains at each time point were sectioned at 10μm and 
immunolabelled for LRP1 (red) and tomato lectin (green). LRP1 is expressed on a 
subpopulation of microglia cell bodies and processes in P2 (A; arrows), P7 (B; arrows) 
and adult brains (C; arrows and inset). Some endothelial cells in P2 and P7 brains were 
also LRP1-positive (A and B inset; grey arrows). Nuclei were counterstained with DAPI 
(blue). 
Scale bar = 50μm; B inset scale bar = 50μm; C inset scale bar = 25μm
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Figure 2.9: Positive and negative controls for LRP1 immunohistochemistry. The 
choroid plexus was used as an LRP1-positive control for post-natal day 2 (P2; A), day 7 
(P7; C) and adult rat brain (E). 3 separate brains at each time point were sectioned at 
10μm and immunolabelled for LRP1 (red) and tomato lectin (endothelial cells; green). 
Ependymal cells of the choroid plexus were strongly positive for LRP1 at every time 
point. Negative controls of sections omitting primary antibodies were immunonegative 
for non-specific secondary binding in P2 (B), P7 (D) and adult rat brains (F). Nuclei 
were counterstained with DAPI (blue). 
Scale bar = 50μm   
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2.3.3 LRP1-POSITIVE NEURONS AND GLIA ARE LOCATED THROUGHOUT THE 
P2 AND ADULT RAT BRAIN 
Semi-quantitative analysis of sections examined by immunohistochemistry 
showed that LRP1 expressing cells were present at higher levels in P2 brains compared 
to adults (Table 2.2; 38.9 ± 5.6 vs 22.3 ± 4.2 cells/mm
2
 respectively). The most 
abundant LRP1-positive cells in P2 brains were neurons throughout grey matter, except 
for the thalamus. The regions with the greatest number of LRP1-positive neurons were 
the cortex and CA region of the hippocampus. Of these two areas, the CA region of the 
hippocampus had about two and a half times as many positive neurons as the cortex 
(273 ± 17 vs 105 ± 7 cells/mm
2 
respectively). In comparison, there were fewer positive 
neurons in the dentate gyrus and hypothalamus, and the thalamus had the least number 
of LRP1-positive neurons. Oligodendrocytes were the most abundant LRP1-positive 
glia cells in white matter regions of the corpus callosum and hippocampal fimbria. 
There were LRP1-positive oligodendrocytes throughout the grey matter, though to a 
lesser extent. LRP1-positive astrocytes and microglia were located throughout both grey 
and white matter regions of the brain.  
LRP1-positive neurons of the adult rat brain were predominately located in the 
CA region and dentate gyrus of the hippocampus. Similar numbers of LRP1 expressing 
neurons were observed in the cortex and hypothalamus. The region with the least 
number of LRP1-positive neurons was the thalamus. The white matter tracts of the 
corpus callosum and hippocampal fimbria were the region’s most prolific in LRP1-
positive astrocytes and oligodendrocytes. As for P2 brains, microglia were the glial type 
that displayed the least number of total LRP1-positive cells, and this was consistent 
across all regions of the brain.  
The number and regional location of LRP1-positive neurons, astrocytes and 
oligodendrocytes changed from P2 to adult rat brains. There were more LRP1-positive 
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neurons in the cortex, thalamus and hypothalamus of the P2 brain compared to the adult 
brain. There were almost twice as many positive neurons of the P2 CA region compared 
to the adult (P2 = 273 ± 17 cell/mm
2
; adult = 162 ± 35 cell/mm
2
). However, there were 
more LRP1 expressing neurons in the adult dentate gyrus than the P2.  
P2 rats had more LRP1-positive astrocytes in the dentate gyrus of the 
hippocampus compared to the adult. However, there were more of these cells positive 
for LRP1 in the adult CA regions and fimbria of the hippocampus, thalamus, 
hypothalamus and corpus callosum compared to the P2 brain. Similar numbers of 
LRP1-positive astrocytes were observed in the cerebral cortex. There were greater 
numbers of LRP1 expressing astrocytes in the adult than P2 brain in all other regions, 
except the dentate gyrus of the hippocampus where there were more in the P2 brain. 
Similar numbers of LRP1-positive oligodendrocytes were observed in the grey matter of 
P2 and adult rat brains. P2 rat brains had more LRP1-positive oligodendrocytes in white 
matter regions of the corpus callosum and hippocampal fimbria than the adult. No 
differences were observed in LRP1-positive microglia between P2 and adult brains 
except for the hippocampal fimbria where there were slightly greater numbers of LRP1-
positive cells in the P2.  
Overall there were more LRP1-positive cells in P2 rat brain compared to adult 
rat brain. This was largely due to greater numbers of LRP1-positive neurons and 
oligodendrocytes, and is consistent with western blot data that demonstrate greater 
LRP1 immunoreactivity in P2 brains compared to adult brains.  
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Table 2.2: LRP1-positive cells are present in different brain regions of the post-natal day 2 (P2) and adult rat brain. LRP1 was immunolabelled in 3 
separate P2 or adult rat brains with either NeuN (neuron cell bodies), olig2 (oligodendrocytes), GFAP (astrocytes) or tomato-lectin (T-L; microglia). 
Photographs were taken of the cerebral cortex, hippocampus (cornu ammonis regions (CA), hippocampal fimbria and dentate gyrus (DG)), thalamus, 
hypothalamus and corpus callosum and LRP1-positive cells counted. Cell counts were recorded as 0-1 (0), 1-10 (+), 10-50 (++), 50-100 (+++) or >100 
(++++) cells/mm
2
.  
NA: not applicable 
 
 
   
Hippocampus 
        
 
Cortex CA Fimbria DG Thalamus Hypothalamus Corpus callosum Total 
 
P2 Adult P2 Adult P2 Adult P2 Adult P2 Adult P2 Adult P2 Adult P2 Adult 
NeuN ++++ ++ ++++ ++++ NA NA +++ ++++ ++ + +++ ++ NA NA +++ ++ 
GFAP + + + ++ ++ +++ ++ + + ++ + ++ ++ +++ ++ ++ 
Olig2 ++ ++ ++ ++ ++++ +++ ++ ++ ++ ++ ++ ++ ++++ +++ +++ ++ 
T-L + + + + ++ + + + + + + + + + + + 
Total 
(cells/mm²) 
++ ++ ++ ++ +++ +++ ++ ++ ++ + ++ ++ +++ ++ 
++ 
(38.9) 
++ 
(22.3) 
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 DISCUSSION 2.4
Western blot and immunohistochemical analysis have demonstrated that LRP1 
is expressed in the brain of P2, P7 and adult rats. The expression pattern of the receptor 
changes during maturation and is predominately located on cell bodies of a 
subpopulation of neurons, astrocytes and oligodendrocytes throughout the cortex, 
hippocampus, hypothalamus, thalamus and corpus callosum. A small subset of 
microglia were also LRP1-positive. 
2.4.1 THE CLEAVAGE PATTERN OF LRP1 CHANGES DURING MATURATION 
OF THE RAT BRAIN 
 A number of bands ranging from ~37kDa to ~150kDa were observed 
throughout whole brain, cortical and hippocampal tissue of P2, P7 and adult rat brain. 
The antibody used for these experiments binds C-terminal end of the intracellular 
domain of the LRP1 light chain. The LRP1 light chain undergoes a number of post-
translational modifications, including cleavage by β- and γ-secretase (May et al., 2002, 
von Arnim et al., 2005), phosphorylation of NPxY intracellular domains (Barnes et al., 
2001, Guttman et al., 2009) and glycosylation of the light chain (Quinn et al., 1999, 
May et al., 2003) (Figure 2.10). These modifications allow for the tight regulation of 
LRP1 function.  
Bands of a molecular weight larger than the ~85kDa light chain were observed 
at 100kDa and 130kDa of P2 and P7 brains, and at 150kDa of adult brain. These forms 
of LRP1 most likely correspond to glycosylated or phosphorylated forms of this 
domain. Wolf and colleagues (1992) observed a 130kDa band in western blots of 
human cerebral cortex using antibodies targeting both the heavy and light chain of 
LRP1. They hypothesised that this corresponded to digestion products of the LRP1 
heavy chain. However, as the antibody used in the present experiments labels the C-
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terminal of the light chain, the product observed here is unlikely to be a heavy chain 
product.  
The main band detected for all time points in whole brain, cortical and 
hippocampal tissue was at ~85kDa. This corresponded to the light chain, which is 
normally non-covalently linked to the heavy chain of LRP1. It is likely that the non-
covalently bound heavy and light chains of the LRP1 receptor dissociate during 
reduction in preparation for western blot analysis. Previous studies have demonstrated 
the detection of similar molecular weight bands (Herz et al., 1990, Wolf et al., 1992, 
Ambjørn et al., 2008).  
Bands of a lower molecular weight than the ~85kDa light chain most likely 
correspond to cleaved forms of the light chain. These bands ranged from 30kDa to 
80kDa in P2, P7 and adult tissues. The extracellular segment of the LRP1 light chain 
can be cleaved by β-secretase to produce a ~30kDa product (von Arnim et al., 2005). It 
is possible that the ~37 to ~80kDa bands observed correspond to the cleaved fraction of 
the LRP1 light chain that has been glycosylated or phosphorylated. Previous data 
demonstrate alterations in light chain LRP1 band sizes between ~50kDa to ~80kDa due 
to glycosylation (Quinn et al., 1999, Ambjørn et al., 2008). Therefore, the different 
sized bands observed here could correspond to different stages of LRP1 post-
translational modifications. 
There was greater expression of the ~85kDa light chain band in P2 and P7 brains 
compared to adult in whole brain, cortical and hippocampal tissue. This demonstrates 
that overall expression of LRP1 is greater in the younger brain, consistent with findings 
from previous studies (Moestrup et al., 1992, Ishiguro et al., 1995). ~100kDa and 
~130kDa bands observed in P2 and P7 whole brain and cortical tissue were not 
observed in any adult tissue, suggesting that these LRP1 forms have a developmental 
role. Adult cortical and hippocampal tissue showed a number of lower molecular weight 
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bands between ~37-70kDa that were absent or faint in P2 and P7 samples. These 
fractions, therefore, may have a role in the mature brain but not in the developing brain. 
These findings demonstrate that the post-translational regulation of LRP1 changes from 
the developing to mature brain. 
Hippocampal tissue in P2 and P7 brain did not express the ~100kDa band and 
only faintly expressed the ~130kDa observed in whole brain and cortical tissue. This 
suggests that higher molecular weight forms do not have as an important role in 
development of this region of the brain. However, hippocampal tissue did express a 
number of lower molecular weight bands that were absent from the cortex in P2 brain, 
and reduced in P7. This demonstrates that the cleavage and maturation of LRP1 is 
regionally specific during the first week of post-natal development. 
Adult whole brain expressed a ~150kDa band that was not observed in cortical 
or hippocampal tissues, suggesting that this form of LRP1 is expressed in a brain region 
other than these. A ~70kDa band observed in whole brain and cortical tissue was not 
present in hippocampal tissue. There were also stronger bands at ~37kDa and ~40kDa 
in cortical tissue than hippocampal, but the latter tissue expressed more lower weighted 
bands between ~40-70kDa. These data provide evidence that post-translational 
modifications and regulation of LRP1 in cortical tissue differ from that of hippocampal 
tissue in adult tissue.  
The identity of each LRP1-positive band in whole brain, cortical and 
hippocampal rat tissue is currently unknown. However, these findings demonstrate that 
post-translational modifications of LRP1 differ between rat brain regions and stages of 
maturity. This suggests that regulation, and therefore function, of LRP1 is dependent on 
the tissue in which it is expressed and its stage of development. 
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Figure 2.10: Post-translational modifications of the LRP1 light chain that may 
correspond to bands detected on western blots. The LRP1 antibody binds the C-terminal 
of the intracellular domain of the light chain. The ~85kDa light chain of LRP1 can be 
phosphorylated or glycosylated to produce a larger molecular weight form. This form 
dissociates from the LRP1 heavy chain that during western blot processing and is 
detected at ~100-150kDa. Alternatively, the ~85kDa light chain can be cleaved by β-
secretase to yield a ~30kDa form of LRP1 and the soluble heavy chain. This form of 
LRP1 can be phosphorylated or glycosylated to produce a ~40-80kDa form.  
Adapted from (Bu, 2009) 
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2.4.2 LRP1 IS EXPRESSED IN CELL BODIES AND PROCESSES OF NEURONS 
AND GLIA 
Immunoreactivity of LRP1 appeared more widespread in P2 and P7 rat brains 
compared to adult brain, supporting western blot data. Immunohistochemical analysis 
demonstrated that LRP1 is localised to cell bodies of a subset of P2 and P7 neurons, and 
cell bodies and proximal segments of apical dendrites of adult neurons. The receptor 
was also expressed in the cell bodies of a subset of astrocytes, and cell bodies and 
processes of a subset of oligodendrocytes and microglia. There appeared to be 
extracellular, punctate staining of LRP1 throughout all regions of the P2 and P7 but not 
in the adult brain. The antibody used in these experiments targets the intracellular 
domain of the receptor, so this LRP1 product cannot be soluble LRP1 as this fragment 
is only composed of the extracellular domain (von Arnim et al., 2005). It is currently 
unclear what this apparent extracellular staining seen in the work shown here is, though 
this pattern of staining has been noted before in human foetal tissue (Moestrup et al., 
1992) and suggests a role for this LRP1 fragment in development. 
The choroid plexus was consistently abundant in LRP1 between pups and adults 
and corresponded to expression patterns previously reported (Zheng et al., 1994). 
Interestingly, LRP1 immunoreactivity has been found to be absent in the choroid plexus 
of human brain (Wolf et al., 1992, Lopes et al., 1994). Whether these discrepancies are 
due to species or technical differences is currently unknown.  
2.4.2.1 LRP1 expression in neurons 
LRP1 regulates the survival and signaling of healthy neurons in vitro (Bacskai et 
al., 2000, Qiu et al., 2002, Hayashi et al., 2007, Martin et al., 2008, Fuentealba et al., 
2009, Sen et al., 2012). Though LRP1 was not expressed in axons and therefore is 
unlikely to be involved in pre-synaptic activity, it was present at the proximal segment 
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of apical dendrites. This site possesses specific synaptic characteristics that LRP1 may 
have a role in. Mossy fibres of the dentate gyrus synapse at the proximal end of apical 
dendrites on CA3 pyramidal neurons of the hippocampus (Blackstad et al., 1970, Henze 
et al., 1996). In addition, synapses on proximal apical dendrites can amplify excitatory 
post-synaptic potentials initiated in distal segments of prefrontal cortical neurons 
(Seamans et al., 1997). Calcium accumulation also varies between proximal and distal 
segments of apical dendrites suggesting different roles at these sites (Yuste et al., 1994). 
LRP1 is able to associate with synaptic proteins including PSD-95 and NMDA receptor, 
and affects neurotransmitter mediated calcium influx (Gotthardt et al., 2000, May et al., 
2004, Martin et al., 2008, Hayashi et al., 2012). Therefore, LRP1 may have a role in 
regulation of synaptic activity at proximal segments of apical dendrites, and therefore 
the signaling potential of LRP1 expressing neurons in the adult brain.  
Numbers of LRP1 expressing neurons decreased from P2 to adult in the CA 
region of the hippocampus, cerebral cortex, thalamus and hypothalamus, suggesting that 
there may be a role of LRP1 in the development of neurons in these regions. Following 
synaptogenesis, which occurs embryonically and post-natally, a large proportion of 
neurons undergo apoptosis to refine neuronal networks (Huttenlocher, 1979, Blaschke 
et al., 1996). However, many neurons need to remain alive and functional and this 
process can be regulated by neurotrophins (reviewed by (Yuan and Yankner, 2000)). 
LRP1 can interact with neurotrophin receptors (Shi et al., 2009) and activate the same 
intracellular pathways as neurotrophins to promote neuronal survival (Fuentealba et al., 
2009). The role of LRP1 in developing neurons may be in the regulation of their 
apoptosis during this critical stage. 
LRP1-positive neurons of the adult brain were found predominately in the CA 
regions and dentate gyrus of the hippocampus. There were more LRP1-positive neurons 
in the adult dentate gyrus of the hippocampus compared to the P2 brain. This suggests 
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that LRP1 has a function specific to mature hippocampal neurons. The hippocampus is 
a region of the brain involved primarily in learning and memory (Scoville and Milner, 
1957). Significant memory impairments and hippocampal neuron loss occur following 
events such as ischaemia and Alzheimer’s disease, suggesting that it is a region of the 
brain that is particularly vulnerable to injury and disease (Zola-Morgan et al., 1986, 
Kesslak et al., 1991, Wood et al., 1993, Laakso et al., 1995). Different regions of the 
hippocampus also display specific vulnerabilities. For example, granule cells of the 
dentate gyrus undergo degeneration following removal of the adrenal glands and 
corticosterone, though neurons of the CA regions of the hippocampus are unaffected 
(Sloviter et al., 1989). In comparison, ischaemia causes significant loss of CA1 neurons 
but the CA3 region and dentate gyrus are unaffected (Zola-Morgan et al., 1986). LRP1 
may be expressed in specific neuron populations to protect them from apoptosis. LRP1 
knock-down both in vivo and in vitro increases the vulnerability of cortical and 
hippocampal neurons to apoptosis. Knock-out of LRP1 in mouse forebrain neurons 
causes neurodegeneration of the cerebral cortex and hippocampus in a manner similar to 
Alzheimer’s disease (Liu et al., 2010). Hippocampal and cortical neurons in vitro also 
undergo increased apoptosis during trophic withdrawal and amyloid-β toxicity when 
LRP1 is knocked-down (Fuentealba et al., 2009). These studies support the idea that 
LRP1 could protect neurons from apoptosis. This may be particularly important in a 
region such as the hippocampus that appears already vulnerable to injury and disease. 
2.4.2.2 LRP1 expression in oligodendrocytes 
The majority of LRP1-positive oligodendrocytes were located in white matter of 
P2 and adult rat brain, though some cells were located throughout grey matter. LRP1 
mRNA has been identified in rat brain cells likely to be oligodendrocytes (Ishiguro et 
al., 1995, Saher et al., 2005) but expression of the LRP1 protein has not been 
definitively identified in these cells previously. In vitro work has demonstrated greater 
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LRP1 mRNA and protein expression in oligodendrocytes than both astrocytes and 
microglia (Gaultier et al., 2009). Interestingly, studies in human tissue have reported the 
absence of LRP1 immunoreactivity in oligodendrocytes of human brain (Moestrup et 
al., 1992, Wolf et al., 1992, Lopes et al., 1994). These disparities may be due to species 
or technical differences.  
LRP1 was expressed in a subset of oligodendrocytes and establishing what 
maturity these cells are could aid in determining whether the receptor is involved in the 
myelination process. Olig2 is a transcription factor expressed by oligodendrocytes 
throughout maturity (Zhou et al., 2000). Oligodendrocytes mature over a number of 
steps that can be identified by specific antigenic phenotypes. Oligodendrocyte precursor 
cells differentiate to progenitor cells, pre-oligodendrocytes, immature non-myelinating 
oligodendrocytes, mature non-myelinating oligodendrocytes and finally to mature 
myelinating oligodendrocytes (reviewed by (Baumann and Pham-Dinh, 2001)). By 
using specific markers for different stages of oligodendrocyte maturity it would be 
possible to identify whether LRP1 expression is specific to one or more of these stages 
of maturity. As oligodendrocytes mature, their capability to proliferate and migrate 
decreases while their ability to myelinate increases (Miller et al., 1985). Silencing of the 
LRP1 gene in Schwann cells inhibits migration of these cells (Mantuano et al., 2010). 
Therefore, there is a possibility that if expressed in precursor oligodendrocyte cells, 
LRP1 could regulate migration of these cells in the CNS. It may also support 
oligodendrocyte survival. LRP1 silencing in Schwann cells increases their susceptibility 
to TNF-α and serum deprivation induced apoptosis, suggesting a role for the receptor in 
pro-survival mechanisms in these cells (Campana et al., 2006). In vivo, Schwann cell 
death following sciatic nerve crush injury is increased from <3% for wild type mice to 
over 35% when LRP1 is knocked out of these cells (Orita et al., 2013). It is possible that 
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LRP1 expression in both the developing and adult brain may be involved in maintaining 
oligodendrocyte health.  
There were more LRP1-positive oligodendrocytes in P2 brain than adult brain. 
Myelination of the central nervous system begins foetally in the spinal cord but extends 
through to the frontal cortex during the first week following birth (Bjelke and Seiger, 
1989, Bjartmar et al., 1994, Hamano et al., 1996).  One major component of myelin is 
cholesterol (Saher et al., 2005) which can bind to and be endocytosed by LRP1  
(Handelmann et al., 1992). Though the bulk of cholesterol used in myelin is synthesised 
by oligodendrocytes, it can also be transferred to these cells from other CNS cell types 
when cholesterol is depleted (Saher et al., 2005). Oligodendrocytes of the developing 
brain may require LRP1 for myelin production during this stage if cholesterol is low. 
LRP1 also regulates phagocytosis of myelin vesicles, as a model of degraded myelin, in 
oligodendrocytes in vitro (Gaultier et al., 2009). In addition, LRP1 may be involved in 
direct myelination of axons. Myelin thickness around axons of the sciatic nerve in LRP1 
knockout in mice is significantly reduced when compared to wild type mice. Sciatic 
nerve crush injury in knockout mice also demonstrate accelerated myelin sheath 
degeneration and decreased re-myelination (Orita et al., 2013). Therefore, the receptor 
may have a role in clearance of myelin in injury and replacement of it through 
cholesterol uptake.  
2.4.2.3 LRP1 expression in astrocytes 
Expression of LRP1 was evident in a subpopulation of astrocytes in both pup 
and adult rat brain. The presence of morphologically and regionally distinct astrocyte 
subpopulations has been recognised for over a century. Protoplasmic astrocytes are 
branched in morphology and located primarily in grey matter, whereas fibrous 
astrocytes have long processes and are located in white matter  (Ramon and Cajal, 
1909).  These two population of astrocytes not only vary in morphology and regional 
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location, but also in protein expression and developmental history (Miller and Raff, 
1984). The greatest number of LRP1-positive astrocytes were in the corpus callosum 
and hippocampal fimbria of both P2 and adult rats. This suggests that the LRP1 may be 
expressed primarily on fibrous astrocytes in both the developing and mature brain. 
There were more LRP1-positive astrocytes in white matter of the adult compared to P2 
brain, suggesting that there is a greater role for LRP1 in astrocytes of the mature brain 
in these regions. Astrocytes in grey matter also expressed LRP1, suggesting that the 
receptor may have a function in a subpopulation of protoplasmic astrocytes. Recent 
microarray studies have begun to reveal that there is even greater astrocyte 
heterogeneity that is region specific, but studies into functional and phenotypic 
differences between these subpopulations are limited (Bachoo et al., 2004, Sofroniew 
and Vinters, 2010). Further investigation is required to determine whether LRP1 is 
expressed on a specific subpopulation of astrocytes. 
Astrocytes have a complex range of roles in the healthy brain in addition to 
providing structural and metabolic support to neurons (Haines, 2002). These glia are not 
only essential for the correct formation and functioning of neuron synapses (Ullian et 
al., 2001) but also regulate subsequent activity at these sites. Upon calcium stimulation, 
astrocytes release neurotransmitters such as glutamate to promote neuron transmission 
(Parpura et al., 1994). LRP1 can regulate calcium signaling (Bacskai et al., 2000, Martin 
et al., 2008, Hayashi et al., 2012) and through similar mechanisms could have a role in 
astrocyte neurotransmitter release. 
2.4.2.4 LRP1 expression in microglia 
Microglia expression of LRP1 has not been noted in rodent brains previously but 
these cells have been reported as being negative for LRP1 in human brain (Wolf et al., 
1992). However, rat microglia are LRP1-positive in vitro (Marzolo et al., 2000, Gaultier 
et al., 2009). Though LRP1 immunoreactivity was present at both the cell body and 
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some processes of ramified microglia, only a small subset of these cells was positive for 
the receptor and there did not appear to be regional specificity. The identification of 
microglia in the brain can be difficult due to their scattered distribution and relatively 
low population in the brain compared to other glia (Lawson et al., 1990, Marzolo et al., 
2000). Therefore, it may be that previous reports have overlooked this co-localisation 
due to the difficultly in identifying the small proportion of cells positive for LRP1.  
While the majority of microglia appear quiescent in healthy brain they actually 
have an active role in maintaining normal brain function and homeostasis. Ramified 
microglia processes are surprisingly dynamic and continually survey the brain’s 
microenvironment to clear accumulations of metabolic products and degraded tissue 
(Nimmerjahn et al., 2005). However, these cells also have an important role in immune 
responses in the brain (reviewed by (Kreutzberg, 1996)). LRP1 may have a role in the 
detection of necrotic cells in infection or injury and the subsequent immune response 
regulated by microglia.  
Upon necrotic cell death, heat shock proteins are released and associate with cell 
derived antigens before binding to antigen presenting cells such as macrophages to 
induce cytokine release and antigen presentation to T-cells (Basu et al., 2000). This 
process has been found to be mediated by LRP1. Peritoneal macrophages and bone 
marrow-derived dendritic cells present antigen bound heat shock protein gp-90 to T-
cells. These effects were inhibited with antibodies against LRP1 (Basu et al., 2001). In 
addition, α2-macroglobulin complexes with antigens such as parasite derived 
proteinases enhance macrophage antigen uptake and presentation to T-cells through 
LRP1 (Morrot et al., 1997). Macrophages incubated with an α2-macroglobulin-
lysozyme complex require 200-250 times less lipopolysaccharide for effective antigen 
presentation to T-cells (Chu and Pizzo, 1993). Furthermore, LRP1 can mediate 
phagocytosis of apoptotic cells in both human monocyte-derived macrophages and 
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alveolar macrophages (Ogden et al., 2001, Vandivier et al., 2002) and 
lipopolysaccharide or amyloid-β activated microglia express LRP1 that binds to 
calreticulin on cerebellar granule neurons to mediate their phagocytosis (Fricker et al., 
2012). LRP1 present on ramified microglia that survey the brain environment may be 
involved in immune responses to cell death. Binding of heat shock proteins and α2-
macroglobulin complexes to LRP1 on microglia may induce their activation and 
contribute to microglia mediated phagocytosis of these cells. 
2.4.2.5 LRP1 expression at the BBB 
LRP1 was expressed in a subset of endothelial cells in P2 and P7 brain, though 
this has only been reported in adult human brain previously (Deane et al., 2004). 
Endothelial cells have specialised tight junctions to limit the ability of molecules to 
move in and out of the brain (reviewed by (Abbott et al., 2006)). Previous work 
demonstrates that LRP1 regulates permeability and transport of molecules across the 
BBB (Shibata et al., 2000, Yepes et al., 2003, Deane et al., 2004). It is likely that this 
process is mediated by endothelial-expressed LRP1. The presence of LRP1 in 
endothelial cells of the pup but not in the adult suggests that there is a greater role for 
the receptor in transport and BBB permeability during development.  
LRP1 was also expressed on astrocytic foot processes lining blood vessels from 
pup through to adult, which are also part of the BBB. This has previously been observed 
in human and rat brain (Moestrup et al., 1992, Wolf et al., 1992, Rebeck et al., 1993, 
Zheng et al., 1994). Astrocytes are able to affect cerebral blood flow through 
neurotransmitter mediated calcium increase. Glutamate and noradrenaline induce 
calcium oscillations in astrocyte end-feet causing vasodilation and vasoconstriction, 
respectively (Zonta et al., 2002, Mulligan and MacVicar, 2004). LRP1 is able to 
regulate NMDA and glutamate mediated calcium influx (Bacskai et al., 2000, Martin et 
al., 2008, Hayashi et al., 2012) and therefore, may be involved in astrocyte mediated 
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vascular flow in the brain. By regulating BBB permeability and cerebral blood flow 
LRP1 may have an important role in the maintaining the microenvironment of the brain. 
  
70 
 
 CONCLUSIONS 2.5
LRP1 is able to regulate survival and function of a range of neuron and glial 
subtypes in vitro and its expression upon neurons and glia in the rat brain suggests that 
it regulates the function of these cells in vivo. Post-translational modifications aid in 
regulating the function of LRP1 and appear to change during maturation and between 
rat brain regions suggesting that the receptors function changes from development to 
maturity. 
LRP1 expression was present on neuronal cell bodies of P2, P7 and adult rats 
where it may be involved in regulating survival through both development and maturity. 
The presence of the receptor on apical proximal dendrites of adult rat neurons suggests 
it may also be involved in neuronal signaling. Expression upon oligodendrocyte cell 
bodies and processes indicate a role for LRP1 in myelin synthesis through cholesterol 
endocytosis, cell survival and migration of precursor cells. The receptor was present on 
astrocyte cell bodies where it may affect astrocyte mediated neurotransmitter release 
and immune responses. LRP1 expressed on microglia could potentially be involved in 
antigen presentation and phagocytosis. The receptor was also located on endothelial 
cells and astrocytic end-feet of the BBB, suggesting that it may regulate the 
microenvironment of the brain through transport of molecules in and out of it. 
Subcellular and regional expression of LRP1 in the rat brain indicates a role of 
the receptor in mediating neuronal survival through direct effects on these cells. 
However, it may also indirectly affect function of these cells through maintaining 
survival and function of glia and modulating the microenvironment of the brain via the 
BBB. While identification of the subcellular and regional localisation of LRP1 allows 
speculation into its function in subsets of neurons and glia of the brain, it does not 
definitively explain the function of the receptor in these cells. In vivo observations 
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provide direction for what to investigate in in vitro models of neuron and glia to 
determine the specific functions that LRP1 regulates in these cells.  
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3 Chapter 3: In vitro characterisation of LRP1 expression in 
hippocampal neurons 
 INTRODUCTION 3.1
LRP1 is expressed in neurons, astrocytes, oligodendrocytes and microglia 
throughout the grey and white matter regions of the rat brain (Chapter 2.3.2). The 
extensive expression of LRP1 in the CNS suggests that it has a role in maintaining a 
healthy, functional brain by regulating neuron and glial survival and function. However, 
the precise function of LRP1 in these cell populations in vivo is unknown. Simpler in 
vitro neuron models have demonstrated that LRP1 can regulate neuron functions such 
as survival, neurite outgrowth and calcium signaling (Qiu et al., 2002, Qiu et al., 2004, 
Hayashi et al., 2007, Martin et al., 2008, Fuentealba et al., 2009, Hayashi et al., 2012, 
Sen et al., 2012, Stiles et al., 2013). Culture systems investigating LRP1 functions in 
CNS glia have been more limited. However, LRP1 expression has been demonstrated in 
astrocytes, oligodendrocytes and microglia in vitro (Marzolo et al., 2000, Gaultier et al., 
2009). These in vitro models allow investigation into the effects of injury or LRP1 
ligand addition on cell biology that can be investigated further in vivo.  
LRP1 is expressed on a range of neuron subtypes in vitro including 
hippocampal, cortical, cerebellar granule and retinal ganglionic neurons (Brown et al., 
1997, May et al., 2004, Hayashi et al., 2007, Ambjørn et al., 2008, Shi et al., 2009). 
Hippocampal neurons have been well characterised in culture and develop well defined 
dendrites and axons (Caceres et al., 1986, Dotti et al., 1987, Dotti et al., 1988). These 
neurons also express functional synaptic networks that begin to form at 10-14 days in 
vitro (DIV) and are fully established by 21DIV (Fletcher et al., 1991, Rao et al., 1998). 
This makes them a useful culture model for studying neuronal functions such as 
survival, neurite outgrowth, regeneration and synaptic signaling.  
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Investigating the regulation of hippocampal neuron survival and function is 
particularly relevant for neurodegenerative conditions such as Alzheimer’s disease. The 
hippocampus undergoes significant neurodegeneration in Alzheimer’s disease. This 
pathology corresponds to the short and long-term memory dysfunction associated with 
the condition (Kesslak et al., 1991, Laakso et al., 1995). LRP1 and some of its ligands, 
including apoE and α2-macroglobulin, have been genetically linked to the risk of 
developing Alzheimer’s disease (Strittmatter et al., 1993, Kang et al., 1997, Blacker et 
al., 1998). LRP1 expression is altered in the hippocampus of patients with early and late 
stages of the disease (Donahue et al., 2006, Sultana et al., 2010). Animal models further 
support a role of LRP1 in Alzheimer’s disease. LRP1 knock-out mouse models display 
Alzheimer’s disease-like pathology as they age, such as neurodegeneration of the 
hippocampus (Liu et al., 2010). Investigating the role of LRP1 in hippocampal neurons 
may aid in understanding how to promote survival and function of these cells and to 
limit the degeneration that occurs in conditions such as Alzheimer’s disease.  
LRP1 is expressed in cell bodies, axons and dendrites of rat hippocampal 
neurons in the first week of culture. After 7DIV it becomes restricted to cell bodies and 
dendrites (Brown et al., 1997). This correlates to observations made in vivo where LRP1 
is expressed on a subset of neuron cell bodies and proximal segments of their dendrites 
but absent from axons (Chapter 2.3.2). Determining subcellular localisation of LRP1 in 
hippocampal neurons will aid in understanding how this receptor regulates neuron 
function. Confirming previous in vivo and in vitro work will allow further investigation 
into the receptor’s function at specific cellular sites.  
Evidence that LRP1 is involved in synaptic function is increasing through both 
in vivo and in vitro work. LRP1 is expressed on the proximal segment of apical 
dendrites of hippocampal neurons in adult rats (Chapter 2.3.2). This is a site in which 
specific neurons can synapse, post-synaptic potentials can be amplified and has distinct 
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calcium accumulation characteristics (Blackstad et al., 1970, Yuste et al., 1994, 
Seamans et al., 1997). In vitro, LRP1 co-localises with the NR2a subunit of NMDA 
receptor in hippocampal neurons (May et al., 2004). The receptor regulates NMDA 
receptor dependent calcium influx of hippocampal neurons, demonstrating an ability to 
modulate synaptic activity. Knock-in of a mutant distal NPxY motif to LRP1 inhibits 
tPA mediated NMDA receptor dependent calcium influx in hippocampal neurons 
(Martin et al., 2008). This demonstrates that LRP1 regulated calcium influx is mediated 
by this motif. It is believed that the mechanism by which this occurs is through an 
interaction with the post-synaptic protein, PSD-95. 
PSD-95 binds to and anchors the NMDA receptor to post-synaptic sites as well 
as regulating its calcium signaling (Kornau et al., 1995, Sattler et al., 1999). Yeast two-
hybrid screening and pull-down assays have demonstrated the ability for the distal 
NPxY motif of LRP1 to associate with PSD-95 (Gotthardt et al., 2000). However, direct 
co-localisation of LRP1 and PSD-95 has not been identified in hippocampal neurons. 
Whether the receptor associates with pre-synaptic proteins such as synaptophysin has 
not been investigated previously. But given the expression of LRP1 on dendrites not 
axons after 7DIV (Brown et al., 1997) when the neurons are becoming synaptically 
active, it is unlikely that the receptor is expressed upon pre-synaptic sites.  
LRP1 ligands are able to regulate calcium influx in an NMDA receptor 
dependent manner. tPA and α2-macroglobulin addition induce an immediate calcium 
influx in hippocampal and cortical neurons, respectively. Both these effects are ablated 
by the NMDA receptor inhibitor, MK801 (Bacskai et al., 2000, Martin et al., 2008). 
Another LRP1 ligand, MT, regulates calcium influx and signaling pathways to mediate 
growth cone turning of dorsal root ganglia. siRNA against LRP1 inhibits the growth 
turning effects of MT (Landowski et al., 2012). These findings demonstrate the 
potential for this ligand to regulate the calcium signaling function of LRP1. The effect 
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of MT on calcium signaling in hippocampal neurons, and whether this is NMDA 
receptor dependent, is unknown. In addition, the effects of a peptide modeled after the 
C-terminus of the MT beta chain, emtinB, on calcium signaling has not been studied 
previously.  
In addition to neuronal expression, LRP1 was identified on cell bodies and 
processes of astrocytes, oligodendrocytes and microglia in the P2, P7 and adult rat brain 
(Chapter 2.3.2). The receptor is expressed in glia of pure astrocyte, oligodendrocyte and 
microglia cultures and regulates myelin vesicle phagocytosis of these cells (Gaultier et 
al., 2009). Microglia also phagocytose cerebellar granule neurons following toxicity and 
cell debris from heat shock treated oligodendrocytes by LRP1 dependent mechanisms 
(Fricker et al., 2012, Fernandez-Castaneda et al., 2013). Expression of LRP1 in 
microglia is also affected by inflammatory mediators, suggesting that the receptor has a 
function in immune responses of these cells (Marzolo et al., 2000). Less work has been 
conducted investigating the function of LRP1 in astrocytes and oligodendrocytes. 
Investigation of LRP1 in glia of mixed cultures provides an environment more closely 
related to what is observed in vivo. Therefore, determining whether LRP1 is expressed 
in astrocytes, oligodendrocytes and microglia in the presence of hippocampal neurons 
may further support previous in vivo and in vitro findings.   
I hypothesise that LRP1 is expressed on hippocampal neuron cell bodies and 
dendrites of hippocampal neurons in culture. As the neurons become synaptically 
mature, LRP1 will co-localise with post-synaptic proteins, such as PSD-95 and NMDA 
receptor subunits, but not pre-synaptic proteins, such as synaptophysin. LRP1 ligands, 
MT and emtinB, will induce calcium influx in synaptically mature neurons in an LRP1 
and NMDA receptor dependent manner. LRP1 will be expressed upon cell bodies and 
processes of contaminating astrocytes, oligodendrocytes and microglia within 
hippocampal neuron cultures.  
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 METHODS 3.2
All experiments involving the use of animals were approved by the Animal 
Experimentation Ethics Committee of the University of Tasmania (ethics number 
A0011957), which is in accordance with the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes. Sprague Dawley rats were used in all 
animal work.  
Buffer recipes and product information for all reagents can be found in 
appendices. 
3.2.1 PRIMARY HIPPOCAMPAL NEURON CULTURE 
Primary hippocampal neuron cultures were prepared from embryonic day 17/18 
Sprague Dawley rats. Embryos were dissected from mothers’ euthanised by carbon 
dioxide asphyxiation, removed from embryonic sacs, placed on ice and decapitated. The 
brain was removed by cutting through the midline of the skull and squeezing the sides 
of the head gently. Tissue was transferred to Hank’s buffered saline solution (HBSS; 
Sigma, USA) where the cerebellum and part of the brain stem were discarded and the 
hemispheres separated. Under a dissection microscope the thalamus and hypothalamus 
were removed and the meninges pulled away to reveal the hippocampus which was 
dissected from the brain and placed in chilled HBSS. Cells were trypsinised using 0.1% 
trypsin (Sigma, USA) at 37°C for 5 minutes. Trypsin was removed and cells were 
resuspended and dissociated by pipette in 1mL Neurobasal media with 10% foetal calf 
serum. Neurobasal refers to Neurobasal media (Gibco, USA) with 0.1% B27 (Gibco, 
USA), 0.5mM L-glutamine (Sigma, USA) and 1% gentamicin (Gibco, USA) unless 
otherwise stated.  
Cell count was performed using Trypan Blue (Sigma, USA) exclusion. Cells 
used for western blot were plated at 1x10
5
 cells/well in 24 well plates (BD Falcon, 
USA) coated with 1:10 poly-L-lysine (Sigma, USA). Cells used for 
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immunohistochemistry were plated at 5x10
4
 cells/well on 13mm glass coverslips in 24 
well plates. Cells used for live calcium imaging were plated at 5x10
4
 cells/well on 
18mm glass coverslips in 12 well plates (BD Falcon, USA). Glass coverslips were 
treated with >69% nitric acid (Fluka, USA) for four hours, washed in tap water 
overnight, ethanol cleaned and sterilised by exposure to ultraviolet light for 30 minutes. 
All coverslips were coated overnight with neat poly-L-lysine. Cultures were maintained 
at 37°C in humidified air with 5% carbon dioxide. A full media change to serum free 
Neurobasal media was conducted 24 hours after plating and every three to four days 
thereafter.  
3.2.2 WESTERN BLOT 
Hippocampal neuron cultures were grown to 3, 7, 14 and 21DIV. 3 separate 
cultures were used for each time point and 5x10
5
 cells were collected for each culture. 
Cultures were washed twice with HBSS free of B27 or serum. While on ice, cells were 
scraped from wells by pipette using 150μL RIPA lysis buffer with 1:100 protease 
inhibitor (Thermo Scientific, USA) and triturated 15-20 times. Samples were 
centrifuged in 4°C at 13,000rpm for 10 minutes. The supernatant was removed, snap 
frozen in liquid nitrogen and stored at -80°C. 
Total protein concentration was determined using a BCA protein assay (Bio-
Rad, USA). Briefly, part A and part B solutions were mixed by a 50:1 ratio. 200μL of 
working reagent was added to each well of a 96 well plate. Protein standards at 0.1, 0.2, 
0.5, 0.7 and 1.0mg/mL were prepared to calculate a protein standard curve. 20μL of 
protein standards and 20μL of cell sample were mixed with the BCA reagent and 
incubated for 30 minutes at 37°C. Triplicates were prepared for each sample. 
Absorbance at 595nm was measured using a SpectraMax M2 plate reader (Molecular 
Devices) and SoftMax Pro computer program (v 4.8). A standard curve was calculated 
and used to determine each sample’s concentration. 
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1mm thick SDS-PAGE gels were prepared as 10% resolving and 5% stacking 
gels (see appendices). 5μL of Spectra protein ladder (Thermo Scientific, USA) was 
loaded into the first lane. 5μg protein was loaded for each sample. Samples were run 
using a Mini-Protean Tetra electrophoresis system (Bio-Rad, USA) in running buffer at 
200 volts for 35-45 minutes. Transfer to nitrocellulose paper (Thermo Scientific, USA) 
was conducted overnight using an XCell Sure Lock electrophoresis system (Life 
Technologies, USA) at 20 volts in 4°C. The nitrocellulose membrane was protein 
blocked using 5% milk powder in 0.05% PBS-Tw for at least 60 minutes. Primary 
antibodies to the LRP1 light chain or β-actin (housekeeping protein) were applied in 5% 
milk powder in PBS-Tw overnight at 4°C (antibody concentrations and combinations in 
Table 3.1). Controls omitting  primary antibodies were incubated with 5% milk powder 
alone. Secondary antibodies in PBS-Tw were incubated while shaking for 1 hour at 
room temperature. Three 10-minute washes with PBS-Tw occurred after each antibody 
incubation. Signal was detected using a chemiluminescent substrate (Millipore, USA). 
Peroxidase and luminol components were mixed at a 1:1 ratio and incubated with the 
membrane for 5 minutes at room temperature. The membrane was exposed for 600 
seconds using a Chemi-Smart 5000 imaging system and Chemi-Capt 5000 computer 
program (v 12.8). Natural light was used to capture the ladder. Image contrast and 
brightness were uniformly enhanced using Adobe Photoshop (v 11.0.2). 
3.2.3 IMMUNOCYTOCHEMISTRY 
Cellular and subcellular specificity of LRP1 was determined by incubating anti-
LRP1 antibody with antibodies against either MAP2 (dendrites), SMI-312 (axons), 
synaptophysin (pre-synaptic site), PSD-95 (post-synaptic site), GFAP (astrocytes), olig2 
(oligodendrocytes) or isolectin (microglia). 3 separate cultures were grown for each 
antibody combination at each time point. Culture purity was determined by 
immunostaining cultures with antibodies against GFAP (astrocytes) and tau (neurons). 4 
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separate coverslips, each from a different culture, were prepared from each time point. 
Cultures were grown to 3, 7, 14 or 21DIV and fixed with 4% paraformaldehyde for 15-
20 minutes at room temperature and stored at 4°C in PBS with 0.01% sodium azide. 
Cells were protein blocked using 10% goat serum (Vector Laboratories, USA) in 0.03% 
triton X-100 (Lab-Chem, USA) in PBS for 30 minutes at room temperature to inhibit 
non-specific antibody binding. Primary antibodies were diluted in 10% goat serum and 
incubated for 1 hour at room temperature and overnight at 4°C. Cultures omitting the 
primary antibody were incubated with 10% goat serum alone to ensure no non-specific 
binding of secondary antibodies. Next, cultures were incubated with secondary 
antibodies for one hour at room temperature before counterstaining with 1μg/ml nuclear 
yellow (Invitrogen, USA). Coverslips were washed three times by gentle shaking in 
PBS for 5 minutes following each antibody incubation. Coverslips were mounted to 
slides using fluorescent mounting media (Dako, USA) and dried overnight.  
Cells from 3 separate 14DIV cultures to be immunolabelled for NMDA receptor 
subunits were fixed with methanol for 10 minutes at -20°C and stored in PBS with 
0.01% sodium azide at 4°C. Cells were protein blocked using 10% goat serum (Vector 
Laboratories, USA) in 0.03% triton X-100 (Lab-Chem, USA) in PBS for 30 minutes at 
room temperature. Primary antibodies to either NR2a or NR2b were diluted in 10% goat 
serum and incubated for 1 hour at room temperature and overnight at 4°C. Cultures 
were incubated with anti-rabbit secondary antibodies conjugated with AlexaFluor®-488 
(Molecular Probes, USA) for one hour at room temperature. Cells were then fixed with 
4% paraformaldehyde for 15 minutes at room temperature and washed three times in 
PBS. Primary antibodies to LRP1 were diluted in 10% goat serum and incubated for 1 
hour at room temperature and overnight at 4°C. Next, cultures were incubated with anti-
rabbit secondary antibodies conjugated with AlexaFluor®-594 (Molecular Probes, 
USA) for one hour at room temperature before counterstaining with 1μg/ml nuclear 
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yellow (Invitrogen, USA). Coverslips were washed three times by gentle shaking in 
PBS for 5 minutes following each antibody incubation. Cultures omitting the primary 
antibody were also prepared to ensure no non-specific binding of secondary antibodies. 
Coverslips were mounted to slides using fluorescent mounting media (Dako, USA) and 
dried overnight.  
Representative photographs for LRP1 cellular and subcellular localisation were 
taken at 40X objective. To determine culture purity, 11 random frames from each 
coverslip were photographed at 20X objective. Tau positive (neurons), GFAP positive 
(astrocytes) and tau and GFAP negative cells (determined by nuclei and classed as 
‘other’) were counted. All images were captured using an Olympus BX50 microscope 
and Photomatrix Cool Snap HQ
2
 camera. Images were uniformly enhanced using 
Adobe Photoshop (v11.0.2).  
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Primary Type Dilution Secondary Conjugate Dilution 
 
LRP1 R 1:1000 Goat anti-rabbit HRP 1:1000 
 
β-actin M 1:20,000 Goat anti-mouse HRP 1:5000 
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Primary Type Dilution Secondary Conjugate Dilution Target 
GFAP M 1:1000 Goat anti-mouse AlexaFluor®-488 1:1000 Astrocytes 
LRP1 R 1:1000 Goat anti-rabbit AlexaFluor®-594 1:1000 
C-terminus of  
LRP1 light chain 
MAP2 M 1:1000 Goat anti-mouse 
 
1:1000 Dendrites 
Olig2 M 1:500 Goat anti-mouse AlexaFluor®-594 1:1000 Oligodendrocytes 
PSD-95 M 1:1000 Goat anti-mouse AlexaFluor®-488 1:1000 Post-synaptic site 
SMI-312 M 1:1000 Goat anti-mouse AlexaFluor®-488 1:1000 Axons 
Synaptophysin M 1:1000 Goat anti-mouse AlexaFluor®-488 1:1000 Pre-synaptic site 
Isolectin (488)   1:500 NA     Microglia 
Tau R 1:1000 Goat anti-rabbit AlexaFluor®-594 1:1000 
Neuron cell body,  
dendrites and axons 
NR2a R 1:100 Goat anti-rabbit AlexaFluor®-488 1:1000 
NMDA receptor 2a 
subunit 
NR2b R 1:100 Goat anti-rabbit AlexaFluor®-488 1:1000 
NMDA receptor 2b 
subunit 
Table 3.1: A list of working dilutions of primary antibodies, their targets and respective 
secondary antibodies used for western blots and immunocytochemistry analysis. 
Antibodies were either polyclonal rabbit (R) or monoclonal mouse (M) antibody. 
HRP: horse radish peroxidase; NMDA: N-methyl-D-aspartate 
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3.2.4 HIPPOCAMPAL NEURON SYNAPTIC ACTIVITY ASSAY 
Hippocampal neuron cultures were grown to 14-15DIV and incubated with 5μM 
Fluo-4 in serum free Neurobasal media for 15 minutes at 37°C in humidified air with 
5% carbon dioxide. Cells were washed once with warm imaging buffer (see 
appendices). Coverslips were mounted onto the mounting chamber and 300μL imaging 
buffer was pipetted gently on top. Imaging was conducted in a microscope incubator 
(TCH885-5; Clear State Solutions Pty Ltd) at 37°C using a Nikon Eclipse Ti 
microscope.  
To determine whether cells were responsive to glutamate or NMDA, 4 regions 
containing healthy and relatively isolated hippocampal neurons were selected based on 
morphology under phase contrast (pyramidal shape with a smooth, raised surface and 
defined nucleus and processes). Cells were imaged using an Evolve™ 512 EMCCD 
camera (Photometrics) every 10 seconds using a 488nm wavelength at 40X objective. A 
phase contrast image was taken only at the start and end of the experiment to limit 
photo bleaching. Baseline fluorescence to determine basal intracellular calcium was 
established by imaging cells for 2 minutes at the start of every experiment. Imaging was 
paused as 0.9% saline, used as a vehicle control, was added and imaging resumed for an 
additional 2 minutes. Imaging was paused again and 10μM NMDA or 10μM glutamate 
added before imaging continued for another eight minutes. At least 6 separate coverslips 
from 3 different cultures were used for each treatment. 
MK801, a NMDA receptor inhibitor, was added to cells to determine that 
NMDA responses were specific. Basal calcium was measured for 2 minutes before the 
experiment was paused, 10μM NMDA applied and imaging continued for 3 minutes. 
Cells were washed for 2 minutes by flowing imaging buffer over the coverslip which 
was vacuum suctioned off. The wash was stopped and imaging buffer replaced with 
300μL of either 10μM MK801 or the equivalent volume of saline in imaging buffer. 
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Cells were left for 7.5 minutes to allow for MK801 inhibition before 10μM NMDA was 
added again and imaging continued for an additional 6 minutes. 2-3 separate coverslips, 
each from a different culture, were used for each experiment. 
The effects of the LRP1 ligands, MT (Bestenbalt LLC, Estonia) and emtinB 
(Schafer-N, Denmark), on NMDA receptor dependent calcium influx were investigated. 
Cells were incubated with Fluo-4 as above and baseline fluorescence determined by 
imaging cells for 2 minutes at the start of the experiment. Imaging was paused and 
10μM NMDA added to determine whether neurons were synaptically active. After 2-3 
minutes of imaging, cultures were washed for 2 minutes by flowing fresh imaging 
buffer onto the coverslip which was vacuum suctioned off to remove any remaining 
NMDA. The wash was stopped and cells allowed to settle for 2 minutes before imaging 
was paused and either 10μg/mL MT (equivalent to 1.5μM) or 25μM emtinB (equivalent 
to 75μg/mL) added and imaging resumed for 6.5 minutes. 6 coverslips from 3 cultures 
were used to determine MT effects, while 2 coverslips from 1 culture were used to 
determine emtinB effects.  
Video of live imaging fluorescence was analysed using the NIS Elements AR 
computer program (v 3.21.00). A region of interest was manually drawn around the 
soma of each cell using the phase contrast image. Raw fluorescence was measured and 
corrected for background. Data were transferred to Microsoft Excel (v14.0.7015.1000) 
and baseline fluorescence calculated as the average fluorescence of the two minute 
baseline period. Raw fluorescence was converted to actual fluorescence using the 
following equation: 
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where F = the raw fluorescence at a the time point being measured and F0 = 
baseline fluorescence (reviewed by (Takahashi et al., 1999)). Results for each cell were 
presented in graph form. Graphs in Figure 3.12 represent the response of a typical cell. 
A synaptic response was classed as an increase of fluorescence above a value of 1 that 
occurred immediately after addition of the neurotransmitter and which quickly reduced 
to near baseline level.  
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 RESULTS 3.3
3.3.1 LRP1 IS EXPRESSED IN HIPPOCAMPAL NEURON CULTURES FROM 3 TO 
21DIV 
Western blot analysis demonstrated that the processing of LRP1 changes during 
maturation in culture. The strongest band observed in 3DIV cultures corresponded to 
the ~85kDa band representing the LRP1 light chain. A faint ~120kDa band was also 
present at this time point (Figure 3.1 A, lanes 1-3). Both the ~85kDa and ~120kDa 
bands became stronger from 3 to 7DIV (Figure 3.1 A, lanes 4-6). Expression of the 
~85kDa band remained similar between 7 and 14DIV cultures, but the ~120kDa band 
appeared fainter at 14DIV compared to 7DIV. 14DIV cultures also faintly expressed 
~50kDa, ~130kDa and ~150kDa bands not present at 3 or 7DIV (Figure 3.1 A, lanes 7-
9). 21DIV cultures expressed the ~85kDa band similar to 7 and 14DIV cultures. The 
~130kDa and ~150kDa were fainter at 21DIV than 14DIV, but the ~50kDa band was 
stronger. A ~37kDa band was present at 21DIV that was not observed at any other time 
point (Figure 3.1 A, lanes 10-12). 
A similar amount of protein was loaded for each sample (β-actin). Negative 
controls of hippocampal culture blots omitting primary antibodies showed no 
immunoreactivity (Figure 3.1 B). 
  
86 
 
 
Figure 3.1: LRP1 is expressed in hippocampal neuron cultures at 3, 7, 14 and 21 days 
in vitro (DIV). 5x10
5
 cells from hippocampal neuron cultures (A) were collected at 
3DIV (lanes 1-3), 7DIV (lanes 4-6), 14DIV (lanes 7-9) and 21DIV (lanes 10-12). 5μg 
total protein for each sample was run on an SDS-PAGE gel and probed with anti-LRP1 
or anti-β-actin antibodies. Similar amounts of protein were loaded for each sample (β-
actin). Controls blots omitting primary antibodies were negative for non-specific 
secondary antibody binding (D). Molecular weights of bands were determined using a 
commercial protein ladder (L). 
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3.3.2 LRP1 IS LOCALISED TO CELL BODIES AND DENDRITES OF 
HIPPOCAMPAL NEURONS IN VITRO  
Hippocampal neuron culture purity was determined using markers for neurons, 
astrocytes and nuclei of unstained cells (other). Purity was determined and presented in 
Figure 3.2.  
 
 
Figure 3.2: Purity of neurons, astrocytes and other glia in hippocampal neuron cultures. 
Cultures were immunolabelled for tau (neurons), GFAP (astrocytes) and nuclear yellow 
(nuclei). Tau positive, GFAP positive and tau/GFAP negative cells (determined by 
nuclei) were counted. Error bars = standard error 
 
Percentage of neurons in cultures decreased due to proliferating glia and 
apoptosis of neurons, evidenced from an increased number of pyknotic nuclei (data not 
shown). Tau positive neurons had pyramidal or round cell bodies with multiple 
prominent neurites that branched as they extended away from the cell body. GFAP 
positive astrocytes appeared flatter than neurons and had larger nuclei and cell bodies 
with thicker, shorter processes. Other glia nuclei were either much larger and less 
condensed than hippocampal neuron nuclei, or were smaller and more condensed. 
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LRP1 was expressed on astrocyte cell bodies and processes from 3 to 21DIV 
(Figure 3.3 A-D). Oligodendrocytes were positive for LRP1 on cell bodies and 
processes from 7 to 21DIV (Figure 3.4 A-C). Oligodendrocytes had small cell bodies 
with condensed nuclei. The oligodendrocyte marker, olig2, was not detected in cultures 
at 3DIV. Microglial expression of LRP1 was heterogeneous. Some cells were strongly 
positive for the receptor throughout the cell body, but others only expressed the receptor 
faintly. This occurred at 3, 7, 14 and 21DIV (Figure 3.5 A-D). Microglia were noted as 
either flat and round or elongated with processes. Differences in LRP1 expression did 
not appear to correspond to specific cell morphology.  
LRP1 immunoreactivity was observed in all hippocampal neurons from 3 to 
21DIV (Figures 3.6 – 3.9). Expression was particularly strong at the cell body of 
hippocampal neurons. The receptor was present along and at growth cones at the ends 
of extending axons of 3DIV neurons (Figure 3.6 A). This expression was reduced in 
7DIV neurons and was absent from axons of 14DIV or 21DIV hippocampal neurons 
(Figure 3.6 B-D). At these later time points LRP1 positive processes were observed 
alongside axons but not upon the axons themselves. LRP1 reactive processes were 
dendrites, which were strongly positive for the receptor from 3DIV to 21DIV (Figure 
3.7 A-D). LRP1 did not co-localise with or PSD-95 (Figure 3.8 A-C) or synaptophysin 
from 7 to 21DIV (Figure 3.9 A-C). Though partial co-localisation with PSD-95 and 
synaptophysin may have appeared to occur in some instances, higher magnification 
demonstrated that this was not the case. Rather it appeared that due to the high density 
of staining, LRP1 immunoreactivity randomly crossed-over with PSD-95 or 
synaptophysin. Controls omitting primary antibodies were incubated with goat anti-
rabbit conjugated to AlexaFluor®-594 and goat anti-mouse conjugated to AlexaFluor®-
488 secondary antibodies and were immunonegative (Figure 3.10 A-D).  
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Cultures at 14DIV were immunolabelled for LRP1 and the NMDA receptor 
subunits, NR2a and NR2b. Hippocampal neurons begin to form mature synapses at 
about 12DIV, with complete synaptic activity reached at 21DIV (Rao et al., 1998). 
14DIV was chosen as healthy cells were relatively easy to grow to this age and 
synaptically mature neurons should be present. LRP1 did not co-localise with NR2a 
(Figure 3.11 A) but did partially co-localise with NR2b (Figure 3.11 B). No primary 
controls for methanol and 4% paraformaldehyde fixed cultures were immunonegative 
(Figure 3.11 C).  
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Figure 3.3: LRP1 is expressed on astrocytes in hippocampal neuron cultures. 
Hippocampal neuron cultures were fixed with 4% paraformaldehyde at 3 (A), 7 (B), 14 
(C) and 21 days in vitro (D) and immunolabelled for LRP1 (red) and GFAP (green). 
Nuclei were counterstained with 1μg/mL nuclear yellow (NY; blue).  
Scale bar = 50μm 
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Figure 3.4: LRP1 is expressed on oligodendrocytes in hippocampal neuron cultures. 
Hippocampal neuron cultures were fixed with 4% paraformaldehyde at 7 (A), 14 (B) 
and 21 days in vitro (DIV; C) and immunolabelled for LRP1 (red) and olig2 (green). 
Nuclei were counterstained with 1μg/mL nuclear yellow (NY; blue).  
Scale bar = 50μm  
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Figure 3.5: LRP1 is expressed on microglia in hippocampal neuron cultures. 
Hippocampal neuron cultures were fixed with 4% paraformaldehyde at 3 (A), 7 (B), 14 
(C) and 21 days in vitro (D) and immunolabelled for LRP1 (red) and isolectin (green). 
Nuclei were counterstained with 1μg/mL nuclear yellow (NY; blue).  LRP1 expression 
in microglia was heterogeneous and while some microglia were strongly immunreactive 
for LRP1 (insets A, and D) others were only faintly positive for LRP1. 
Scale bar = 50μm; A, C, D inset scale bar = 50μm 
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Figure 3.6: LRP1 is expressed along axons of neurons at 3 and 7 days in vitro (DIV) 
but not at 14 or 21DIV. Hippocampal neuron cultures were grown to 3 (A), 7 (B), 14 
(C) or 21DIV (D) and fixed with 4% paraformaldehyde. Cells were immunolabelled 
with antibodies against LRP1 (red) and SMI-312 (green; axonal marker). Nuclei were 
counterstained with 1μg/mL nuclear yellow (NY; blue). At 3DIV, LRP1 was expressed 
along (A; inset a) and at the ends (A; inset b) of extending axons. Some 7DIV axons 
were LRP1 positive, (B; inset) but 14 and 21DIV axons were negative for LRP1 (C and 
D; arrows). Axons appeared to follow alongside LRP1 positive dendrites (C and D 
insets). 
Scale bar = 50μm; A.a., A.b., B, C and D inset scale bar = 25μm 
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Figure 3.7: LRP1 is expressed on dendrites of hippocampal neurons in vitro. 
Hippocampal neuron cultures were fixed with 4% paraformaldehyde at 3 (A), 7 (B), 14 
(C) and 21 days in vitro (DIV; D) and immunolabelled for LRP1 (red) and MAP2 
(green). Nuclei were counterstained with 1μg/mL nuclear yellow (NY; blue). LRP1 was 
expressed along MAP2 positive processes at every time point and was also present at 
the ends of dendrites in 3DIV neurons (inset). 
Scale bar = 50μm; A inset scale bar = 25μm  
95 
 
 
Figure 3.8: LRP1 does not co-localise with PSD-95 in hippocampal neurons in vitro. 
Hippocampal neuron cultures were fixed with 4% paraformaldehyde at 7 (A), 14 (B) 
and 21 days in vitro (DIV; C) and immunolabelled for LRP1 (red) and the post-synaptic 
protein, post-synaptic density-95 (PSD-95; green), and counterstained with 1μg/mL 
nuclear yellow (NY; blue).  
Scale bar = 50μm 
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Figure 3.9: LRP1 does not co-localise with synaptophysin in hippocampal neurons in 
vitro. Hippocampal neuron cultures were fixed with 4% paraformaldehyde at 7 (A), 14 
(B) and 21 days in vitro (DIV; C) and immunolabelled for LRP1 (red) and the pre-
synaptic protein, synaptophysin (green), and counterstained with 1μg/mL nuclear 
yellow (NY; blue).  
Scale bar = 50μm 
97 
 
 
 
Figure 3.10: Cultures omitting primary antibodies are immunonegative. Hippocampal 
neuron cultures were fixed with 4% paraformaldehyde at 3 (A), 7 (B), 14 (C) and 21 
days in vitro (D). Cultures were incubated with goat serum omitting primary antibodies 
followed by goat anti-rabbit conjugated to AlexaFluor®-594 and goat anti-mouse 
conjugated to AlexaFluor®-488 secondary antibodies. Nuclei were counterstained with 
1μg/mL nuclear yellow (NY; blue). Secondary antibodies did not bind non-specifically 
to hippocampal neurons.  
Scale bar = 50μm 
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Figure 3.11: LRP1 co-localises with NR2b but not NR2a in vitro. Hippocampal 
neurons cultures were fixed with methanol at 14 days in vitro (DIV) and 
immunolabelled for NMDA receptor subunits, NR2a (A) or NR2b (B; both green). 
Cells were then fixed with 4% paraformaldehyde and immunolabelled for LRP1 (red). 
Nuclei were counterstained with 1μg/mL nuclear yellow (NY; blue). LRP1 did not co-
localise with NR2a (A inset) but did partially co-localise with NR2b (B inset and 
arrowheads). Cultures omitting primary antibodies were immunonegative (C). 
Scale bar = 50μm; A inset scale bar = 30μm; B inset scale bar = 20μm 
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3.3.3 14-15DIV HIPPOCAMPAL NEURONS RESPOND TO NMDA AND 
GLUTAMATE 
14DIV hippocampal neurons express the NMDA receptors subunits NR2a and 
NR2b (Figure 3.10 A and B). Live cell calcium imaging was used to determine whether 
hippocampal neurons were synaptically mature and able to respond to NMDA or 
glutamate. 52% (23 of 44 cells) and 54% (19 of 35 cells) of 14-15DIV hippocampal 
neurons responded to NMDA and glutamate, respectively. This response was 
characterised by an immediate and large increase in intracellular calcium following 
neurotransmitter addition, with a subsequent decrease in calcium near to baseline 
(Figure 3.12 A and B). Addition of 10μM MK801 inhibited NMDA responses in cells 
that had previously responded to the neurotransmitter (14 cells; Figure 3.12 C). A saline 
control did not inhibit NMDA responses (11 cells; Figure 3.12 D).  
Live imaging was used to determine whether the LRP1 ligands, MT and emtinB, 
affect calcium signaling in hippocampal neurons via an NMDA receptor dependent 
mechanism. 10μM NMDA was added to neurons following loading of the calcium 
fluorophore and neurons that responded with an increased uptake of calcium were 
further exposed to MT or emtinB. Addition of either MT or emtinB failed to induce 
calcium influx in neurons (Figure 3.13 A and B; MT: 17 NMDA responsive neurons; 
emtinB: 6 NMDA responsive neurons).  
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Figure 3.12: Hippocampal neurons respond to NMDA and glutamate at 14-15 days in 
vitro. Hippocampal neurons were loaded with 5μM Fluo-4 calcium indicator at 14-15 
days in vitro and imaged every ten seconds. Baseline fluorescence was determined by 
imaging cells for two minutes at the start of every experiment. Imaging was paused 
(faded red line) as a saline control was added and imaging resumed (faded green line) 
for an additional 2 minutes. Imaging was paused again (red line) and either 10μM 
NMDA (A) or 10μM glutamate (B) added and imaging resumed (green line) for 8 
minutes. The NMDA receptor inhibitor, MK801, was added to determine that NMDA 
responses were specific. 10μM NMDA was added and cells imaged for 3 minutes 
before a 2 minute wash (blue line). Imaging was paused as the wash was stopped (faded 
red line) and imaging buffer replaced with 10μM MK801 (C) or a saline control (D) and 
imaging resumed (faded green line) for 7.5 minutes. NMDA was added again and 
imaged for another 6 minutes. NMDA and glutamate caused an immediate increase in 
intracellular calcium in 23 of 44 (52%) and 19 of 25 (54%) cells, respectively. The 
NMDA response was inhibited by MK801 but not by the saline control. Representative 
traces demonstrate the typical response from a single responding neuron. 
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Figure 3.13: 10μg/mL MT or 25μM emtinB do not induce calcium influx in NMDA 
responsive hippocampal neurons at 14-15 day in vitro. Hippocampal neurons were 
loaded with 5μM Fluo-4 calcium indicator and imaged every ten seconds. Baseline 
fluorescence was determined by imaging cells for two minutes at the start of the 
experiment. Imaging was paused (faded red line) as 10μM NMDA was added and 
imaging resumed (faded green line) for an additional 2-3 minutes. Cells were washed 
for 2 minutes (light blue line) before the wash was stopped (dark blue) and cells allowed 
to settle for 2 minutes. Imaging was paused again (red line) and 10μg/mL MT (A) or 
25μM emtinB (B) added and imaging resumed (green line) for 6.5 minutes. NMDA 
caused an immediate increase in intracellular calcium that quickly returned to near 
baseline, but MT or emtinB did not cause any change in intracellular calcium. 
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 DISCUSSION 3.4
Western blot and immunocytochemistry analysis have demonstrated expression of 
LRP1 in hippocampal neurons cultures at 3, 7, 14 and 21DIV. The receptor was 
expressed upon cell bodies and dendrites of all neurons at all time points. Expression of 
LRP1 was present along and at the ends of axons of 3DIV neurons. Some axons at 
7DIV were also LRP1 positive, but axons at 14DIV and 21DIV did not express the 
receptor. LRP1 did not co-localise with pre- or post-synaptic proteins from 7DIV to 
21DIV or with the NMDA receptor subunit NR2a at 14DIV. However, it did appear to 
co-localise partially with the NR2b NMDA receptor subunit at 14DIV. About 50% of 
hippocampal neurons at 14-15DIV responded to NMDA and glutamate by 
demonstrating an immediate calcium influx following neurotransmitter addition and 
were therefore deemed to be synaptically active. LRP1 ligands, MT and emtinB, did not 
induce calcium influx in NMDA responsive neurons. LRP1 was also expressed on cell 
bodies and processes of astrocytes, oligodendrocytes and microglia in hippocampal 
neuron cultures.  
3.4.1 THE CLEAVAGE PATTERN OF LRP1 CHANGES DURING MATURATION 
OF HIPPOCAMPAL NEURON CULTURES 
A number of LRP1 positive bands between ~37kDa and ~150kDa were detected 
in hippocampal neuron cultures at 3, 7, 14 and 21DIV. As for in vivo western blots 
(Chapter 2.3.1), the LRP1 antibody used targeted the C-terminal end of the intracellular 
domain. Therefore, the different molecular weighted bands correspond to LRP1 light 
chain forms that have undergone different post-translational modifications. Post-
translational modifications of LRP1 can include cleavage by β- and γ-secretase (May et 
al., 2002, von Arnim et al., 2005), phosphorylation of NPxY motifs (Barnes et al., 2001, 
Guttman et al., 2009) and glycosylation (Quinn et al., 1999, May et al., 2003). 
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Modification of LRP1 by these mechanisms regulates the receptors’ function by 
affecting intracellular proteins ability to bind to it and the ability of the intracellular 
domain to translocate to the nucleus (Trommsdorff et al., 1998, Gotthardt et al., 2000, 
Kinoshita et al., 2003, Guttman et al., 2009).  
Previous in vitro work with cerebellar granule neurons demonstrated 
immunoreactivity on western blots at ~85kDa which corresponds to the LRP1 light 
chain (Ambjørn et al., 2008). The ~85kDa band was the strongest band expressed in 
hippocampal neuron cultures at every time point. Though the LRP1 light and heavy 
chains are normally non-covalently bound to form a 600kDa product, these domains 
most likely dissociate during western blot preparation, resulting in the detection of the 
light chain. Bands at ~120kDa, ~130kDa and ~150kDa were observed in hippocampal 
neuron cultures during maturation. As these bands have higher molecular weight than 
the ~85kDa LRP1 light chain it is reasonable to assume that these forms of the 
intracellular domain have undergone phosphorylation or glycosylation. Molecular 
weight bands of LRP1 greater than ~85kDa have been observed in vivo previously 
(Wolf et al., 1992). However, very few studies have used western blots to identify LRP1 
expression in vitro. Of the studies that have used western blot analysis, the presence of 
higher molecular weight bands was not mentioned (Ambjørn et al., 2008) or the 
molecular weight of LRP1 positive bands observed were not mentioned at all (Hayashi 
et al., 2007, Fuentealba et al., 2009).  
LRP1 positive bands observed between ~37kDa and ~50kDa, being lower 
molecular weight than the ~85kDa, are likely to be cleaved forms of the LRP1 light 
chain. Cleavage of the extracellular domain of LRP1 by β-secretase releases a ~30kDa 
fragment (von Arnim et al., 2005). This fragment can be further modified by 
phosphorylation of the distal NPxY motif or glycosylation (Barnes et al., 2001, Guttman 
et al., 2009). Glycosylation of the LRP1 light chain has been reported previously to 
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yield LRP1 positive fragments of ~55kDa from trophoblast cell lines (Quinn et al., 
1999). Therefore, glycosylation, and possibly phosphorylation, of the cleaved light 
chain fragment could produce the bands observed between ~37kDa and ~50kDa.  
Expression of the ~85kDa LRP1 band appeared weakest at 3DIV, but increased 
and remained consistent from 7 to 21DIV. This is in contrast to in vivo data that 
demonstrated greater expression of the ~85kDa fragment in P2 and P7 hippocampi 
when compared to the adult rat hippocampus (Chapter 2.3.1). Hippocampal neurons 
were cultured from embryonic day 17-18 rats. It may be that LRP1 expression is lower 
at this stage of development than in P2 or P7 rats. However, northern blot analysis 
demonstrates greater expression of LRP1 mRNA in embryonic day 18 and 21 rat brains 
than in post-natal day 3 rat brain (Ishiguro et al., 1995). Whether this corresponds to 
protein expression in hippocampal neurons is unknown. While mRNA expression of the 
receptor throughout whole brain may be greater during embryonic development, protein 
expression may be lower. In addition, the expression of LRP1 in the hippocampus 
specifically may be lower in the embryo. Alternatively, the trauma of dissection and 
dissociation during culture preparation may cause a reduction in LRP1 expression that 
is recovered during the first week of culture.  
A ~120kDa band was present in 3DIV and 7DIV cultures, but this band became 
fainter in 14DIV and 21DIV cultures. The function of this fragment could be in initial 
neurite outgrowth and establishment of neuronal networks throughout the culture. LRP1 
can regulate neurite outgrowth in other neuron subtypes. Outgrowth of cerebellar 
granule neurons is inhibited following 48 hours treatment with myelin associated 
glycoprotein, an effect abolished by siRNA against LRP1 (Stiles et al., 2013). In 
contrast, α2-macroglobulin promotes neurite outgrowth and increases LRP1 expression 
in cortical neuron cultures, which is inhibited by RAP (Qiu et al., 2004, Shi et al., 
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2009). Therefore, the ~120kDa LRP1 positive band in developing cultures may regulate 
neurite outgrowth of hippocampal neurons.  
At 14DIV there was the appearance of bands at ~37kDa, ~50kDa, ~130kDa and 
~150kDa. The ~37kDa and ~50kDa bands became stronger at 21DIV though the 
~130kDa and ~150kDa bands were weaker when compared to 14DIV. The appearance 
of lower weight molecular bands in more mature hippocampal neuron cultures 
corresponds to in vivo data. The presence of lower weight bands was observed in the 
adult hippocampus but not in P2 or P7 hippocampus (Chapter 2.3.1). Hippocampal 
neurons become increasingly synaptically mature from 14DIV to 21DIV and these 
fragments may be involved in synaptic function of these neurons. Addition of tPA to 
hippocampal neuron cultures induces NMDA receptor dependent calcium influx, which 
is inhibited when LRP1 is dysfunctional (Martin et al., 2008). 48 hour treatment of 
hippocampal neurons with α2-macroglobulin and lactoferrin inhibits NMDA mediated 
calcium influx. This was abolished by RAP (Qiu et al., 2002). These findings 
demonstrate the ability of LRP1 to regulate NMDA receptor activity. The low 
molecular weight fragments present in 14DIV and 21DIV cultures that are not present at 
3DIV or 7DIV may be involved in this function. However, from 14DIV the proportion 
of neurons to glia drops significantly (14DIV: 40% neurons, 60% glia; 21DIV: 25% 
neurons, 75% glia). This is due to proliferation of glia and apoptosis of neurons. It is 
possible that these lower molecular weight forms are expressed in glia and become 
stronger as the percentage of these cells increase. LRP1 regulates the ability of 
astrocytes, oligodendrocytes and microglia to phagocytose myelin vesicles (Gaultier et 
al., 2009). Microglia are also able to phagocytose apoptotic cerebellar granule neurons 
following lipopolysaccharide and β-amyloid treatment (Fricker et al., 2012). Therefore, 
low molecular weight fractions of LRP1 may be expressed in glia that are involved in 
phagocytosis of apoptotic neurons as cultures age. 
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Changes in the post-translational modification of LRP1 during maturation in 
culture partially reflect what is observed in the hippocampus in vivo. Though the precise 
function of these LRP1 fractions is unknown, these data demonstrate a change in 
function of the receptor as cultures develop. This indicates that investigation into the 
role of LRP1 during neuronal maturation is possible in culture. 
3.4.2 LRP1 IS EXPRESSED IN CELL BODIES AND PROCESSES OF 
HIPPOCAMPAL NEURONS FROM 3 TO 21DIV 
LRP1 was expressed upon cell bodies and dendrites of all hippocampal neurons 
from 3DIV to 21DIV. The receptor was present along and at the ends of extending 
axons at 3DIV but axonal expression was reduced in 7DIV neurons and absent in 
14DIV and 21DIV cultures. This pattern of expression was consistent with previous 
reports. Brown and colleagues (1997) demonstrated the presence of LRP1 on rat 
hippocampal neuron cell bodies and processes from 1DIV. Axonal expression of LRP1 
was present on axons of 3DIV, but only residual expression was found on 5DIV 
cultures and was absent by 7-8DIV. From this time onwards LRP1 was restricted to 
neuronal cell bodies, dendrites and dendritic spines. While Brown’s study found no 
expression at 7DIV, the present data did demonstrate this, though to a lesser degree than 
at 3DIV. These discrepancies could be due to technical differences such as the antibody 
used. Otherwise, the expression pattern of LRP1 is consistent between the two studies 
and demonstrates reproducibility of LRP1 expression in hippocampal neuron cultures. 
LRP1 is expressed on hippocampal neuron cell bodies and apical segments of 
dendrites in the adult rat brain (Chapter 2.3.2). Similarly, LRP1 is identified on 
hippocampal neuron cell bodies and dendrites in vitro. However, dendritic expression is 
also located at the distal ends of dendrites in vitro in both developing and mature 
cultures. Hippocampal neurons in P2 rat brains displayed little dendritic LRP1 
immunoreactivity, and P7 neurons had none. Cultures at 3DIV represent a stage of 
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development younger than P2 brains when neurites are extending through their 
environment to form neuronal connections. This better represents embryonic 
development and suggests that the receptor may be expressed along and at the ends of 
neurites as they extend processes through the brain during this stage of development. 
The expression of LRP1 at growth cones of extending hippocampal neuron dendrites at 
3DIV suggests that the receptor may be involved in neurite extension. 
LRP1 mediated neurite extension has been demonstrated in DRGs, cerebellar 
granule cells and cortical neurons (Qiu et al., 2004, Stiles et al., 2013, Yamauchi et al., 
2013). Cortical neuron outgrowth is increased by 71% following 24 hours incubation 
with α2-macroglobulin. Cerebellar granule neuron neurite outgrowth is almost 3 times 
greater following 48 hour treatment with the ligand binding region of α2-macroglobulin. 
Outgrowth in both these cell types was inhibited by RAP (Qiu et al., 2004, Shi et al., 
2009). In contrast, 48 hour treatment with myelin-associated glycoprotein inhibits 
cerebellar granule neuron neurite length to 40% of untreated controls. These effects 
were inhibited by RAP and siRNA against LRP1 (Stiles et al., 2013). These studies 
demonstrate that LRP1 is able to both promote and inhibit neurite outgrowth. Both these 
processes need to occur in order to establish functional neuronal connections and 
suggest a role for LRP1 in regulation of developmental neurite outgrowth. 
Expression of LRP1 in vitro was most prominent at the cell body, consistent 
with in vivo observations. Its role at this subcellular location could be in neuronal 
survival, in which it has been implicated previously. Hippocampal neurons are protected 
from amyloid-β toxicity through treatment with apoE bound cholesterol, effects that are 
inhibited by RAP and antibodies against LRP1 (Sen et al., 2012). ApoE3 and apoE4 
bound lipoproteins promote retinal ganglionic cell survival following trophic 
withdrawal and glutamate toxicity. Antibodies or siRNA against LRP1 suppressed this 
protection (Hayashi et al., 2007, Hayashi et al., 2012). In addition, LRP1 knock-down in 
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mixed cortical and hippocampal neuron culture results in increased susceptibility to 
trophic withdrawal mediated apoptosis and amyloid-β toxicity. However, knock-down 
did not affect untreated neuron viability (Fuentealba et al., 2009). Therefore, LRP1 may 
not be essential for survival of hippocampal neurons in healthy conditions, but becomes 
vital in cases of stress. LRP1 may be expressed upon hippocampal neurons in culture to 
inhibit their apoptosis in response to stressful or toxic stimuli. 
In addition to expression at the cell body, LRP1 was immunoreactive along 
dendrites at all time points in vitro. Dendrites receive and interpret incoming neuronal 
signals, and LRP1 expression along these structures suggests that the receptor may be 
involved in this process. The formation of mature hippocampal synapses in vitro begins 
at about 12DIV and continues to 21DIV, though the construction of synapses begins as 
early as 2DIV (Rao et al., 1998). The function of dendritic LRP1 could be in synaptic 
function. 
3.4.3 LRP1 DOES NOT CO-LOCALISE WITH PSD-95, SYNAPTOPHYSIN OR NR2A 
BUT DOES PARTIALLY CO-LOCALISE WITH NR2B 
LRP1 has been implicated in regulation of synaptic activity due to its ability to 
associate with synaptic proteins and modulate calcium influx in neurons in response to 
neurotransmitters. Previous studies have used immunoprecipitation and pull down 
assays to demonstrate an association between LRP1 and PSD-95 (Gotthardt et al., 2000, 
May et al., 2004), an interaction that may occur through binding of the LRP1 distal 
NPxY motif to PSD-95. This in turn might lead to the association of LRP1 and the 
NMDA receptor and may be how LRP1 regulates NMDA and glutamate mediated 
calcium influx (Bacskai et al., 2000, Martin et al., 2008, Hayashi et al., 2012). In the 
present study, LRP1 did not co-localise with PSD-95 or the pre-synaptic protein, 
synaptophysin, in hippocampal neurons at 7, 14 or 21DIV, though this latter observation 
was expected as LRP1 is not present on axons where pre-synaptic sites are located. The 
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association of LRP1 with PSD-95 is believed to lead to the interaction of LRP1 and the 
NMDA receptor. May and colleagues (2004) found that LRP1 co-localised directly with 
the NMDA receptor subunit, NR2a, in hippocampal neurons in vitro, though the age of 
these cultures was not specified. LRP1 did not co-localise with NR2a in 14DIV 
hippocampal neurons in the current culture model, which may be expected as it did not 
associate with PSD-95. 14DIV was chosen as a time point to investigate LRP1 and 
NMDA receptor interactions as hippocampal neurons begin to become synaptically 
mature at about 12DIV, and full synaptic maturity occurs between 15-21DIV (Rao et 
al., 1998). The age of May and colleagues’ (2004) hippocampal neurons in which co-
localisation occurred may have been at a later stage of synaptic maturity. Alternatively, 
co-localisation of LRP1 with post-synaptic proteins may only occur when stimulated by 
either a ligand or neurotransmitter such as NMDA or glutamate.  
In hippocampal neurons, α2-macroglobulin has no immediate effect on calcium 
influx upon addition, but 48 hours incubation with this ligand reduces NMDA mediated 
calcium influx, effects inhibited by RAP (Qiu et al., 2002, Qiu et al., 2004). In contrast, 
tPA directly stimulates NMDA receptor mediated calcium influx in hippocampal 
neurons. This is inhibited by both RAP and mutation to the distal NPxY LRP1 motif 
(Martin et al., 2008). These findings demonstrate that LRP1 regulation of NMDA 
receptor mediated calcium influx is ligand specific and may provide some insight as to 
why LRP1 and PSD-95 do not co-localise in unstimulated neurons. This interaction may 
only occur when stimulated by a specific ligand. However, despite lack of co-
localisation with PSD-95 or NR2a, LRP1 did partially co-localise with the NR2b 
subunit. 
The NMDA receptor is a heterotetramic complex consisting of at least one NR1 
subunit and one or more of the NR2 subunits, NR2a, NR2b, NR2c or NR2d (Moriyoshi 
et al., 1991, Monyer et al., 1992, Ishii et al., 1993). NR2 subunits are defined by 
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different calcium kinetics and pharmacological properties and display development and 
regional specificity (Ishii et al., 1993, Monyer et al., 1994, Vicini et al., 1998). During 
development, NR2b is the predominant NR2 subunit expressed throughout the brain. 
During post-natal maturation, expression of NR2a at synapses increases while NR2b 
expression decreases at these sites (Liu et al., 2004). Excitatory post-synaptic currents 
(EPSCs) produced by NR1/NR2a channels are shorter in duration than NR1/NR2b 
channels. As the ratio of NR2a to NR2b channels increases during early post-natal 
development, EPSC duration decreases (Flint et al., 1997, Stocca and Vicini, 1998, 
Vicini et al., 1998, Lu et al., 2001). The longer duration EPSCs mediated by NR2b 
channels are believed to be through association of the subunit with CaMKII. CaMKII is 
activated by calcium influx following NMDA receptor activation and is essential for 
initiation of long-term potentiation (Reymann et al., 1988, Malenka et al., 1989, Giese 
et al., 1998). CaMKII has a lower affinity for binding to NR2a than NR2b (Leonard et 
al., 1999). The shift in EPSC potential between NR2a and NR2b channels may be 
associated with the decrease in synaptic plasticity between the immature and mature 
brain (Sheng et al., 1994). The partial co-localisation of LRP1 with NR2b subunits 
suggests that the receptor could have a role in developmental synaptic activity and 
plasticity. However, in vivo data demonstrate expression of LRP1 at the apical segments 
of dendrites in the adult brain but very little expression in dendrites of P2 and P7 
hippocampal neurons (Chapter 2.3.2). In addition, co-localisation in vitro occurred at 
14DIV when neuronal networks were reasonably mature. These findings argue against a 
role for LRP1 in developmental synaptic function. However, it may have a role in NR2b 
receptor function in the mature brain. Though NR2b is primarily expressed in 
developing brains, it is present both synaptically and extrasynaptically in the mature 
brain (Thomas et al., 2006).  
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Extrasynaptic NMDA receptors demonstrate different pharmacological and 
signaling properties to synaptic receptors. Extrasynaptic NMDA receptors preferentially 
bind glycine and are involved in propagation of long-term depression, whereas synaptic 
receptors have a higher affinity for D-serine and modulate long-term potentiation 
(Papouin et al., 2012). Astrocytes also preferentially activate extrasynaptic NMDA 
receptors to produce EPSCs. These display slow EPSC kinetics, suggesting that 
extrasynaptic NMDA receptors are composed predominately of NR1/NR2b rather than 
NR1/NR2a subunits (Fellin et al., 2004). LRP1 co-localisation with NR2b in vitro could 
be specific for either synaptic or extrasynaptic sites and may regulate the function of 
NMDA receptors at these sites. If the association is specific for one of these sites it may 
account for the partial co-localisation of LRP1 and NR2b. Alternatively, LRP1 may 
only associate with NR2b at mature, active synapses.  
About 50% of hippocampal neurons were determined to be synaptically active at 
14DIV as they demonstrated calcium influx consistent with synaptic activation 
following NMDA or glutamate addition and this may account for the partial co-
localisation of LRP1 and NR2b. If left for longer in vitro the percentage of NMDA and 
glutamate responsive neurons would most likely increase and the co-localisation of 
LRP1 with NR2b may increase. In addition, the receptor may also be found to associate 
with other synaptic proteins such as PSD-95 or NR2a as the neurons become more 
synaptically mature. 
3.4.4 LRP1 LIGANDS, MT AND EMTINB, DO NOT INDUCE CALCIUM INFLUX IN 
HIPPOCAMPAL NEURONS 
A number of ligands induce NMDA receptor dependent calcium influx through 
LRP1. Immediately following addition of tPA and α2-macroglobulin, intracellular 
calcium concentration increases in hippocampal and cortical neurons, respectively. In 
both cases, RAP and the NMDA receptor inhibitor, MK801, abolished calcium 
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responses (Bacskai et al., 2000, Martin et al., 2008). Another LRP1 ligand, MT, is also 
able to regulate calcium signaling via the receptor. Calcium concentration in dorsal root 
ganglion growth cones is increased following addition of MT, effects inhibited by 
siRNA against LRP1 (Landowski et al., 2012). However, both ligands failed to induce 
any calcium response in NMDA responsive hippocampal neurons.  
The effects of LRP1 ligands on calcium signaling appear to be both ligand and 
cell specific. tPA induces an immediate LRP1 and NMDA receptor dependent calcium 
response in hippocampal neurons but has no immediate effect on cortical neurons 
(Martin et al., 2008, Samson et al., 2008). A similar effect is observed for α2-
macroglobulin which induces an immediate calcium influx following addition to 
cortical neurons but not hippocampal neurons (Bacskai et al., 2000, Qiu et al., 2002). 
Interestingly, chronic treatment with α2-macroglobulin for up to 48 hours reduced 
NMDA mediated calcium influx in hippocampal neurons (Qiu et al., 2002). Lactoferrin 
also inhibits hippocampal neuron NMDA receptor dependent calcium influx following 
48 hour incubation, but has no direct effect on calcium concentration in cortical neurons 
(Bacskai et al., 2000, Qiu et al., 2002). Therefore, while MT and emtinB may not 
induce an immediate calcium response in hippocampal neurons, they could directly 
affect calcium influx in other neurons such as cortical neurons.  
3.4.5 LRP1 EXPRESSION IN ASTROCYTES, OLIGODENDROCYTES AND 
MICROGLIA OF HIPPOCAMPAL NEURON CULTURES 
LRP1 was expressed in the cell bodies and processes of astrocytes, 
oligodendrocytes and microglia in hippocampal neuron cultures from 3 to 21DIV. This 
is consistent with data demonstrating that LRP1 is expressed on glia in vivo throughout 
development (Chapter 2.3.2). Astrocytes, oligodendrocytes and microglia have been 
found to express LRP1 in vitro previously (Marzolo et al., 2000, Gaultier et al., 2009). 
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The few studies that have investigated the role of LRP1 in glia in vitro have provided 
evidence that the receptor regulates phagocytosis and immune responses in these cells. 
Astrocytes, oligodendrocytes and microglia are all able to phagocytose myelin 
vesicles by a LRP1 dependent mechanism (Gaultier et al., 2009). A microglial cell line 
phagocytoses heat shock treated necrotic oligodendrocytes, an effect that is reduced by 
35% when microglia were pre-treated with RAP. In addition, LRP1 is able to bind 
components of myelin normally located intracellularly (Fernandez-Castaneda et al., 
2013). This demonstrates a role of the receptor in recognising and removing necrotic 
cell debris from the extracellular environment. The function of the receptor on microglia 
in vitro could be in the removal of cell debris caused by culture preparation and 
apoptotic neurons. This is supported by data that demonstrate the ability for microglia to 
phagocytose cerebellar granule neurons in response to lipopolysaccharide or amyloid-β 
induced apoptosis. These effects were inhibited by both RAP and antibodies against 
LRP1 (Fricker et al., 2012).  
The expression of LRP1 in microglia in hippocampal neuron cultures was 
heterogeneous and did not appear to be specific to different cell morphologies. Some 
cells expressed LRP1 strongly while others only expressed the receptor faintly. 
Heterogeneous expression of LRP1 in microglia in vivo was not observed, but it may be 
that immunohistochemistry was not sensitive enough to detect this. The expression of 
LRP1 in microglia in vitro is in agreement with previous work that demonstrates 
heterogeneous expression of LRP1 in pure microglia cultures. In this same study, 
treatment with the anti-inflammatory agent dexamethasone increased LRP1 expression, 
which subsequently became homogeneous. Treatment with pro-inflammatory agents 
lipopolysaccharide and interferon-γ reduced LRP1 expression (Marzolo et al., 2000). 
These findings demonstrate the ability of LRP1 to respond to inflammatory factors and 
possibly contribute to an immune response. Microglia activation is response to 
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lipopolysaccharide can also be promoted by the LRP1 ligand tPA. Activation of tPA-
deficient microglia in cortical neuron cultures is inhibited, demonstrated by decreased 
activated morphology and tumour necrosis factor-α secretion (Rogove et al., 1999). 
These data demonstrate that microglial LRP1 is able to respond to inflammatory 
mediators in vitro, and that in some instances this could be through stimulation by 
ligands such as tPA. These in vitro findings support a role of LRP1 in microglial 
mediated immune responses. 
Few studies have investigated the function of LRP1 in astrocytes previously. 
Expression of LRP1 is decreased in astrocytes when incubated with lipopolysaccharide 
and interferon-γ in combination. However, there was no change in expression following 
treatment with either of these inflammatory agents alone or with dexamethasone 
(Marzolo et al., 2000). Therefore, LRP1 could be involved in astrocyte responses in 
strong pro-inflammatory conditions. Astrocytes are also involved in neurotransmission 
and release glutamate following calcium influx (Parpura et al., 1994). Though LRP1 is 
able to regulate calcium influx in neurons (Bacskai et al., 2000, Qiu et al., 2002, Martin 
et al., 2008, Hayashi et al., 2012), whether it does this in astrocytes to modulate 
glutamate release of these cells is unknown. 
The function of LRP1 in oligodendrocytes of hippocampal neuron cultures may 
not be in phagocytosis. Oligodendrocytes that phagocytosed myelin vesicles in previous 
work were identified as CNPase positive (Gaultier et al., 2009). CNPase is an enzyme 
involved in myelin synthesis (Kim and Pleasure, 1978), and is expressed at a more 
maturate stage of differentiation than the oligodendrocyte appear to be in the present 
culture model. The establishment of hippocampal neuron and oligodendrocyte co-
culture to study myelination requires the addition of oligodendrocytes to 14DIV neurons 
and the subsequent maturation of cells for up to 21 days (Gardner et al., 2012). It is 
therefore unlikely that oligodendrocytes in the current culture model are actively 
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myelinating hippocampal neurons. By determining the maturation stage of 
oligodendrocytes using markers other than olig2, such as CNPase, and labelling cultures 
for myelin would confirm whether this is the case. Oligodendrocytes appear to 
proliferate as cultures mature, suggesting that the majority of them are progenitor cells 
as more mature oligodendrocytes do not proliferate (reviewed by (Baumann and Pham-
Dinh, 2001)). Whether LRP1 is involved in regulating proliferation of these cells is 
unknown. Given that LRP promotes Schwann cell migration (Mantuano et al., 2010) it 
is more likely that the receptor is involved in oligodendrocyte progenitor cell migration, 
an important function of these cells if they are to connect to and myelinate neurons.  
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 CONCLUSIONS 3.5
LRP1 is expressed in hippocampal neuron cultures at 3, 7, 14 and 21DIV. The 
post-translational modifications of the receptor changes as the cultures mature. These 
differences may reflect changes in regulation of the receptor during neuron and glia 
maturation.  
Immunoreactivity is present along and at the ends of axons and dendrites of 
3DIV neurons, suggesting a function of the receptor in developmental neurite 
outgrowth. LRP1 expression is reduced in axons of 7DIV and absent from 14DIV and 
21DIV cultures. Localisation of LRP1 remains at the cell body and along dendrites at all 
time points where it may have a role in neuronal survival or synaptic signaling. 
However, LRP1 did not co-localise with PSD-95 or synaptophysin at any time point, or 
with NR2a at 14DIV. Partial co-localisation with NR2b was observed at 14DIV, 
suggesting it may be involved in synaptic activity of these NMDA receptors. 50% of 
hippocampal neurons were synaptically active, demonstrated by responses to NMDA 
and glutamate. Older cultures that are completely synaptically active may demonstrate 
greater co-localisation of LRP1 with NR2b and possibly with other synaptic proteins. In 
addition, stimulating neurons with neurotransmitters or LRP1 ligands may induce co-
localisation with other synaptic proteins. LRP1 was also expressed upon astrocytes, 
oligodendrocytes and microglia in vitro, supporting in vivo data and implicating a 
function for the receptor in these cells. 
LRP1 ligands have been found to induce calcium influx in cortical and 
hippocampal neurons previously in an NMDA receptor dependent manner. However, 
two LRP1 ligands that affect calcium signaling in dorsal root ganglion growth cones, 
MT and emtinB, did not induce calcium influx in hippocampal neurons.  
The subcellular expression of LRP1 in hippocampal neurons adds further 
support for a role of the receptor in neuronal biology. This may be in neurite outgrowth, 
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neuronal survival or functioning of NR2b containing NMDA receptors. Establishing 
and characterising an in vitro neuron model of LRP1 expression allows further 
investigation into the receptor’s function in processes such as neurite outgrowth, injury, 
toxicity or synaptic function. 
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4 Chapter 4: Effects of the LRP1 ligands, MT and emtinB, on 
hippocampal neurite extension following scratch injury 
 INTRODUCTION 4.1
LRP1 is expressed on rat hippocampal neurons both in vivo and in vitro as 
reported in chapters 2 and 3 respectively. The receptor is expressed in the cell body and 
dendrites of hippocampal neurons at 3, 7, 14 and 21DIV. LRP1 expression on axons is 
present at 3DIV, reduced at 7DIV and absent from 14DIV and 21DIV cultures. The 
presence of LRP1 at the ends of extending neurites in 3DIV cultures suggests that it is 
involved in hippocampal neurite outgrowth during development (Chapter 3.3.2). Given 
that LRP1 is expressed at ends of developing neurites, it could also be expressed in 
regenerating neurites following injury. This is suggested by previous work which 
demonstrates that LRP1 is necessary for apoE containing lipoprotein mediated axon 
extension of axotomised retinal ganglion cells. Addition of apoE containing lipoproteins 
promoted axon extension by 50%, but only when applied to axons. When applied to cell 
bodies axon extension was the same as for controls (Hayashi et al., 2004, Matsuo et al., 
2011). This is evidence that LRP1 located on injured axons mediates neurite extension.  
Another LRP1 ligand, MT, is also able to promote neurite regeneration 
following injury. MT increases the average length of cortical neurites 12 hours after 
scratch injury from 41.5 ± 1.7μm to 70.1 ± 3.4μm. Regeneration of in vivo cortical 
needlestick injury after 4 days is also enhanced with application of MT (Chung et al., 
2003). MT also increases regenerative sprout length of dorsal root ganglion cells by 
66% when applied to axons following scratch injury. Addition  of MT to cell bodies 
produced an even greater increase in sprout length by almost fourfold (Leung et al., 
2011). Whether MT promotes regeneration of hippocampal neurites following scratch 
injury is unknown. 24 hour treatment with MT enhances hippocampal neurite extension 
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by 1.6 times that of controls (Køhler et al., 2003). Therefore, it is conceivable that it 
may have an effect on hippocampal outgrowth following injury.  
EmtinB, a synthetic peptide modeled after the C-terminus of the MT β-domain 
(Figure 4.1), also promotes neurite outgrowth, but whether it promotes regeneration 
following injury is unknown. 24 hour treatment with emtinB increases neurite length of 
hippocampal and  cerebellar granule neurons by 7 and 3 times that of controls, 
respectively (Ambjørn et al., 2008, Sonn et al., 2010). Investigating whether this peptide 
has an effect on neurite regeneration may be of therapeutic importance as emtinB is able 
to cross the blood brain barrier (Sonn et al., 2010) and could be used to promote neuron 
function following brain injury. 
I hypothesise that (1) LRP1 is expressed at the ends of regenerating neurites 
following scratch injury in hippocampal neuron cultures; and (2) the LRP1 ligands, MT 
and emtinB, promote extension of neurites following scratch injury. 
 
  
120 
 
 
Figure 4.1: Simplified schematic and amino acid sequence of rabbit MT and the 
synthetic peptide, emtinB. Rabbit MT, used in the experiments of this thesis, is 
composed of a β- and α-domain. EmtinB is modeled after the C-terminal end of the 
human β-domain of MT, which possesses a serine residue (S) instead of a glycine 
residue (G) that is present in rabbit MT. Some cysteine residues (bold black C’s) in the 
MT sequence were substituted with serine (bold black S’s) in emtinB to inhibit 
inappropriate peptide aggregation.  
Adapted from (Asmussen et al., 2009) 
Rabbit MT GenBank accession number: 1515428A 
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 METHODS 4.2
All experiments involving the use of animals were approved by the Animal 
Experimentation Ethics Committee of the University of Tasmania (ethics number 
A0011957), which is in accordance with the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes.  
Buffer recipes and product information for all reagents can be found in 
appendices. 
4.2.1 PRIMARY HIPPOCAMPAL NEURON CULTURE 
Primary hippocampal neuron cultures were prepared from embryonic day 17/18 
Sprague Dawley rats as described previously (Chapter 3.2.1). Briefly, hippocampi were 
dissected from embryos and trypsinised using 0.1% trypsin in HBSS at 37°C for 5 
minutes. Following trypsin removal, cells were resuspended in 1mL Neurobasal with 
10% foetal calf serum and dissociated by pipette. Cells were counted using Trypan Blue 
exclusion and plated at 5x10
4
 cells/well on 13mm nitric acid etched glass coverslips 
coated overnight with neat poly-L-lysine in 24 well plates. A full media change to 
serum free Neurobasal media was conducted 24 hours after plating and every three to 
four days thereafter. Cultures were maintained at 37°C in humidified air with 5% 
carbon dioxide.  
4.2.2 SCRATCH INJURY AND IMMUNOCYTOCHEMISTRY 
Scratch injury was performed on hippocampal neuron cultures at 6DIV and 
13DIV using a fine goniotomy knife (Kaisers). Two scratches were made to form an ‘X’ 
across each coverslip (Figure 4.2). Cells were fixed either immediately after injury or 24 
hours later at 7DIV or 14DIV with 4% paraformaldehyde for 15-20 minutes at room 
temperature. All coverslips were stored at 4°C in PBS with 0.01% sodium azide. 
Cells were protein blocked using 10% goat serum in 0.03% triton X-100 in PBS 
for 30 minutes at room temperature to inhibit non-specific antibody binding. To assess 
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whether LRP1 was expressed on regenerating neurites, rabbit polyclonal anti-LRP1 
antibodies were incubated with mouse monoclonal antibodies against axons and 
dendrites. These were either anti-tau, which labels hippocampal neuron cell bodies, 
dendrites and axons (Dotti et al., 1987), anti-SMI-312, which specifically labels 
phosphorylated axons (Masliah et al., 1993), or anti-MAP2 antibodies, which 
specifically labels dendrites (Matus et al., 1981). To determine whether tau positive 
neurites that extended into or along the scratch injury site were primarily axons or 
dendrites, rabbit polyclonal anti-tau antibodies and mouse monoclonal anti-SMI-312 or 
anti-MAP2 antibodies were incubated with cultures. All primary antibodies were diluted 
together in 10% goat serum in PBS with 0.03% triton X-100 and incubated with 
cultures for 1 hour at room temperature and overnight at 4°C. Next, cultures were 
incubated with goat anti-rabbit AlexaFluor®-594 and goat anti-mouse AlexaFluor®-
488 secondary antibodies (both Molecular Probes, USA) for one hour at room 
temperature before counterstaining with 1μg/ml nuclear yellow. Coverslips were 
washed three times by gentle shaking in PBS for 5 minutes following each antibody 
incubation. Coverslips were mounted to slides using fluorescent mounting media and 
dried overnight. At least 1 coverslip from 3 separate cultures were prepared for each 
antibody combination.  
Photographs of scratch injuries were taken using an Olympus BX50 microscope 
and Photomatrix Cool Snap HQ
2
 camera. Photographs of 7DIV and 14DIV cultures 24 
hours after scratch injury were taken at 60X objective to assess LRP1 expression at 
extending neurites. Representative images of cultures 0 or 24 hours after injury at 6DIV 
or 7DIV, respectively, were captured at 20X objective. All images were uniformly 
enhanced and analysed using Adobe Photoshop (v11.0.2). 
Whether the LRP1 ligands MT and emtinB promote neurite extension following 
injury was investigated. 10μg/mL MT has been shown to promote neurite outgrowth 
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previously (Køhler et al., 2003, Fitzgerald et al., 2007, Ambjørn et al., 2008, Chung et 
al., 2008). Our lab has demonstrated that 25μM emtinB ameliorates β-amyloid toxicity 
in 7DIV hippocampal neuron cultures (Eaton et al., 2012). Concentrations between 200-
500nM RAP have been used previously to inhibit LRP1 mediated neurite outgrowth and 
regeneration (Hayashi et al., 2004, Qiu et al., 2004, Stiles et al., 2013). Therefore, 6DIV 
cultures were treated with 10μg/mL MT (equivalent to 1.5μM), 25μM emtinB 
(equivalent to 75μg/mL) or the equivalent volume of saline with or without 500nM 
RAP (Progen Biotechnik, Germany) immediately prior to the injury. For each treatment 
2-3 coverslips were prepared from 3 separate cultures.  
Cultures were protein blocked and underwent immunocytochemistry as 
described above. Briefly, rabbit polyclonal anti-LRP1 and mouse monoclonal anti-tau 
antibodies were diluted together in 10% goat serum in PBS with 0.03% triton X-100 for 
1 hour at room temperature and then overnight at 4°C. Cultures were then incubated 
with goat anti-rabbit AlexaFluor®-594 and goat anti-mouse AlexaFluor®-488 
secondary antibodies, counterstained with nuclear yellow, mounted and dried overnight. 
Counts for tau positive neurites were analysed from 3 photographs taken at 10X 
objective in each direction extending from where the two scratch injuries intersected 
(Figure 4.2). All images were uniformly enhanced and analysed using Adobe Photoshop 
(v11.0.2). 
The majority of neurites were cleanly cut immediately after scratch injury 
(Figure 4.6 A), and therefore neurites that extended along or entered the injury site 24 
hours later were counted as regenerating neurites. It is likely that poly-L-lysine substrate 
was removed from the coverslip during scratch injury, inhibiting neurite extension 
across the injury site. As growth across the injury site was impeded, neurites instead 
extended along the side of the injury. It was difficult to accurately track and measure 
most individual neurites as they joined and clumped, so quantitation of neurite 
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extension was conducted by counting the numbers of neurites that extended along or 
entered the injury site.  Neurites were counted blind by one observer and converted to 
neurites per cm of injury site. Data analysis was performed using Microsoft Excel 
(v14.0.7015.1000). Data for cultures treated with MT and emtinB were pooled 
separately and statistics performed using single factor ANOVA. Statistically significant 
results were indicated by p<0.05. Data were expressed as averages ± standard error of 
the mean. 
 
  
125 
 
 
Figure 4.2: Pattern of photographs taken for scratch injury analysis. Three photographs 
(black boxes) were captured in each direction from where the two scratch injuries (red 
lines) intersected. Neurites that extended along or into the injury site were counted. 
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 RESULTS 4.3
4.3.1 THE MAJORITY OF REGENERATING TAU POSITIVE NEURITES ARE 
AXONS AND EXPRESS LRP1  
The majority of tau positive neurites were cut cleanly immediately following 
scratch injury at 6DIV, though some did appear to be ‘dragged’ slightly along the injury 
site (Figure 4.3 A). 24 hours after injury some neurites touched, extended along or 
entered the injury site (Figure 4.3 B). To determine whether these neurites were axons 
or dendrites, cells were immunolabelled for tau and SMI-312 or MAP2 respectively. 
The majority of tau positive neurites that extended along or into the injury site were 
SMI-312 positive (Figure 4.4 A), but very few were immunoreactive for MAP2 (Figure 
4.4 B). These results demonstrate that the majority of tau positive neurites that extended 
along or into the scratch injury site 24 hours after injury were axons. 
LRP1 was expressed along and at the ends of most, but not all, tau and SMI-312 
positive neurites that extended along or into the scratch injury site at 7DIV (Figure 4.5 
A and B). LRP1 immunoreactivity was similar in both tau and SMI-312 positive 
neurites. Intensity of LRP1 staining was faint along most extending axons, similar to 
immunoreactivity observed in axons of uninjured cultures. Expression at the growth 
cone was strong and comparable to LRP1 immunoreactivity detected in dendrites of 
uninjured cultures. A greater number of axons appeared to express LRP1 in injured 
cultures compared to uninjured cultures. Some extending tau positive neurites 
demonstrated LRP1 immunoreactivity at 14DIV (Figure 4.5 C), but the majority did 
not. Neurites that were LRP1 positive demonstrated faint staining when compared to 
cell body and dendritic staining of uninjured 14DIV neurons. LRP1 positive neurites 
that extended across the injury site were not MAP2 positive at 7DIV (Figure 4.6). These 
results demonstrate that LRP1 is expressed at growth cones of regenerating 
hippocampal neuron axons following injury.  
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Figure 4.3: The majority of neurites are cut during scratch injury. Hippocampal neurons 
were grown to 6 days in vitro (DIV), fixed at either 0 (A) or 24 hours (B) following 
scratch injury (white dashed lines) and immunolabelled for tau. Some neurites appeared 
to be ‘pulled’ by the scratch injury (A, white arrowheads) but the majority were cut. 24 
hours after injury, some neurites appeared to touch (B, grey arrow), follow (B, grey 
arrowhead) or extend into the injury site (B, white arrow).  
Scale bar = 500μm 
128 
 
 
Figure 4.4: The majority of neurites that extend into or along the injury site 24 hours 
after scratch injury at 7 days in vitro (DIV) are axons. Scratch injury was performed on 
6DIV hippocampal neuron cultures that were fixed 24 hours later at 7DIV. Cultures 
were immunolabelled for tau, which labels axons and dendrites (red) and either the axon 
marker SMI-312 (red; A) or the dendritic marker MAP2 (red; B) and counterstained 
with nuclear yellow (blue). Tau positive neurites that followed or extended into the 
injury site (dashed lines) were SMI-312 positive (A arrows), but very few were MAP2 
positive (B arrows).  
Scale bar = 100μm   
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Figure 4.5: LRP1 is expressed at the ends of extending hippocampal neurites 24 hours 
after scratch injury at 7 and 14 days in vitro (DIV). Scratch injury was performed on 
hippocampal neuron cultures at 6DIV which were fixed 24 hours later at 7DIV and 
immunolabelled for LRP1 and tau (A) or SMI-312 (B). Hippocampal neuron cultures 
grown to 13DIV were scratch injured, fixed 24 hours later at 14DIV and 
immunolabelled for LRP1 and tau (C).  LRP1 was expressed at the ends of most tau and 
SMI-312 positive neurites extending towards and into the scratch injury site at 7DIV, 
but only some tau positive neurites at 14DIV. 
Scale bar = 25μm  
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Figure 4.6: Most LRP1 positive processes that extend across or along the injury site are 
not dendrites. Hippocampal neuron cultures were fixed at 7 days in vitro (DIV), 24 
hours after scratch injury (dotted lines). Cultures were immunolabelled for LRP1 and 
the dendritic marker MAP2. LRP1 positive processes that extended across the injury 
site were negative for MAP2 (inset and arrowheads).  
Scale bar = 50μm; inset scale bar = 25μm  
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4.3.2 EMTINB INCREASES THE NUMBER OF NEURITES THAT EXTEND ALONG 
OR INTO THE SCRATCH INJURY SITE BUT MT DOES NOT 
Neurites that touched, extended along or entered the injury site were observed in 
all cultures treated with saline, MT and emtinB with or without RAP (Figure 4.7 A-F). 
The numbers of neurites that extended along or entered the injury site were counted per 
cm of injury site. No significant difference in the number of neurites that extended 
along or into the injury site were observed when MT, RAP or MT + RAP were added to 
cultures when compared to saline controls (Figure 4.8 A). EmtinB significantly 
increased the number of neurites that extended along or entered the injury site (57.8 ± 
4.6 neurites/cm injury site) compared to both saline (27.7 ± 3.3 neurites/cm injury site; 
p<0.005) and emtinB + RAP treated cultures (36.5 ± 3.2 neurites/cm injury site; 
p<0.005; Figure 4.8 B). No difference in the number of neurites that extended along or 
into the injury site was observed between saline treated controls and cultures treated 
with RAP or emtinB in combination with RAP. Therefore, emtinB appears to promote 
hippocampal neurite extension in an LRP1 dependent manner 24 hours following 
scratch injury but MT does not. 
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Figure 4.7: Representative images of neurite extension 24 hours after scratch injury 
with saline, MT or emtinB with or without RAP. Hippocampal neurons were grown to 6 
days in vitro (DIV) and either saline, 10μg/mL MT or 25μM emtinB alone (A, C, E, 
respectively) or with 500nM RAP (B, D, F, respectively) was added immediately prior 
to scratch injury (white dashed lines). Cultures were fixed 24 hours later at 7DIV and 
immunolabelled for tau. Neurites appeared to touch and follow the injury site (grey 
arrowheads) or extended into or across it (white arrows).  
Scale bar = 100μm
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Figure 4.8: Effect of MT and emtinB on the number of neurites that extended along or 
into the scratch injury site. Saline, 10μg/mL MT or  25μM emtinB with or without 
500nM RAP was added to hippocampal neuron cultures immediately prior to scratch 
injury at 6 days in vitro (DIV). Cells were fixed and immunolabelled for tau 24 hours 
later at 7DIV. Neurites that extended along or into the injury site were counted and 
converted to extending neurites per cm of injury site length. Addition of MT had no 
effect on the number of neurites that extended along or into the injury site (A). EmtinB 
increased the number of neurites that extended along or entered the injury site when 
compared to saline treated controls (B). RAP inhibited emtinB mediated neurite 
extension. RAP by itself did not increase the neurite extension when compared to the 
saline control. 
* = p<0.005 compared to all other treatments; error bars = standard error of the mean 
* 
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 DISCUSSION 4.4
LRP1 is expressed at the ends of extending neurites 24 hours following scratch 
injury in both 7DIV and 14DIV hippocampal neuron cultures. The majority of these 
neurites are axons which are cleanly cut following scratch injury at 6DIV and appear to 
touch, extend into or enter the scratch injury site after 24 hours at 7DIV. MT did not 
promote neurite extension, but emtinB increased the number of neurites that extended 
along or into the injury site by two-fold when compared to the saline control. RAP 
inhibited this effect, demonstrating that emtinB promotes neurite extension through an 
LRP1 mechanism.  
4.4.1 LRP1 IS EXPRESSED AT THE ENDS OF EXTENDING HIPPOCAMPAL 
NEURITES AFTER SCRATCH INJURY 
24 hours following scratch injury, LRP1 immunoreactivity is present at the ends 
of most 7DIV and some 14DIV extending tau positive neurites. This demonstrates the 
potential for LRP1 to direct neurite extension in relatively immature neurons (7DIV) as 
well as in some mature, synaptically active neurons (14DIV). The majority of tau 
positive neurites that expressed LRP1 and extended into or along the injury site were 
determined to be axons. Very few axons in uninjured 7DIV cultures were LRP1 positive 
(Chapter 3.3.2). However, most extending axons 24 hours after scratch injury at 7DIV 
were immunoreactive for LRP1, particularly at growth cones. Therefore it appears that 
expression of the receptor changes in response to injury and suggests that it may be 
involved in axon extension. 
The ability of LRP1 to promote axon extension has been demonstrated both in 
vitro and in vivo previously. ApoE containing lipoprotein enhances retinal ganglion cell 
axon extension by 50% following axotomy (Hayashi et al., 2004). An increase in axon 
extension only occurred when the ligand was added to axons, not cell bodies, and was 
inhibited by addition of RAP, siRNA and antibodies against LRP1 (Hayashi et al., 2004, 
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Matsuo et al., 2011). In vivo work demonstrates that the receptor binding domain of α2-
macroglobulin, another LRP1 ligand, also promotes axon regeneration following dorsal 
column lesion in rats. Intrathecal injection of the ligand into the lesion increases the 
total proportion of axons into the site by 71% and the length of axons by 3.6-fold when 
compared to vehicle infused controls, presumably through LRP1 (Yoon et al., 2013). 
These studies demonstrate that LRP1 is located at the ends of severed axons and that it 
mediates regeneration of these processes. It is possible then that LRP1 located at the 
ends of hippocampal axons also promotes neurite extension following scratch injury of 
this neuronal subtype. 
4.4.2 MT DOES NOT APPEAR TO PROMOTE HIPPOCAMPAL NEURITE 
EXTENSION FOLLOWING INJURY 
Hippocampal neurite length during development is enhanced by 1.6 times 
following 24 hours treatment with 10μg/mL MT (Køhler et al., 2003). In injury models, 
MT addition to both cortical neurons and dorsal root ganglion cells increased neurite 
length by 60-70% when compared to vehicle treated controls following scratch injury 
(Chung et al., 2003, Leung et al., 2011). Given these reports, it was unexpected that MT 
did not promote the number of neurites that extended along or into the scratch injury 
site of 7DIV hippocampal neurons. However, these current findings are not comparable 
to previous literature that report regeneration as neurite length (Chung et al., 2003, 
Leung et al., 2011) as opposed to the number of neurites/unit length of injury site. 
Previous work has demonstrated that while MT promotes neurite length it does not 
enhance the number of reactive cortical processes per 100μm of the scratch injury site 
(Chung et al., 2003). Therefore, it appears that counting the number of neurites 
extending into or along the injury site could be a less sensitive measurement of 
regeneration and it cannot be definitively concluded that MT does not promote neurite 
regeneration based on current data. Measurement of neurite length was not possible in 
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the current hippocampal neuron injury model as it was difficult to accurately track and 
measure individual neurites that joined and clumped with other neurites. Using 
compartmentalised chambers, such as microfluidic chambers, to sever all axons from a 
specific point would enable precise measurement of neurite length and regeneration 
(Taylor et al., 2005). This may reveal regenerative effects of MT masked using the 
current analysis.  
Additional explanations as to why MT did not appear to promote neurite 
extension may include masking of its effects by endogenous MT production in response 
to scratch injury. MT is expressed in astrocytes both in vivo and in vitro and its 
expression is significantly upregulated from 1 to 24 hours following scratch injury in 
mixed cortical neuron and astrocyte cultures (Young et al., 1991, Chung et al., 2004). It 
has been demonstrated that astrocyte MT expression is induced specifically by neuron 
injury. The total concentration of secreted MT detected in media of uninjured cultures 
was less than 0.1μg/mL, but local concentrations of MT that occur between astrocytes 
and neurons in vivo or in co-cultures were likely to be much higher (Chung et al., 2008). 
The amount of MT secreted by astrocytes following scratch injury in neuron cultures is 
likely to be even higher (Chung et al., 2004). At 7DIV, 15% of cells in hippocampal 
neuron cultures were astrocytes (Chapter 3.3.2). These astrocytes may secrete MT in 
response to the hippocampal neuron injury and mask effects of exogenous MT. Though 
addition of 5μg/mL MT to cortical neuron cultures significantly promoted the length of 
regenerating neurites following injury (Chung et al., 2003), astrocytes may behave 
differently in hippocampal neuron cultures to secrete greater amounts of MT. However, 
the lack of an MT mediated increase in hippocampal neurite extension following injury 
may also be due to experimental procedure and analysis.  
In the current study, hippocampal neurons were analysed for neurite extension 
24 hours following injury. Though MT mediated cortical neuron and dorsal root 
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ganglion cell neurite outgrowth was evident 12 and 16 hours post-scratch injury 
respectively (Chung et al., 2003, Leung et al., 2011), hippocampal neurite extension 
may take longer to occur. Length of retinal ganglion cell neurite extension significantly 
increased 4 days after injury following treatment with apoE3 containing lipoproteins 
through an LRP1 dependent mechanism (Hayashi et al., 2004). Therefore, increasing 
the time after injury before analysis may reveal effects of MT in this cell model. This 
would also increase the number of hippocampal neurites that extend into the injury site, 
which at 24 hours was relatively low. The number of reactive cortical processes per cm 
of injury site observed 16 hours after injury were up to 300 times greater than that 
observed for hippocampal neurites (Chung et al., 2003). With so few neurites contacting 
the injury site, significant differences may be masked between treatments.  
4.4.3 EMTINB INCREASES THE NUMBER OF HIPPOCAMPAL NEURITES THAT 
EXTEND ALONG OR ENTER THE INJURY SITE  
EmtinB doubled the number of hippocampal neurites that extended along or into 
the scratch injury site when compared to the saline control. It cannot be definitely 
concluded whether these neurites are severed neurites regenerating or newly formed 
sprouting neurites. Previous work has demonstrated that 24 hour emtinB treatment 
increases developmental hippocampal neurite outgrowth by 7 times that of controls 
(Sonn et al., 2010). The peptide also enhances neurite outgrowth of cerebellar granule 
neurons by up to 3 times that of controls following 24 hours incubation, effects 
inhibited by RAP (Ambjørn et al., 2008). These findings support a role for emtinB in 
promotion of neurite extension following injury. By measuring neurite length it can be 
determined whether these neurites are newly formed or regenerating after being cut. As 
discussed previously, measurement of neurite length was not possible in this culture 
model but can be conducted using compartmentalised chambers and severing all axons 
from a precise point (Taylor et al., 2005). Measuring neurite length over a number of 
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time points would also aid in determining that regeneration is occurring as opposed to 
sprouting. However, this current work has provided evidence that emtinB may be 
involved in neurite extension following injury and that this needs to be confirmed. 
The emtinB induced increase in the number of hippocampal neurites that 
extended into or along the injury site was abolished by treatment with RAP. These 
results demonstrate that neurite extension mediated by emtinB is through LRP1. 
However, MT and emtinB are also ligands for the LDL receptor family member LRP2, 
which binds to and is inhibited by RAP (Orlando et al., 1992, Ambjørn et al., 2008). 
Therefore, the emtinB effects observed in these current experiments may not be 
specifically through LRP1 but also through LRP2. Specific inhibition of LRP2 with 
antibodies or siRNA abolishes MT mediated increases in retinal ganglion cell axon 
formation and cortical neurite length (Fitzgerald et al., 2007, Chung et al., 2008). 
Therefore, emtinB mediated neurite extension may be through LRP2. However, LRP1 
and LRP2 can mediate their effects by associating with each other and forming a 
signaling domain (Landowski et al., 2012). The two receptors co-localise in growth 
cones of developing dorsal root ganglion cells and modulate MT mediated growth cone 
attraction by working synergistically with each other. siRNA against either LRP1 or 
LRP2, as well as in combination, inhibits MT mediated growth turning (Landowski et 
al., 2012). EmtinB mediated neurite extension may occur through a similar mechanism 
in which LRP1 and LRP2 recruit each other to mediate signaling.  
4.4.4 DIFFERENT EFFECTS OF LRP1 LIGANDS ON NEURITE EXTENSION 
The different effect of MT and emtinB on hippocampal neurite extension 
following injury further supports the importance of ligand composition in LRP1 
mediated responses. This has been demonstrated with regard to neurite extension 
previously. EmtinB modeled after the C-terminus of the MT beta chain increases neurite 
outgrowth of cerebellar granule neurons but emtinB modeled after the N-terminus does 
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not (Ambjørn et al., 2008, Asmussen et al., 2009). Retinal ganglion cell axon extension 
following axotomy is enhanced by apoE3 containing lipoproteins by 28%, but apoE4 
containing lipoproteins and α2-macroglobulin have no effect (Matsuo et al., 2011). It 
was assumed that the apoE3 containing lipoproteins acted through LRP1 as a mix of 
apoE containing lipoproteins promoted similar neurite extension and these effects were 
inhibited by siRNA and antibodies against LRP1 (Matsuo et al., 2011). These studies 
support the current findings that even structurally similar ligands, such as MT and 
emtinB, can have different effects on LRP1 function in neurite extension.  
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 CONCLUSIONS 4.5
LRP1 is expressed at the ends of extending hippocampal axons 24 hours 
following scratch injury. EmtinB increased the number of neurites that extended along 
or into the injury site, but MT did not. RAP inhibited emtinB mediated neurite 
extension, demonstrating that the effect of emtinB was through an LRP1 dependent 
mechanism.  
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Chapter 5: Conclusions and future directions 
The aim of this thesis was to establish a model to investigate the diversity and 
specificity of LRP1 on neuron function. Subcellular localisation of the receptor in 
neurons and glia in vivo and in vitro provides evidence that LRP1 is involved in these 
cell’s activity. Potential roles may be in survival, signaling or outgrowth, which the 
receptor has been demonstrated to modulate in previous literature (Hashimoto et al., 
2000, Hayashi et al., 2007, Shi et al., 2009, Matsuo et al., 2011, Hayashi et al., 2012, 
Stiles et al., 2013, Yamauchi et al., 2013). By establishing an in vitro neuron model that 
recapitulated aspects of in vivo LRP1 expression patterns, it was possible to further 
investigate the role of LRP1 in calcium signaling and regeneration following injury 
through the use of its ligands, MT and emtinB.  
LRP1 is expressed in the brains of P2, P7 and adult rats. Different molecular 
weight LRP1 fragments were detected in whole brain, cortical and hippocampal tissue 
at each time point, suggesting that regulation of LRP1 may be region specific. P2 and 
P7 whole brain, cortex and hippocampus exhibited different LRP1 profiles by western 
blotting when compared to the same brain regions in adults. LRP1 fragments detected in 
hippocampal neuron cultures also differed from 3 to 21DIV. These findings 
demonstrate that regulation, and possibly function, of LRP1 changes during maturation. 
To identify the composition of each LRP1 positive fragment, brain lysate can be run on 
2-dimensional gels to further separate protein fractions and stained to identify LRP1 
molecules that correspond to the same size detected with western blots. Following 
digestion and by referring to the LRP1 structure, mass spectrometry can be used to 
determine fragment composition (Shevchenko et al., 1996, Guttman et al., 2009). 
Cultured cells can then be transfected with a LRP1 receptor possessing knock-in 
mutations in each specific fragment to determine whether these fractions are required 
for LRP1 functions such as ligand binding, endocytosis or intracellular protein 
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signaling. For example, transfection of the mutant receptor into the LRP1-null Chinese 
hamster ovary cell line can be conducted to evaluate the endocytic capabilities of LRP1 
(FitzGerald et al., 1995, Li et al., 2000). Co-immunoprecipitation of fragments with 
specific intracellular proteins or ligands can be conducted using pull down assays to 
determine whether these fractions associate with signaling proteins and may be involved 
in their activation (Gotthardt et al., 2000). By identifying these fractions and 
determining their function, it may be possible to better understand LRP1 functions and 
how they are regulated.  
LRP1 was expressed in the cell bodies of a subset of neurons in the cortex, 
hippocampus, thalamus and hypothalamus of P2, P7 and adult brains. This correlated 
with the immunoreactivity of LRP1 in cultured hippocampal neurons, which was 
particularly evident at the cell body. Previous data have demonstrated the ability of 
LRP1 to promote neuronal survival (Hayashi et al., 2007, Fuentealba et al., 2009, 
Hayashi et al., 2012, Sen et al., 2012). As the cell body is the site involved primarily in 
protein synthesis for processes such as survival (Haines, 2002), LRP1 expressed on 
neuronal cell bodies may be involved in this process. In vivo, mice with an LRP1 
knock-out in forebrain neurons have increased neurodegeneration in the cortex and 
hippocampus compared to wild type mice (Liu et al., 2010). Similar knock-out models 
could be used to investigate the role of LRP1 in neuronal survival in conditions such as 
excitotoxicity and ischaemia. These conditions can be induced in vivo by intraperitoneal 
kainic acid injection (Schwob et al., 1980, Yang et al., 1997) or cerebral artery 
occlusion (Longa et al., 1989), respectively. If neuronal LRP1 knock-out mice are more 
susceptible to neurodegeneration it would support a role for the receptor in promoting 
neuron survival. Alternatively, LRP1 ligands such as MT could be injected following in 
vivo excitotoxicity or ischaemia to determine whether stimulation of the receptor can 
protect against neurodegeneration. 
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Cortical and hippocampal neurons in the adult brain also expressed LRP1 on 
apical dendrites where it may be involved in synaptic signaling. LRP1 
immunoreactivity was also present on dendrites of cultured hippocampal neurons at 3, 
7, 14 and 21DIV. However, LRP1 did not co-localise with PSD-95 or the NMDA 
receptor subunit NR2a. It may be that neurons require stimulation either by NMDA or 
glutamate, or LRP1 ligands, such as tPA, that induce NMDA receptor dependent 
calcium influx to induce LRP1 to physically associate with synaptic proteins. This can 
be tested in vitro by adding agents to synaptically mature hippocampal neuron cultures 
and fixing cells in 30 second intervals from 0 up to 2 minutes afterwards. Neurons can 
then be co-immunolabelled for LRP1 and synaptic proteins to observe whether the 
receptor associates with these proteins to induce calcium responses. In unstimulated 
neurons, LRP1 did partially co-localise with the NMDA receptor subunit NR2b which 
is expressed at synapses of the developing brain but also synaptically and 
extrasynaptically in mature brain (Malenka et al., 1989, Giese et al., 1998, Stocca and 
Vicini, 1998, Vicini et al., 1998, Liu et al., 2004). LRP1 expression was present at 
apical dendrites of adult brains, but there was very little LRP1 expression in dendrites of 
P2 and P7 brains. These findings suggest that the receptor may regulate NDMA 
receptor dependent calcium influx through interaction with the NR2b subunit in the 
mature rather than in the developing brain. LRP1 co-localisation with NR2b or other 
synaptic proteins in vivo can be conducted to investigate whether the receptor may be 
involved in synaptic signaling in the brain.  
The LRP1 ligands, MT and emtinB, did not induce calcium influx in 
hippocampal neurons expressing functional NMDA receptors. MT and emtinB may 
mediate NMDA receptor calcium influx through long term pathways that require 
chronic incubation, similar to those reported for the LRP1 ligand α2-macroglobulin 
(Qiu et al., 2002). This can be investigated by incubating MT and emtinB with 
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hippocampal neurons for a longer time course, such as 48 hours, and then assessing 
calcium influx in response to NMDA. The potential ability of  MT and emtinB to 
induce calcium influx may also be neuron specific similar to the scenario reported for 
other LRP1 ligands, such as tPA and α2-macroglobulin (Bacskai et al., 2000, Qiu et al., 
2002, Martin et al., 2008, Samson et al., 2008). Analysing live cell calcium influx in 
cortical neurons, or other neuron subtypes, following MT and emtinB addition would 
determine whether this is the case. 
Axonal expression of LRP1 was absent from P2, P7 and adult brain but was 
present along and at the ends of 3DIV and some 7DIV hippocampal axons. These 
disparities are unlikely to be due to 3DIV and 7DIV cultures better representing 
embryonic rather than post-natal hippocampal neurons as the majority of hippocampal  
cytogenesis and synaptogenesis occurs within the first two post-natal weeks (Crain et 
al., 1973, Bayer and Altman, 1974, Fricke and Cowan, 1978, Pokorný and Yamamoto, 
1981). The differences between in vivo and in vitro axonal expression of LRP1 may be 
due to differences between the systems involved. This thesis demonstrates that LRP1 
expression is increased at the ends of axons following injury in mature neurons, and 
suggests that localisation of the receptor changes in response to traumatic stimuli.  
Therefore, hippocampal neurons may express axonal LRP1 in response to the stress of 
culture preparation. Stressing hippocampal neurons in other manners, such as through 
glutamate excitotoxicity or trophic withdrawal, and identifying localisation of the 
receptor may aid in understanding whether this is the case. This can be taken further in 
vivo to investigate whether localisation of LRP1 changes in response to stressful stimuli 
such as ischaemia or excitotoxicity, as described above. 
MT did not promote the number of hippocampal neurites that extended along or 
into the injury site following scratch injury. This is despite previous studies 
demonstrating the ability of the protein to promote neurite outgrowth following injury 
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in cortical neurons and dorsal root ganglion cells (Chung et al., 2003, Leung et al., 
2011). This may be due differences in hippocampal neuron responses compared to other 
neuron models or alternatively, it may reflect the methods used to quantitate 
regeneration. Previous studies have measured regeneration as neurite length rather than 
the number of neurites/unit length of injury site, which may be a more sensitive method 
to quantitate regeneration (Chung et al., 2003, Leung et al., 2011). Culturing 
hippocampal neurons in compartmentalised chambers, such as microfluidic chambers, 
and severing axons from the axon compartment would enable measurement of neurite 
length following injury (Taylor et al., 2005). Additionally, other studies have 
demonstrated that the MT mediated increase of neuron outgrowth and survival is dose 
dependent with an effective range usually between 1 to 10μg/mL (Køhler et al., 2003, 
Fitzgerald et al., 2007, Ambjørn et al., 2008). However, differences in the optimal dose 
are observed between cortical neurons, retinal ganglion cells, dopaminergic neurons and 
hippocampal neurons (Køhler et al., 2003, Fitzgerald et al., 2007, Ambjørn et al., 2008). 
Therefore, 10μg/mL MT may not be the optimal concentration to promote hippocampal 
neurite outgrowth following injury. Conducting a dose response ranging from 0.1 to 
10μg/mL MT following scratch injury may reveal the best concentration of MT to use 
to stimulate neurite regeneration.  
EmtinB doubled the number of neurites that extended along or entered the injury 
site, but it was not possible to conclude that these were regenerating as opposed to 
sprouting neurites in the current injury model. Definitively determining that both 
emtinB and MT promote hippocampal neurite regeneration following injury can be 
conducted by measuring neurite length of severed axons in compartmentalised 
chambers, as mentioned previously, over a number of time points. The current finding 
that emtinB promoted the number of neurites extending into or along the injury site was 
abolished by RAP suggesting that its effects were through an LRP1 mechanism. 
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However, emtinB also binds to LRP2 and may induce its effects through a synergistic 
mechanism between LRP1 and LRP2 (Landowski et al., 2012). To determine whether 
this is the case, hippocampal neurons can be immunolabelled for LRP2 to evaluate 
whether they express the receptor. If so, specifically inhibiting LRP1 or LRP2 with 
siRNA would prove whether one or both of the receptors are required for emtinB 
mediated neurite outgrowth.  
LRP1 was expressed in oligodendrocytes, astrocytes and microglia in P2, P7 and 
adult brain and in hippocampal neuron cultures at 3, 7, 14 and 21DIV. Expression of 
LRP1 in astrocytes has been reported in vivo and in vitro previously (Rebeck et al., 
1993, Zheng et al., 1994, Ishiguro et al., 1995, Marzolo et al., 2000, Gaultier et al., 
2009). However, this is the first time that in vivo LRP1 expression has been reported in 
oligodendrocytes and microglia despite being identified in vitro (Marzolo et al., 2000, 
Gaultier et al., 2009). Using in vitro models, the specific function of LRP1 on glia can 
be further investigated by inhibiting it using siRNA. Through the use of transgenic mice 
that express Cre recombinase under the control of oligodendrocyte, astrocyte or 
microglial specific promoters (Niwa‐Kawakita et al., 2000, Uhlmann et al., 2002, 
Brockschnieder et al., 2004, Garcia et al., 2004, Willemen et al., 2010) LRP1 can be 
specifically knocked out of these cell populations in vivo (Rohlmann et al., 1996, Liu et 
al., 2010). Myelination and migration of oligodendrocytes, neurotransmitter release of 
astrocytes or phagocytosis and antigen presentation of microglia can be evaluated in 
both these in vivo and in vitro models to determine whether LRP1 has a role in these 
glial functions. 
LRP1 was also expressed on endothelial cells and astrocytic end-feet of the 
BBB, consistent with previous work that show LRP1 expression on these structures and 
that the receptor regulate transport of molecules of the brain (Moestrup et al., 1992, 
Wolf et al., 1992, Shibata et al., 2000, Yepes et al., 2003, Deane et al., 2004). LRP1 
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may also modulate cerebral blood flow by regulating glutamate mediated calcium 
signaling in astrocytic end-feet to induce vasodilation or vasoconstriction (Zonta et al., 
2002, Hayashi et al., 2012). Through regulating transport of molecules in and out of the 
brain and cerebral blood flow, LRP1 can aid in controlling the brains’ 
microenvironment and indirectly promote the survival and function of neurons. 
Inhibiting LRP1 function by injection of antibodies against the receptor can be 
conducted in vivo to assess whether it increases vascular permeability and blood flow or 
transport of molecules across the BBB (Yepes et al., 2003).  
The work in this thesis has provided the groundwork to further explore the 
function of LRP1 in neurons and glia, both in vivo and in vitro. It is apparent through 
previous work and the current data that the role of LRP1 in neurons and glia is ligand 
and cell specific, and changes during development. This thesis demonstrates that the 
expression pattern of LRP1 in vitro resembles that observed in vivo. Therefore, culture 
models are a useful and relevant tool to investigate the specific functions of the receptor 
in neuron and glia subtypes. The confirmation of these effects in vivo may lead to a 
better understand of mechanisms underlying neurodegenerative disease or injury and 
possible therapeutic targets. 
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Appendix 1: Solution and buffer recipes 
GENERAL SOLUTIONS AND BUFFERS 
0.9% SALINE 
0.45g sodium chloride was dissolved in 50mL milliQ water and filter sterilized. 
4% PARAFORMALDEHYDE 
40g prilled paraformaldehyde was dissolved in 500mL 60°C milliQ water with 10M 
sodium hydroxide added until solution became clear. Solution was then added to 500mL 
2X PBS and stored at 4°C. 
PHOSPHATE BUFFERED SALINE 
10mL 200mM sodium dihydrogen orthophosphate, 40mL 200mM sodium phosphate 
dibasic dihydrate and 100mL 0.9% saline were mixed together in 850mL milliQ water. 
 
TISSUE PROCESSING 
CITRATE BUFFER 
1.92g citric acid was added to 900mL milliQ water, pH-ed to 6.0 and made up to 1L. 
Buffer was stored at 4°C and could be reused five times for antigen retrieval. 
SUCROSE 
1g, 2g or 3g sucrose was dissolved in 10mL milliQ water to make sucrose solutions of 
10%, 20% and 30% respectively. 
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NEURON CULTURE 
HANK’S BUFFERED SALINE SOLUTION 
One vial of Hank’s buffered saline solution and 0.35g sodium bicarbonate was 
dissolved in 1L distilled water and filtered through a 0.22μm bottle top filter in a sterile 
environment. Stored at 4ºC. 
SERUM FREE MEDIA (NEUROBASAL) 
500mL neurobasal was supplemented with 0.1% B27, 0.5mM L-glutamine, 0.1% 
gentamicin. 
 
WESTERN BLOTTING 
0.05% PBS-TWEEN 
500μL Tween-20 was added to 1L PBS. 
4X REDUCING BUFFER 
5mL 1M Tris hydrochloride (pH 6.8), 2mL 20% sodium dodecyl sulfate, 2mL glycerol, 
2mL β-mercaptoethanol and 0.02% bromophenol blue were mixed together and stored 
at -20°C. 
5% MILK POWDER 
5g skim milk powder was dissolved in 100mL PBS-Tween. 
5% STACKING GEL 
3.55mL milliQ, 833μL 30% acrylamide-bis, 625μL 1M Tris hydrochloride (pH 6.8) and 
50μL 10% sodium dodecyl sulfate were mixed together. 150μL 10% ammonium 
persulfate and 6μL N,N,N,N-tetramethylethylenediamine were added immediately prior 
to pouring gel into cast. 
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10% RESOLVING GEL 
4.4mL milliQ water, 5mL 30% acrylamide-bis, 5.6mL 1M Tris hydrochloride (pH 8.7) 
and 150μL 10% sodium dodecyl sulfate were mixed together. 150μL 10% ammonium 
persulfate and 22.5μL N,N,N,N-tetramethylethylenediamine were added immediately 
prior to pouring gel into cast. 
10X RUNNING BUFFER 
5g SDS, 15g Trizma base and 72g glycine were mixed together in 500mL milliQ water. 
1X running buffer was prepared by mixing 80mL 10X running buffer in 720mL milliQ 
water. 
30% ACRYLAMIDE-BIS 
150g acrylamide and 4g bis were mixed together in 300mL milliQ water. Total volume 
was brought to 500mL and allowed to warm to room temperature before being stored at 
4°C. 
RADIO IMMUNOPRECIPITATION ASSAY (RIPA) BUFFER 
0.394g Tris hydrochloride, 0.4383g sodium chloride, 0.0186g EDTA, 500μL Triton X-
100, 0.5g sodium deoxycholate and 0.05g sodium dodecyl sulfate was added to 50mL 
milliQ and mixed on an orbital shaker overnight. Buffer was pH-ed to 7.4. 
TRANSFER BUFFER 
11.5g glycine and 2.4g Trizma base were dissolved in 160mL methanol and 640mL 
milliQ water at 4°C. 
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LIVE CELL CALCIUM IMAGING 
IMAGING BUFFER STOCKS 
The following amounts were dissolved in 50mL milliQ to make 1M stocks: 
Calcium chloride: 7.35g dihydrous calcium chloride 
Magnesium chloride: 10.17g hexahydrous magnesium chloride 
Glucose: 9.00g D-(+)-glucose  
IMAGING BUFFER 
100mL buffer was made up with sterile milliQ water containing 2mM calcium chloride 
(200μL of 1M), 1mM magnesium chloride (100μL of 1M stock), 10mM glucose (1mL 
of 1M stock), 10mM HEPES (1mL of 1M stock) and 10mM HBSS (10mL of 10X 
stock), adjusted to a pH of 7.2-7.4 and filter sterilised. 
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Appendix 2: Reagent and equipment information 
Reagent Catalogue number Supplier 
General     
Hydrochloric acid 1367-2.5L GL Ajax 
Methanol M3641 Sigma 
Paraformaldehyde 441244 Sigma 
Sodium azide 71289 Fluka 
Sodium chloride S9625 Sigma 
Sodium dihydrogen orthophosphate 31463 Ajax 
Sodium hydroxide S5881 Sigma 
Sodium phosphate dibasic dishydrate 30412 Sigma 
      
Peptides     
EmtinB 
Modeled after the MT-II β-domain C-terminus 
(Swiss Protein Database P02795) 
  Schafer-N (Denmark) 
Metallothionein-II (zinc bound) 
>98% HPLC purified protein from rabbit liver 
  Bestenbalt LLC (Estonia) 
Receptor associated protein 62321 Progen Biotechnik 
      
Tissue dissection and processing     
Sucrose S5391 Sigma 
Cryomatrix resin 6769006 Thermo Shandon 
Pentobarbitone 61108 Ilium 
      
Neuron culture     
B27 supplement 17504-044 Life Technologies/Gibco 
Foetal calf serum 10099-141 Gibco 
Gentamicin 15710-064 Gibco 
Hank's buffered saline solution H2387-1L Sigma 
HEPES powder H3375 Sigma 
L-glutamine 21051-024 Sigma 
Neurobasal 10888-022 Life Technologies 
Poly-L-lysine P4832 Sigma 
Sodium bicarbonate S-5761 Sigma 
Trypan blue T8154 Sigma 
Trypsin T4549 Sigma 
      
Immunochemistry     
Citric acid C-0759 Sigma 
DAPI D3571 Molecular Probes 
Fluorescence mounting media S3023 Dako 
Goat serum S-1000 Vector Laboratories 
Goat α-mouse (488 conjugate) A11029 Molecular Probes 
Goat α-mouse (HRP conjugate) P0447 Dako 
Goat α-rabbit (594 conjugate) A11012 Molecular Probes 
Goat α-rabbit (HRP conjugate) P0448 Dako 
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Reagent Catalogue number Supplier 
Immunochemistry continued   
Isolectin (488) I-21411 Molecular Probes 
Monoclonal mouse anti-GFAP MAB360 Millipore 
Monoclonal mouse anti-MAP2 MAB3418 Millipore 
Monoclonal mouse anti-NeuN MAB377 Millipore 
Monoclonal mouse anti-olig2 MABN50 Millipore 
Monoclonal mouse anti-PSD-95 120-27230 Abcam 
Monoclonal mouse anti-SMI-312 SMI-312R Covance 
Monoclonal mouse anti-synaptophysin sc-17750 Santa Cruz 
Monoclonal mouse anti-tau sc-32274 Santa Cruz 
Nitric acid >69.0% 84385 Fluka 
Nuclear yellow N21485 Invitrogen 
Polyclonal rabbit anti-LRP1 L1270 Sigma 
Polyclonal rabbit anti-NR2a AB1555P Millipore 
Polyclonal rabbit anti-NR2b AB1557P Millipore 
Polyclonal rabbit anti-tau A0024 Dako 
Tomato lectin (biotin conjugate) L0651 Sigma 
Triton-X-100 LC262801 LabChem 
β-actin A2228 Sigma 
      
Live cell calcium imaging     
10X Hank's buffered saline solution 14185-052 Life Technologies/Gibco 
D-(+)-Glucose G5767-500G Sigma 
Dihydrous calcium chloride 10070.0500 Merck 
Fluo-4 AM F-14217 Invitrogen 
HEPES (1M) 15630-080 Life Technologies/Gibco 
Hexahydrous magnesium chloride M2670 Sigma 
L-Glutamate 11048-014 Gibco 
MK801 M107 Sigma 
N-methyl-D-aspartate M3262 Sigma 
      
Western blots     
Acrylamide A3553 Sigma 
Albumin from bovine serum A2153 Sigma 
Ammonium persulfate A3678-25G Sigma 
BCA protein kit 23225 Thermo Scientific 
Bis (N,N-methylenebisacrylamide) M7279 Sigma 
Bromophenol blue B5525 Sigma 
Ethelenediaminetetra acetic acid ED2SC Sigma 
Glycerol G5516 Sigma 
Glycine 26634 Thermo Scientific 
Immobilon Western  
Chemiluminescent Substrate 
WBKLS0050 Millipore 
Methanol 2500-S Millipore 
N,N,N,N-tetramethyletheylenediamine T9281-25ML Sigma 
Re-blot Plus 2500-S Chemicon 
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Reagent Catalogue number Supplier 
Western blots continued      
Instant skim milk powder  Woolworths Homebrand 
Sodium deocycholate D6750 Sigma 
Sodium dodecyl sulfate 1610302 Bio-Rad 
Spectra™ protein ladder 26634 Thermo Scientific 
Trizma base T1503-500G Sigma 
Tris hydrochloride 161-0719 Bio-Rad 
Tween-20 P1379-500 Sigma 
β-mercaptoethanol M7154 Sigma 
   
 
Equipment Catalogue number Supplier 
General     
Eppendorf tubes 1.5mL TUBE-170-C Extra Gene 
Falcon tubes 15mL 352096 BD Biosciences 
Falcon tubes 50mL 352070 BD Biosciences 
      
Neuron culture     
0.22μm bottle top filter SCGPT05RE Millipore 
0.22μm syringe filter SLGP033RS Millipore 
12 well plate 351143 BD Falcon 
13mm glass coverslips CB00130RA1 Menzel-Gläser 
18mm glass coverslips CB00180RA1 Menzel-Gläser 
24 well plate 353047 BD Falcon 
30mL syringe SS*30LE1 Terumo 
90mm petri dish with lid S9014S20 Technoplas/Interpath 
Goniotomy knife   Kaiser 
      
Immunochemistry     
Cover glasses HDLD22501.01PO HD Scientific 
Frosted 1 end glass slides 7107-PPN Livingstone 
MX35 Premier plus microtome blades 3051835 Thermo Scientific 
Superfrost Ultra Plus® glass slides J3800AHD# Menzel-Gläser 
      
Western blots     
Filter paper     
Nitrocellulose membrane 88018 Thermo Scientific 
      
 
 
